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Summary 
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory 
arthropathies of heterogeneous aetiology affecting 2-3% of the general population. 
Extensive in vivo and in vitro studies have identified the multiple pro-inflammatory 
cytokines and enzymes implicated in the pathogenesis of these disorders culminating in 
therapeutically beneficial cytokine targeted therapies. Cytokine blockade however exhibits 
variable responses across patient populations and importantly disease activity recurs upon 
cessation of therapy. The critical challenge in therapeutics now is to uncover the 
underlying immunological processes responsible for the generation and perpetuation of 
inflammatory arthritis such that peripheral tolerance can be re-established and therapeutic 
remission can be maintained. Of particular interest are the co-stimulatory interactions 
bridging the innate and adaptive immune response, notably those initiated by the 
interaction of dendritic cells (DC) with T cells, as the evolution of the latter is profoundly 
influenced by these cognate interactions. Moreover. DC are the only APC recognized to 
date as capable of provoking autoimmune disease and therefore embody an important line 
of investigation in determining the initial triggers that generate and (of therapeutic 
significance) maintain chronic inflammatory arthritis. However. to date there have been 
very few investigations of the phenotype and function of DC, in particular with reference 
to DC lineage. This partly reflects difficult in adequately identifying the DC subsets, 
plasmacytoid (P) DC and myeloid (m) DC, in peripheral blood and tissues - most 
methodologies rely on complex combinations of antibody markers. Recently. novel 
markers useful in human, and murine, DC studies have been defined that can improve 
resolution of DC subset heterogeneity. This study therefore focused on utilizing novel DC 
markers in a combination of in vitro and in vivo analyses in order to elucidate the 
contribution of different DC subsets to the initiation, modulation and perpetuation of the 
inflammatory arthritides, rheumatoid arthritis (RA) and psoriatic arthritis (PsA). 
The first part of this thesis examined by comparative analysis the phenotype, tissue 
distribution and functional profile of the human DC subsets, myeloid (m) DC and 
plasmacytoid (DC), in RA and PsA. This study demonstrated that circulating pDC and 
mDC are reduced in the peripheral blood (PB) of RA and PsA patients, but are 
accumulated to the inflammatory synovial fluid (SF) and synovial membrane (SM), 
commensurate with altered migration. Furthermore, it was demonstrated that the majority 
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of pDC and mDC within the synovial compartment displayed a predominantly immature 
phenotype as identified by the low to absent expression of specific co-stimulation and 
maturation markers including CD80, CD83, CD86 and dendritic cell lysosome-associated 
membrane protein (DC-LAMP). However, pDC and mDC purified from SF underwent ex 
vivo phenotypic maturation and released cytokines to TLR stimulation at comparable 
levels to their normal PB purified counterparts. Commensurate with that observation, 
cytokine profiling of SM localized pDC and mDC revealed expression of the pro-
inflammatory cytokines IL-12p70, IL-23pI9, IL-15, IL-18 and IFN-a/~. Together these 
data indicated no apparent intrinsic cellular defect, suggesting that extrinsic factors in the 
local synovial environment may be culpable for inhibition of DC maturation. In addition 
mDC in SM expressed predominantly IL-12p70 and IL-23pI9, suggesting a central role in 
the regulation and expansion of T cells, in particular Th 17, which have been ascribed a 
pathologic role in arthritis. In contrast, pDC expressed predominantly IL-15 and IL-18, 
cytokines that can enhance IL-12 induced IFN-y release and inhibit T cell apoptosis, thus 
indicating a role in the amplification and prolongation of inflammatory arthritis. Of 
particular interest it was demonstrated that pDC also expressed IFN-a/~ in abundance. As 
pDC constituted the dominant DC subset in the SM in both RA and PsA, this may have 
pathological implications as JFN-a has been critically linked to pathology in other 
auto immune diseases, including systemic lupus erythematosus (SLE) and, of particular 
import to PsA, psoriasis. 
Thereafter I aimed to elucidate the effect of cytokine modification on the function of mDC 
and pDC in regard to synovial inflammation, and the resolution thereof, to gain further 
insight into the contribution of DC to disease pathology. Specifically, we examined DC 
subsets in synovium after TNF-a blockade (infliximab) in RA and PsA patients and 
compared and thereafter contrasted the effects of both ofTNF-a and IL-15 on DC subsets 
in in vitro assays. While this component of the study was hampered by cell rarity, low 
number of participant patients and the early time point examined after infliximab infusion, 
it indicated a number of potentially informative trends. Pre-eminent amongst these was the 
observation that TNF blockade may have differential effects on mDC and pDC. In 
particular, we observed a trend towards decreased mDC in RA and PsA synovium 48 hours 
after infliximab infusion. Consistent with this, TNF neutralization down-regulated mDC 
release of the pro-inflammatory chemokines CCL2, CCL4 and CXCL8 in in vitro 
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experiments of mDCIT cell contact. In contrast, pDC were neither decreased in synovium 
after infliximab infusion nor did TNF neutralization reduce chemokine release in pDC/T 
cell contact. Indeed, TNF neutralization appeared to increase the release of pro-
inflammatory chemokines from pDC/T cell contact, which may be explained by IFN-a 
which has been demonstrated to drive CCL2, CCL3 and CCL4 secretion from pDC, but 
not mDC. Together the data suggest the intriguing possibility that TNF blockade could 
actually enhance pDC arthritogenicity, presenting a potential explanation as to why some 
patients fail TNF therapy. We also observed that these effects were apparently TNF 
specific, since IL-I5 neutralisation appeared to decrease, TNF -a and pro-inflammatory 
chemokine production from both mDCIT cell and pDCIT cell contacts. Our in vitro 
analyses of the biological action of IL-IS suggested that this may be attributable to the 
direct inhibition of DC cognate interactions with T cells by IL-IS blockade via down-
regulation of CD69 and inhibition of IL-2 enabled T cell expansion. As such IL-lS 
blockade may offer an appealing complementary therapy to TNF directed therapy. 
Finally, this study sought to compare the functional role of mDC and pDC in the OVA 
TcR transgenic T cell adoptive transfer model of arthritis by means of depletion of the 
former using pDC specific antibodies. This study revealed that depletion of pDC at the 
time of OVA challenge increased the histopathological severity, serum autoantibody 
concentration and (auto) antigen-specific T cell re-stimulation significantly, as such 
demonstrating that pDC may be critical to the suppression of autoimmunity, by 
(presumably) induction of peripheral tolerance. By association, these results also 
suggested that mDC were capable of inducing inflammatory arthritic autoimmunity in the 
absence of pDC. 
In conclusion, these studies indicate that mDC and pDC possess multi-faceted roles in 
inflammatory arthritis, involved in both the initiation and perpetuation of arthritis, but also 
the potential suppression thereof. The data provide a firm basis upon which to build 
rational tolerance induction regimes in due course as the appropriate biological targeting 
agents become available in the clinical environment. 
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Chapter 1: Introduction 
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1.1 Inflammatory Arthritis: Rheumatoid Arthritis and Psoriatic Arthritis 
The inflammatory arthritides comprise a heterogeneous group of autoimmune disorders 
characterised by chronic joint inflammation, immune cell infiltration to the synovium, 
fibroblast-like synoviocyte (FLS) expansion and irreversible destruction of cartilage and 
bone. A source of significant health care expenditure worldwide, arthritis affects 2-3% of 
the general population and is projected to affect 67 million people by 2030 in the United 
States of America (USA) alone (1-3). Rheumatoid arthritis (RA) is the most prevalent of 
the chronic inflammatory arthropathies affecting 0.5-1.0% of the general population (4, 5). 
Psoriatic arthritis (PsA) is the second most common inflammatory arthritis (6). Defined as 
a (predominantly) seronegative arthritis associated with psoriasis, the exact prevalence of 
PsA is unknown due to a lack of specific diagnostic criteria, but is estimated at 0.3-1.0% of 
the general population and 6-42% of all psoriasis sufferers (7-10). While RA has been the 
focus of intensive clinical, immunological and genetic investigations, PsA has been 
comparatively less well defined, perhaps in part because it was only recognised as a 
distinct disease entity in 1964 (11). PsA was originally considered by many to share 
similar if not identical pathogenesis mechanisms with RA. Subsequent analyses however 
have indicated a stronger association of PsA with the spondyloathropathies, including 
ankylosing spondylitis (AkS), enteropathic arthritis and reactive arthritis (12). It is now 
widely accepted that both RA and PsA are distinct diseases, arising from multifactorial 
conditions. Whereas epidemiological studies have highlighted numerous genetic and 
environmental risk factors associated with disease occurrence and expression, the 
immunological mechanisms that initiate and perpetuate these diseases remain unclear. As 
a consequence the pursuit of novel therapies is impaired. 
1.1.1 History 
The earliest evidence of RA comes from paleopathological analysis of 6500 year old 
skeletons, discovered near the Tennessee and Green rivers in the USA, displaying a 
polyarticular, symmetrical erosive arthritis with no sacroiliac joint or postcervical 
vertebrae involvement (13). The lack of any similar palcopathological or written evidence 
to support a history of RA in Europe pre-1800, has led to the suggestion that the disease 
may have been transmitted from the so-called New World to the Old (14). The first 
detailed description of RA in Europe has been attributed to Augustin-Jacob Landre-
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Beauvois who described in 1800, an inflammatory polyarthritis he termed 'primary 
aesthenic gout'. The term rheumatoid arthritis was first proposed in 1859 by Sir Alfred 
Garrod, but was not adopted until 1921 by the British Ministry of Health, 1941 by the 
American Rheumatism Association (ARA) and 1957 by the International League Against 
Rheumatism (ILAR) (14, 15). 
Paleopathological evidence indicates that PsA, like osteoarthritis (OA), AkS and gout, has 
existed since antiquity (16). Skeletal remains uncovered from a fifth century monastery in 
the Judaen desert displayed typical features of PsA including characteristic arthritis 
mutilans, and their presence in a monastery suggests that psoriasis was, at this time, 
considered biblical leprosy (17). The discovery of a 13th century male skeleton in England 
exhibiting typical PsA characteristics such as widespread arthritis with ankylosis of the 
interphalangeal joints and 'cup and pencil' deformity of the distal interphalangeal joints, 
further confirms its history (18). It is perhaps surprising then that unlike RA, PsA was not 
accepted as a disease in its own right until relatively recently when in 1964 it was included 
in the ARA classification of arthritis (11) following substantial support from 
epidemiological and clinical studies (19-22). 
1.1.2 Definition and Classification 
RA is commonly defined as a chronic inflammatory disease of the synovium causing joint 
damage and destruction of bone resulting in disability and increased mortality. The current 
accepted criteria for the classification of RA have been set by the 1987 revised American 
Co]]ege of Rheumatology (ACR) criteria. The criteria are: (1) morning stiffness, (2) 
simultaneous arthritis in 3 or more joint areas with soft tissue swelling or fluid, (3) arthritic 
swelling of the hand joints, (4) symmetrical presentation of arthritis, (5) rheumatoid 
nodules over bony prominences, extensor surfaces or subarticular regions, (6) serum 
rheumatoid factor (RF) positive and (7) radiographic changes including erosions or bony 
decalcifications. For classification purposes, a patient is diagnosed as having RA if they 
present with at least 4 of the 7 criteria, with the first four criteria present for at least 6 
weeks (23). 
In contrast to RA, criteria for the classification of PsA have not been definitively 
established. Initially delineated from RA based on composite clinical features including 
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asymmetrical erosive polyarthritis, particularly with distal interphalangeal involvement, 
association with psoriasis and the absence of serum RF (24), between 3 and 5 distinct 
clinical sub-groups of PsA have since been proposed (25-27). However, as patterns of 
clinical involvement can over-lap between subgroups there remains continued debate as to 
the most appropriate diagnostic criteria for PsA. One example is a classification system 
proposed by Veale et al comprising (1) asymmetric oligoarthritis, (2) frequently erosive, 
seronegative, symmetric polyarthritis and (3) sacroiliitis with predominant spondylitis (28). 
Simpler classifications based upon synovial inflammation or enthesitis have also been 
proposed (29, 30). The difficulty in defining specific criteria is further confounded by the 
evolving nature of joint involvement. Over 60% of patients change from their initial 
pattern, for example an oligoarticular pattern may evolve to polyarthritis and vice-versa 
(31, 32). Importantly it has been recognised that PsA is not the mild disease originally 
believed but can, like RA, cause progressive functional disability (33) and increased 
mortality (34). 
1.1.3 Epidemiology 
Community and population based studies of the incidence and prevalence of RA have been 
numerous and indicate considerable geographic variation in disease occurrence. In the 
United Kingdom (UK) the prevalence of RA in the adult popUlation is estimated at 0.8% 
(5) with an annual incidence of36 per 100,000 in women and 14 per 100,000 in men (35). 
In other Northern European areas and in North America the prevalence is estimated at 0.5-
1.1 % of the general population with an annual incidence of 20-50 per 100,000 inhabitants 
(36-39). An even higher prevalence of 5.3-6.0% and incidence of up to 90 in 100,000 has 
been reported in Native Americans and Native Alaskans, potentially linked to high human 
leukocyte antigen (HLA) DRB 1"'1402 genetic risk associations (discussed in 1.1.6.1.2) 
(40). Prevalence is lower in Southern European areas at 0.3-0.7% and annual incidence of 
10-20 per 100,000 inhabitants (41-43). Studies from developing countries have been few 
but report similarly low prevalence between 0.1 % and 0.3% (44). 
Rather fewer epidemiological analyses have been undertaken on PsA. Prevalence is 
estimated at between 0.2-0.5% in Northern European and North American Caucasians (45, 
46). It is less prevalent in African-Americans, Native Americans (unlike RA) and South 
American Indians (47, 48). Prevalence of PsA is increased in patients with psoriasis, 
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occurring in 6-42% of sufferers (7-10). Only a small number of population based 
incidence studies of any note have been undertaken on PsA. Incidence has been reported 
as between 6-8 in 100,000 in Finland (49, 50), 8 in 100,000 in Sweden (51), 6.62 in 
100,000 in USA (52),3.02 in 100,000 in Northwest Greece (53) and 3.5 in 100,000 in the 
UK (54). Importantly, the last was a study of early PsA and may represent an 
underestimate of prevalence, particularly as psoriasis does not precede arthritis in 15-25% 
of cases (55). Until common standardised criteria are established for the diagnosis of PsA 
it remains difficult to determine its true incidence in different populations. 
Both RA and PsA can occur at any age, however RA most commonly occurs between the 
ages of 40 and 70 (56) whilst PsA usually develops between 35 and 45 years of age (57). 
Of interest, while RA favours females over males estimated at 2.5:1 and PsA occurs with 
equal frequency in both males and females, in both diseases an earlier age of onset and the 
female gender are associated with disease severity (58) (59). 
1.1.4 Clinical Features 
RA and PsA are inflammatory conditions. PsA and RA patients present a heterogeneous 
and sometimes overlapping combination of articular and extra-articular features, as 
summarised in Table 1.1. Although PsA often displays many features in common with the 
spondyloarthropathies such as enthesopathy and HLA-B27 associations, some clinical 
features overlap with RA, particularly in severe arthritis. For example, although PsA is 
classically described as presenting a predominantly asymmetric distribution, symmetry is 
demonstrated by up to 53% of patients who go on to develop polyarticular disease (60). 
Moreover, it has been proposed that asymmetry is not a distinctive qualitative feature of 
PsA, but a function of low clinical joint involvement particularly in early disease, and as 
such is not a robust diagnostic criterion (61). In addition psoriasis, the defining extra-
articular feature of PsA, does not develop in all patients. Therefore PsA is not solely 
distinguished from RA via the clinical presentation, but also by the lack of gender 
preference (62), less aggressive (usually) clinical course (58, 63) and absence (usually) of 
rheumatoid factor (20, 64) . 
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Table 1.1 Comparison of clinical features of RA and PsA 
Distribution 
Articular 
Features 
Extra-articular 
features 
Rheumatoid 
Factor 
Standard 
Mortality Ratio 
RA 
Symmetrical (65) 
Palpation tenderness, synovial thickening, 
effusion, erythema, decreased range of 
motion (23), ankylosis, subluxation (66, 
67). 
Skin (rheumatoid nodules, vasculitis) (73, 
74) ; Ocular (keratoconjunctivitis sicca, 
iritis, episc1eritis) (75, 76); Oral (salivary 
inflammation)(77); Respiratory (78); 
Cardiac (79, 80); Neurological (81); 
Hepatic (82); Haematological (anaemia, 
thrombocytosis) (83); Vascular 
(vasculitis) (84); Ischaemic heart disease 
(II-ID) (85, 86). 
Positive (80%) (23, 87) 
2.3-2.7 (89, 90) 
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PsA 
Asymmetrical(25) 
Dactylitis (30%) (68-70); 
Enthesopathy(7l); Spondyloarthropathy 
(33%) (sacroiliitis, spinal disease)(60); 
Distal interphalangeal joint 
involvement(72). 
Skin: Psoriasis (psoriasis vulgaris 
(predom.), pustular psoriasis, guttate 
psoriasis, erythrodemla), Nail lesions (67-
90%) (pitting, ridging, onycholysis); 
Ocular (7-33%) (Conjunctivitis, iritis)(25, 
76); Aortic incompetence «4%) (25, 28) 
Negative (90%) (25, 60, 88) 
1.59-1.65 (91) 
1.1.5 Histopathology 
1.1.5.1 The Normal Synovium 
The nonnal synovium covers the inner surface of joints and is a relatively acellular 
structure of approximately 0.5-5mm thickness, with a delicate intimal lining layer of 
approximately 1-2 cells in depth and a thicker sublining connective tissue layer. The 
intimal lining layer is composed of two types of interdigitating synoviocytes, the cluster of 
differentiation (CD) 68+/major histocompatability complex (MHC) 
n+/FcyR+/CDI4+/CD4S+/a6pl-integrin- macrophage-like synoviocyte (or 'type A') and the 
vascular cell adhesion molecule-l (VCAM-l t /CD5S+ / a6p l-integrin + /uridine 
diphosphoglucose dehydrogenase (UDPGDt fibroblast-like synoviocyte (FLS, or 'type 
B') (92, 93). The sublining layer forms a matrix composed of collagen types I, Ill, IV, V 
and VI as well as fibroncctin, lamin and proteoglycan, interspersed with machrophages, 
adipocytes and VCAM-l-/CDSY/ a6p l-integrin + IUDPGD- fibroblasts (94). The synovium 
maintains homeostasis and viscosity of the synovial fluid, which fills the joint cavity, 
through production of hyaluronidan, lubricin and surface-active phospholipid, synthesised 
by both type A and type B cells (95-97). The normal synovial fluid is also a relatively 
acellular compartment with mean counts of 35cells/IlI (98). In combination, the normal 
synovium and synovial fluid provide joint protection and lubrication as well as a means by 
which nutrients can be transported to the joint cartilage and debris can be cleared (99). 
1.1.5.2 The Inflamed Synovium 
During chronic arthritic inflammation, the synovium rapidly evolves from a protective 
nutritional structure into an aggressively invasive tissue, characterised by hyperplasia of 
the intimal lining layer, pronounced angiogenesis and concomitant influx of immune cells 
to the sublining layer (Figure 1.1). The resulting inflammatory activated synovial tissue, 
also termed "pannus", causes irreversible destruction of cartilage and bone through 
osteoclast-mediated bone resorption. Macrophages and synovial fibroblasts release matrix-
metalloproteinases (MMPs), aggrecanases and serine proteascs that digest collagen and 
proteoglycans, degrading the extracellular synovial matrix. In addition, the synovial fluid 
expands abnormally, accumulating in the order of 10-1000 cellS/ill (99), enriched in 
predominantly polymorphonuclear cells, but also mononuclear cells including monocytes, 
myeloid dendritic cells (mDC), plasmacytoid (p) DC, T cells, B cells and natural killer 
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Figure 1.1 Schematic representation of a normal joint compared to an inflamed 
arthritic joint, showing the associations between the joint capsule, synovium, bone 
and cartilage* 
In the nonnal joint the relatively thin, acellular synovium maintains homeostasis and 
visocity of the synovial fluid, which fills the joint cavity. Together the synovium and 
synovial fluid provide joint protection and lubrication as well as a means by which 
nutrients can be transported to the joint cartilage and debris can be cleared. In the inflamed 
arthritic joint the synovium (or "pannus") thickens, undergoing hyperplasia, angiogenesis 
and leukocyte infiltration, invading neighbouring cartilage and bone through 
osteoclastogenesis. The synovial fluid also expands, accumulating polymorphonuclear 
cells, mononuclear cells, cellular and matrix debris. (Original magnification x400). 
*Adapted from (101) 
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(NK) cells as well as cellular and matrix debris (101-106). Although the fundamental 
features of synovial inflammation are similar in RA and PsA, there are a number of 
qualitative and quantitative differences between the two diseases. 
1.1.5.2.1 Synovial tltickening 
In RA, the intimal lining layer thickens to a depth of over 8 cells, whereas in PsA intimal 
lining layer thickening is in the order of 2-3 cells deep (107, 108). Macrophage-like 
synoviocytes account for up to 80% of the hyperplastic intimal lining layer however only a 
small proportion of this is thought to be attributable to in situ proliferation. Reduced Ki67 
staining (109) and synovial explant culture proliferative capacity (110), as well as 
expression of leukocyte common antigen (LeA) on the majority of cells in the RA 
synovial lining demonstrates their bone marrow origin (111), indicating that the majority 
of synovial thickening can be accounted for by immigrating monocytes and macrophages 
from the peripheral blood. 
Consistent with this a number of studies report significantly fewer macrophages in the PsA 
synovium compared to RA synovium, most probably due to lower expression of 
macrophage recruiting selectin CD62E (E-selectin) in the former compared to the latter, 
hence the thinner intimal lining layer (107, 112). However, the validity of this observation 
has been disputed as comparative studies may not have matched RA and PsA patients for 
duration of disease, hence the differences may be artefact (113). In addition, cadherin-ll 
has recently been described at elevated levels in the rheumatoid synovial1ining layer and is 
a key determinant of lining layer formation by facilitating FLS-FLS adhesion (114). The 
expression of cadherin-ll has not yet been described in PsA, but an altered expression 
could account for the differing lining layer thickness between RA and PsA. 
1.1.5.2.2 Angiogenesis 
Angiogenesis is a prominent early feature of synovitis, fundamental to disease pathology 
by transmitting oxygen and nutrients to the hypertrophic synovium in addition to providing 
a means by which inflammatory cells are recruited to the anatomical compartment. In RA 
and PsA the pro-angiogenic factors angiopoetin-l and -2, vascular endothelial growth 
factor (VEGF) and transforming growth factor ~ (TGF~) are detectable at early stages of 
disease. However, levels are significantly higher in PsA as compared to RA, and this can 
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be correlated to significantly more blood vessels per square millimetre in the former 
compared to the latter (107, 115). Moreover, and in common with other 
spondyloarthropathies, the PsA synovium contains a tortuous vasculature, whereas the RA 
synovium contains a straight vasculature in 89% of early cases, and this specific difference 
may be of diagnostic value early in disease (116, 117). In addition, pro-angiogenic factors 
including insulin-like growth factor (IGF), epidermal growth factor (EGF), fibroblast 
growth factor (FGF), hepatocyte growth factor (KGF) and platelet derived growth factor 
(PDGF), produced by macrophages and synovial fibroblasts, are up-regulated in synovial 
fluid and have been co-localised to perivascular regions of the sublining layer of the 
synovium (118, 119). Of importance, angiogenic inhibitors including endostatin and 
thrombospondin-l and -2 have also been identified in RA, suggesting that the marked 
angiogenesis results from an imbalance that favours angiogenic promoters over inhibitors 
(120-122). 
1.1.5.2.3 Cellular Imnllmopathology 
A characteristic of the inflamed synovium m RA and PsA is the rapid influx of 
mononuclear cells including CD4+ and CD8+ T cells, plasma cells, B cells, NK cells, 
monocytes, mast cells and dendritic cells (DC) (lOI-105, 107, 123-125). The cellular 
infiltrate is in a predominantly perivascular distribution and recruitment is enabled by 
enhanced expression of adhesion molecules including CD62E (E-selectin) on endothelial 
cells, intracellular adhesion molecule (TCAM) -1 and VCAM-l (126). Fibroblast-like 
synoviocytes (FLS) and macrophages (M~) within the inflamed synovium have been 
demonstrated to be comparable between RA and PsA (127). In addition, CD4+ T cells are 
the most abundant inflammatory cell in the synovium, however their presence in the PsA 
synovium is significantly less than that observed in RA SM (107, 127, 128). In contrast, 
CDS+ T cells exceed CD4+ T cells in the PsA, but not RA, SF and enthesis. Futhermore 
CDS+ T cells infiltrate lesional psoriatic plaques earlier than do their CD4+ T cell 
counterparts (129, 130). This may suggest a role for CDS+ T cells in PsA pathology, 
commensurate with MHC class I genetic associations to PsA (discussed in 1.1.6.1.2) and 
CDS+ T cell receptor (TCR) oligoclonality (discussed in 1.1.7.2.1)(131). 
The organisation of HLA-DR expressing CD4+ T cells into lymphocytic aggregates in 
close association with MHC expressing macrophages and DC, as well as B cells, has led to 
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the frequent referral to the inflamed synovium as an ectopic lymphoid organ. However, 
the appearance of lymphoid-like architecture has been identified in only 50% of Ps A cases, 
with the majority expressing a diffuse lymphocytic infiltrate. Similarly, in RA 
lymphocytic aggregates occur in only 40-50% of cases, with germinal centre formation 
occurring in as few as 23% of cases (132). Moreover, immunohistochemical analysis of 11 
RA synovial biopsies by Page and Miossec indicated a fundamental lack of characteristic 
lymphoid features, including germinal centre formation in only 3/11 samples, as compared 
with paired lymph node biopsies (133). The extent to which lymphoid -like features 
correlate to disease duration in PsA has not been addressed, however studies by Baeten et 
al. and Tak et al. suggest that there are no significant histological differences between early 
and established RA, although significant differences can be observed between clinically 
active and inactive disease (116, 134). Moreover, the lack of classical lymphoid 
topographical segregation in the majority of cases may enhance disease pathology, 
particularly with respect to the potential for in situ antigen presentation. 
1.1.5.2.4 Joint erosioll 
The release of proteolytic enzymes by macrophages and synovial fibroblasts is considered 
a key early event in the pannus mediated degradation of cartilage and bone intrusion. 
MMP-l (collagenase) expression in synovial fluid, serum and synovium derived mRNA 
correlates to the development of radiological erosions in early, and established, RA and 
PsA (135-137). MMP-3 (stromelysin) is also elevated in PsA and RA scrum and synovial 
fluid (137-139). It has been proposed that the low level resistance of collagen VI to MMP 
mediated degradation may account for the continued stability of the synovial matrix during 
active inflammation (140), however collagen type 11 is the dominant component of 
cartilage. 
Activation of bone-resorbing osteoclasts by macrophage colony-stimulating factor (M-
CSF) and receptor activator of nuclear factor KB ligand (RANK-L), both of which are up-
regulated by IL-l and TNF-a, is a critical event in bone damage in both RA and PsA (141-
143). In PsA, bony erosions, particularly at the pannus/cartilage interface, are less 
common and appear at a slower rate than in RA, and instead present in a distal pattern most 
probably at the entheseallbone junction (26, 144). Consistent with this, levels of 
aggrecans, components of the cartilage structure and an indicator of cartilage destruction, 
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are lower in PsA synovial fluid than in RA synovial fluid (145, 146). Recent analyses by 
Jimenez-Boj (147) and Bugatti (148) revealed that in erosive inflammatory arthritis, bone 
marrow exposed by violation of the cortical barrier by the adjacent inflamed synovial 
tissue, may constitute an additional disease compartment as a pool from which mature B 
cell aggregates are formed. Of interest, it has been hypothesised that these B cell 
aggregates form a physical barrier shielding the bone sub-cortical bone marrow from the 
invading pannus, in addition to triggering new bone formation (147). 
1.1.6 Aetiology 
The precise aetiology of RA and PsA is unknown, but i.s believed to comprise a composite 
blend of numerous genetic, environmental, medical, lifestyle, hormonal and reproductive 
risk factors as well as dysregulated immunological processes. 
1.1.6.1 Genetic Factors 
There is strong evidence from population and twin studies to support the influence of 
heritable factors on the disease development of RA and, to a lesser extent, PsA as the 
former has been the focus of larger and more numerous analyses than the latter. Studies 
suggest that as much as 60% of a population's pre-disposition to RA can be accounted for 
by genetic factors (149). In both RA and PsA, association studies with human leukocyte 
antigens (HLA), genome-wide linkage scans and analysis of the major histocompatability 
complex (MHC) region, have revealed that the genetics of both diseases are complex and 
unique, with polygenic characteristics of inheritance influencing occurrence, expression 
and age of onset (150). 
1.1.6.1.1 Twill Studies 
Twin studies have indicated that in RA, there is higher concordance among monozygotic 
twins at 12-15% than in dizygotic twins at 4% (151, 152). No formal twin studies have as 
yet been undertaken on PsA, probably due to its low frequency. Of interest, one case has 
been reported by Moll and Wright concerning triplets, two identical and one non-identical, 
where the identical twins developed psoriasis with arthritic associations but the non-
identical twin developed neither (153). Furthermore, studies of psoriasis alone have 
revealed a strong concordance among monozygotic twins at 65-72% compared to dizygotic 
twins at 15-30% (154-156). In addition, several studies have identified familial clustering 
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in PsA with a first-degree relative risk of 8.3-14% (153, 157), thus supporting heritable 
risk in PsA aetiology. 
1.1.6.1.2I1LA Associatiolls 
RA and PsA have strong associations with HLA genes, which reside in the MHC region, 
and in both cases these have been found to be predictive of progression of clinical damage. 
In RA it is estimated that 50% of the genetic component of disease susceptibility may be 
accounted for by genes in the HLA region, particularly HLA-DBRl (149, 158). HLA 
associations in RA have been identified as HLA-DRl alleles (*0101, *0102), the HLA-
DR4 alleles (*0401, *0404, 0405, 0408), the HLA-DR6 alleles ('" 1401 and'" 1402) and 
HLA-DRI0 alleles (*1001)(159-162). The susceptibility across different ethnic 
populations to RA is closely correlated to the expression of the short amino acid sequence 
QKRAAlQRRAA in the third hypervariable region common to all HLA-DRB 1 alleles 
associated with RA, and this is commonly defined as the "shared epitope" hypothesis (160, 
163). 
Unlike RA, PsA is not strongly associated with the HLA class 11 alleles, but is associated 
with the HLA class I alleles. Reported associations include the HLA antigens A3, Cw6, 
B7, BB, B17, B27, B38, B39 DR7u, DRBOIO and HLA-DRB0301(164-168). HLA-B27 
is one marker considered indicative of the association of PsA with the 
spondyloarthropathies and may also be predictive of clinical features such as joint 
deformity (169). Other HLA antigens considered predictive of clinical progression include 
HLA-DR7 and HLA-B39, which are associated with joint damage when in the presence of 
HLA-B27, whereas HLA-B22 is protective (91). Individuals exhibiting severe PsA on a 
par with RA have increased levels of HLA-DR4 (166, 170). PsA has also been associated 
with polymorphisms in the MHC class I chain-related gene A (MICA), which was not 
associated with psoriasis alone (171, 172). MICA is expressed by heat-stressed epithelial 
cells and is recognised by CD8 up T cells, y8 T cells and NK cells, and thus 
polymorphisms in this loci may have adverse consequences for the innate immune 
response (173), a position supported by studies highlighting the integral association of 
CD8 T cells and NK cells with PsA immunopathology. 
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While the association of the HLA-DR alleles with RA have been known for at least 27 
years, recent analyses have indicated a strong association between the shared epitope 
containing HLA-DRBl *0404 and HLA-DRBl *0401 and autoantibodies against cyclic 
citrullinated peptides (anti-CCP antibodies) (discussed in 1.1.7.2.3) (174-177). It has been 
proposed that the HLA-DRBlIanti-CCP antibodies association represents a specific 
disease phenotype (177), a proposition supported by Verpoort et al. who showed that 
HLA-DR3 is not associated with anti-CCP positive arthritis, but is associated with anti-
CCP negative arthritis (178). Similar analyses in PsA have been limited, but one analysing 
126 PsA patients showed that while only 5.6% of patients were positive for anti-CCP 
antibodies, ofthese patients there was a significant association with the HLA-DRB 1 shared 
epitope and disease progression (179). 
A number of theories have been proposed to account for the strong association ofHLA-DR 
alleles and inflammatory arthritis, including mUltiple copies, disease penetrance, time of 
onset and severity. The shared epitope may act as a reccptor for arthritogenic peptide, 
directing the T cell repertoire towards an autoreactive response. The demonstration of 
follicular aggregates containing lymphocytes and high HLA-DR expressing antigen-
presenting cells (APC) within the inflamed synovia of patients with active RA is consistent 
with such a hypothesis (180). There may also exist molecular mimicry of the shared 
epitope by pathogens such as Epstein-Barr virus (EBV), Cytomegalovirus (CMV) and 
DNA J heat shock protein from E.coli (discussed section 1.1.7.1), thus serving as a target 
for autoreactive T cells (158, 181). The effect may be exacerbated by the unique contacts 
between T cell receptors and MHC molecules on APC in follicular aggregates within the 
inflamed synovia leading to enhanced T cell reactivity (15, 180). 
1.1.6.1.3 Non-HLA gelletic associatiolls 
Genome wide linkage scans have identified a number of non-HLA genes that may explain 
the remainder of the genetic component of susceptibility to RA and PsA. Regions have 
been located on chromosome 1 q, 5p, 3q 13, 6q, 8p, 14q and 16p (182-185). 
1.1.6.1.3.1 Protein tyrosine phosphatase N22 A number of genes emerging as convincing 
candidates for RA associations include that encoding protein tyrosine phosphatase N22 
(PTPN22), which is linked to negative regulation of T cell activity (186, 187). A recent 
study from Sweden found that in a patient cohort, the combination of polymorphisms in 
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the PTPN22 gene 1858 and positive anti-CCP antibody titres conferred 100% specificity 
for RA development (188). However a similar German study of 390 patients found that 
PTPN22 1858 was associated with RA irrespective of RF or anti-CCP production (189). 
Of interest, synergy between the SNP in the minor PTPN22 allele R620W and the shared 
epitope have been identified in the early failure of self-tolerance toward the cartilage 
determinant Cl (Ill) in RA (190). Only moderate associations between PsA and PTPN22 
polymorphisms have been observed in a patient cohort in Canada (191), however other 
studies have detected no associations (187) and more analyses are required to clarify the 
strength, if any, of this association. 
1.1.6.1.3.2 Macrophage illlribitory factor Polymorphisms in genes encoding macrophage 
migration inhibitory factor (MIF) (192, 193), which has pro-inflammatory properties, have 
also been associated with RA. Although no link with MIF has yet been observed in PsA, 
MIF has been positively associated with disease in a cohort of psoriasis patients (194). 
1.1.6.1.3.3 Programmed death receptor 1 A number of studies have identified SNP in the 
gene encoding programmed death receptor 1 (PDCD-l), an immunoinhibitory reccptor 
expressed by T and B cells, which confers susceptibility to RA (195, 196). A relationship 
between PDCD-l polymorphisms and disease susceptibility has also been identified in 
SLE (197) and diabetes mellitus but not PsA (198). 
1.1.6.1.3.4 Peptidylargillille deimillase type 4 A relationship of SNP in peptidylarginine 
deiminase type 4 (PADI4), a gene that encodes enzymes to change arginine into 
citrullinated proteins, has been associated with RA but not PsA (199, 200). PADI4 
expressIon has been identified in macrophagcs and granulocytes within rheumatoid 
synovlUm. 
1.1.6.1.3.5 Caspase recruitment domain-colltaitliltg protein-IS (CARDI5) Genome wide 
scans of PsA have been few, but a susceptibility locus has been identified at chromosome 
16q (201), which overlaps with CAROlS, a susceptibility gene for Crohn's disease (202). 
Interestingly, prevalence of psoriasis and PsA in Crohn's patients exceeds that in the 
general popUlation (203, 204). CARD15 mutations may potentially inhibit the innate 
immune response to pathogens by altering recognition of bacterial polysaccharide and 
subsequently diminishing nuclear factor (NF) KB activation (205). 
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Strong support for the vital role of genetic risk factors in arthritic aetiology has come from 
numerous animal models particularly those involving genetic-risk DBA-l. However, a 
number of models have been described whereby collagen-induced arthritis (CIA) can be 
induced in non-genetically sensitive animals provided that a sufficiently strong adjuvant is 
given (206). This evidence, coupled with numerous models describing infection induced 
arthritis, supports a definite role for environmental factors in disease aetiology. 
1.1.6.2 Environmental and Medical Factors 
Environmental factors, including infectious agents and trauma, have long been suspected 
as potential triggers in the pathogenesis of RA and PsA. 
1.1.6.2.1 Infectious agents 
The putative association of RA and PsA with chromosomal mutations that may diminish or 
dysregulate innate immune responses is consistent with a contribution of pathogens in 
disease risk. Indeed, psoriatic flares have been closely linked to streptococcal infection 
(207-209). Moreover keratinocytes within psoriatic plaques produce large quantities of 
antimicrobial peptides p-defensins and cathelicidins commensurate with an inflammatory 
response to pathogens (210). 
Several infectious agents including bacteria, mycobacteria, viruses and parasites, have 
been implicated in the aetiology of RA. Mycoplasma such as M. /ermentans (211-214) and 
M pneumoniae (215), have been implicated as cofactors in inflammatory arthritis, 
particularly RA. Proposed viral triggers associated with RA include EBV, CMV, rubella 
virus and parvovirus B 19 (216-219). Comparative analysis of existing data has 
demonstrated synovial virus infections, in particular coincident infections, are far more 
common in autoimmune arthritis, such as RA and PsA, than in reactive arthritis or septic 
arthritis (220, 221). Associations between infectious agents and RA remain controversial 
as serological studies vary widely between patient cohorts and many have been negative 
when applied to large cohorts of recent onset disease. Combined with the lack of time and 
space clustering in RA onset, which would be expected in the case of a strong and direct 
association between disease and specific infection, and the link becomes somewhat 
tenuous (222). Of interest however is the relatively recent increase in the incidence of Ps A 
in Africa, which has been attributed to infection with the human immunodeficiency virus 
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(HIV) (223, 224). This has been accompanied by the contrary observation that HIV 
infection appears to be associated with RA remission. It is possible that HIV triggered T 
cell dysregulation or regulatory T cell depletion may contribute to, or indeed cause, PsA, 
supported by the lack of an HLA-B27 antigen association in PsA in sub-Saharan African 
HIV patients (225). Importantly, the fact that RA and PsA are not only clinically distinct, 
but immunologically and pathologically distinct entities is highlighted. 
1.1.6.2.2 Blood Transfusion 
Studies have noted a consistent association between prevIOUS blood transfusion and 
subsequent RA development, possibly due to transfusion induced RF production (226-
228). The risk however appears to have dropped in recent years coincident with new blood 
processing techniques. 
1.1.6.2.3 Trauma 
In RA there appears to be little evidence to support a link between physical trauma and 
disease onset. In PsA trauma likened to Koebner's phenomenon, whereby psoriasis occurs 
following mechanical, physical or chemical irritation of the skin, is recognised as an 
important aetiological factor in disease onset (229-231). It is thought that arthritis may be 
triggered by trauma due to the release of vasoactive, pro-inflammatory neuropeptides such 
as substance P (232, 233). This hypothesis is supported by case studies identifying the 
inhibition of arthritis of the distal interphalangeal joint by traumatic digital paralysis (234, 
235). Furthermore substance P release from the synovial membrane (SM) to the synovial 
fluid (SF) can be blocked by nerve damage (234). Additional credence to the link between 
PsA and physical trauma is the established observation that PsA, but not RA, is associated 
with enthesopathy, an inflammatory involvement of the tendon, ligament and joint capsule 
attachments collectively known as the enthesis. Indeed fibrocartilage, a prominent feature 
of the enthesis organ, increases with joint stress, a significant event in genetically 
susceptible individuals as fibrocartilage directed autoimmunity has been linked to both the 
human spondyloarthopathies and animal models of disease (236-238). Moreover 
enthesopathy has been found to feature lymphocyte, plasma cell and polymorphonuclear 
cell infiltration (239), as well as bone structure alterations (erosion and proli feration), 
linked to adjacent synovitis and possible fibrocartilage autoimmunity (240-242). 
Angiogenesis is also highly active in early onset PsA (more so than in RA), resulting in a 
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pronounced tortuous vessel pattern in up to 93% of PsA patients but not in RA patients 
(243), and this is consistent with trauma as a risk factor for PsA (116). 
1.1.6.3 Lifestyle Factors 
To date, there has been a paucity of studies analysing the association of various lifestyle 
factors and the relative risk of developing PsA. There have however been a number of 
studies examining the influence of lifestyle factors on the occurrence of RA. 
1.1.6.3.1 Smoking 
Smoking significantly increases the risk, severity and outcome of RA in men and women, 
particularly in heavy smokers, supported by both cross-sectional and longitudinal 
epidemiological analyses (244-246). While the exact mechanism of association is unclear, 
smoking has been linked to increased RF production, decreased antioxidants in the blood 
and altered hormone levels (247). A significantly increased risk of developing seropositive 
RA has also been observed in shared epitope HLA-DR positive smokers (248). Of 
particular interest, Klareskog et al. have extended this observation by identifying a specific 
relationship between tobacco smoke induced peptide deimination and subsequent anti-CCP 
antibody production in HLA-DRBl positive smokers, thus providing evidence of a 
biological explanation for smoking as a risk factor (249). 
1.1.6.3.2 Socioeconomic Status 
Increased socioeconomic status has been shown by a number of studies to be inversely 
correlated with course, outcome and risk of RA (250-252), although the relative risk 
appears more robust in the female population (252). 
1.1.6.3.3 Obesity and Diet 
Obesity has been found to be a risk factor for RA in women, but not men (228, 253). 
Dietary factors contributing to risk of RA include high red meat and meat product 
consumption (254), while diets high in olive oil, cooked vegetables, alcohol consumption 
and omega-3 long chain polyunsaturated fatty acid (PUF A) found in oily fish, may have a 
protective effect (253, 255, 256). Considering the epidemiological evidence indicating Iow 
prevalence and incidence of RA in Mediterranean regions (see section 1.1.3), it appears 
that a Mediterranean style diet may be protective against the onset of RA. 
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1.1.6.4 Hormonal and Reproductive Factors 
RA is more common in women than men, particularly in the pre-menopausal age group, 
suggestive of a role for hormonal factors in disease susceptibility. Of interest, pregnancy is 
associated not only with remission of existing RA, but reduced susceptibility to RA, 
followed by an increased susceptibility in the post-partem period (257, 258). However, the 
increased susceptibility of females to RA is only true of individuals with low HLA-DRB 1 
shared epitope expression. The gender bias decreases to absentia with increasing numbers 
of shared epitope alleles (259). Furthermore, a study linking PTPN22 1858 
polymorphisms with the HLA-DRB 1 shared epitope in a male, but not female, cohort may 
indicate that the genetic contribution to disease is more prominent in men (189). 
PsA shows no gender bias, although a nested case control study of the Rochester 
Epidemiology Project reported pregnancy as a protective factor in the risk of developing 
PsA in patients with pre-existing psoriasis (260). The same study indicated that 
corticosteroid use in psoriasis increased the risk of developing PsA. The oral contraceptive 
pill has been recognised since 1968 as reducing the relative risk, and potentially the 
severity, of RA, but similar studies have not yet been undertaken in PsA (261, 262). 
The considerable and interrelated contribution of both genetic and environmental factors to 
disease aetiology, as eloquently demonstrated by the strong association of cigarette 
smoking, HLA-DR shared epitope and anti-CCP antibodies to disease suseceptibility, 
infers involvement of both the innate and adaptive immune system to the underlying 
immunopathology of disease. This is supported by a murine model whereby collagen-
induced arthritis can be demonstrated in non-genetically susceptible C57BLl6 (H-2b) mice 
provided that the adjuvant gives a sufficiently strong environmental insult (206). In 
addition spontaneous arthritis has been reported in numerous genetically susceptible 
models such as the MRL /pr/lpr model of arthritis (263, 264). Models combining both of 
arms of the immune response (innate and adaptive) induce severe, chronic arthritic disease, 
as exemplified by collagen type II challenge in oil-induced arthritis susceptible rats (265). 
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1.1.7 Immunopathology 
RA and PsA are generally acknowledged to be diseases of dyresgulated inflammation, 
driven and maintained by multiple interacting components of the innate and adaptive 
immune system. 
1.1.7.1 Innate Immunity 
The innate immune response constitutes the body's first line of defence against infectious 
organisms and is composed of constitutive and inducible mechanisms. The constitutive 
mechanisms are continuously expressed and include, for example, physical barriers 
provided by mucosal layers and epithelial cell shedding at surfaces continuously exposed 
to microorganisms including the skin, intestinal and genital tracts. In contrast, the 
inducible mechanisms of innate immunity are inducted by DC, macrophages, NK cells, T 
yo lymphocytes and neutrophils following recognition of pathogen-associated molecular 
patterns (PAMPs) expressed by the majority of microorganisms. PAMP recognition is 
mediated by pattern-recognition receptors (PRR), including lectins, mannose-binding 
receptors, dectin-l, DEC-205, pentraxins, NOD proteins and toll-like receptors (TLR) 
expressed, to a varying degree, by the cells of the innate immune system. PRR signalling 
triggers diverse functions such as complement activation and opsonization; phagocytosis 
and clearance of pathogens and cellular debris; and antimicrobial peptide, superoxide, 
nitric oxide, pro-inflammatory cytokine and chemokine release. While bacteria, 
mycobacteria, viruses and parasites have long been implicated in triggering and 
exacerbating RA and PsA (211-214, 220, 221), the relatively recent identification of active 
TLR ligands within the inflamed synovium has renewed interest in the role of innate 
immunity in disease pathology (see also 1.2.2.5). In particular TLR2, and TLR4, and their 
endogenous ligands, have been identified in the inflamed synovial compartment (266-269). 
Moreover they have been demonstrated to be central to a number of murine models of 
arthritis including that induced by collagen type 11 and LPS (270). Of importance, 
triggering of these TLR contributes significantly to matrix metalloproteinase (MMP) 
production, as well as the release of cytokines and chemokines and co-stimulatory 
molecule up-regulation by DC that could dictate the skewing of ongoing adaptive immune 
response. 
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It is likely that exogenous or endogenous TLR agonists expresed within the synovial 
compartment may promote the perpetuation of chronic inflammation, and potentially even 
provoke the leukocyte infiltration to the synovium. However, the presence of 
immunocompetent cells in the inflamed SM coupled with the identification of autoantigens 
in patient sera and SF underlines the contribution of the adaptive immune response to 
chronic inflammation (Fig. 1.2). 
1.1.7.2 Adaptive immunity 
In contrast to the innate immune response, adaptive immunity revolves around cellular and 
humoral immunity inducted by clonally expanded antigen specific up T cells and B cells 
and forms the basis of immunologic memory. 
1.1.7.2.1 T cells 
up T cells can be divided into two subgroups, CD4+ and CD8+. CD4+ T cells, also referred 
to as T helper (Th) cells, confer cellular immunity (Thl) or humoral immunity (Th2) (271). 
Strong evidence indicates a role for CD4+ T cells in the pathogenesis of both RA and PsA. 
First, CD4+ T cells are enriched to between 16-75% of all infiltrating cells in RA (272) and 
PsA (107, 128) SF and SM. Second, the strong association of HLA genes to aggressive 
pathology in RA and PsA, may reflect presentation of arthritogenic peptide to, and 
expansion of, autoreactive T cell clones (see also 1.1.6.1.2). Commensurate with this T 
cells can be co-localized to MHC Il expressing APC in the RA and PsA synovium (15, 
273, 274). Furthermore, a large number of SM localized T cells are CD45RO+, indicative 
of immunological memory and clonal expansion. Third, several murine models of 
arthritis, including CIA and adjuvant arthritis, are CD4+ T cell dependent (275, 276). 
Fourth, administration of T cell directed therapies, such as cyclosporine and leflunomide, 
have conferred considerable clinical benefit in RA and PsA (277-279). RA in particular, 
but also PsA, is considered to be a Th 1 mediated disease due to a predominance of Th 1 
cytokines, although Th2 cytokines are also detectable (280-282) (see also 1.1.8.1). The 
mechanisms by which this occurs remain elusive, although the influence of direct cellular 
contact is believed to be a central mechanism of arthritic pathology. 
In contrast to CD4+ T cells, CDS+ T cells, or cytotoxic T cells, mediate effector function by 
MHC I directed antigen specific killing of target cells and through cytokine production, in 
21 
Figure 1.2 A proposed model of the collaboration of innate and adaptive immunity in 
the induction and amplification of chronic inflammatory arthritis. 
In this model stimulation ofTLR ligands expressed by DC, M~ and fibroblasts can activate 
innate immune up-regulation of pro-inflammatory cytokines, chemokines and adhesion 
molecules facilitating leukocyte recruitment to the inflamed tissue. DC presentation of 
antigenic peptide/self (auto) antigen in the lymph node induces clonal expansion of 
autoreactive CD4+ and CD8+ T cells and B cell differentiation and autoantibody 
production. In the presence of pro-inflammatory cytokines and chemokines, fibroblast-like 
synoviocytes upregulate RANK-L expression activating osteoclast-mediated bone 
resorption and cartilage invasion. The subsequent release of necrotic cellular and matrix 
debris, as well as heat-shock proteins, can stimulate TLR ligands on APe of the innate 
immune system, thus eliciting amplification and perpetuation of inflammation in 
genetically susceptible individuals. 
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particular IFN-y and TNF-a.. Increasingly, a role for autoreactive CDS+ T cells in disease 
progression in RA and PsA has been indicated. A popUlation of highly expanded CDS+ T 
cell clones with identical or highly homologous inferred CDR3 amino acid sequences, 
indicative of clonal expansion driven by the same antigenic peptide, has been identified in 
PsA SM (131). Furthermore these clones persisted during methotrexate treatment. 
Similarly, in RA clonally dominant CD8+CD57+ T cells carrying T cell ~ receptors with 
identical amino acid sequences, indicative of clonal expansion driven by a common 
antigen, have been identified in unrelated patients (283-285). Whether these CD8+ T cell 
clones are clonally expanded to autoantigen or not, has not yet been clarified. Of interest, 
studies have reported greater CD8+ T cell enrichment to PsA SF than in RA SF and may 
reflect a more important role for CDS+ T cells in the former as compared to the latter, 
commensurate with strong PsA MHC class I genetic and HIV associations (166, 286-288). 
1.1.7.2.2 B cells 
B cells mediate adaptive immunity principally through the secretion of antigen-specific 
antibodies that promote pathogen elimination, but are also capable of antigen-presentation. 
Much evidence points to a key role for B cells in the perpetuation of arthritic pathology 
including the formation of germinal centres in the synovium (134), the clinical benefits of 
anti-CD20 (Rituximab) targeted therapy (289, 290) and the presence of autoantibodies. Of 
particular importance, it is increasingly recognised that B cells may be critical to the 
initiation of RA as autoantibodies directed against self-antigens including type 11 collagen, 
rheumatoid factor and cyclic citrullinated peptides (CCP) have been identified in the serum 
of RA patients many year before clinical manifestations of disease, consistent with an early 
breach in B cell tolerance (291-293). A similar finding is yet to be demonstrated in PsA. 
1.1.7.2.3 Autoalltigells ill IlIflammatory Arthritis 
It has been proposed that DC presentation of arthritogenic antigen to T cells, may drive 
memory T cell responses, promoting B cell activation and immunoglobulin class 
switching, hence playing a central role in the pathogenesis of inflammatory arthritis (273, 
294-296). Commensurate with this, antibodies to denatured collagen were first detected in 
RA synovial effusions in 1978 (297). Numerous putative autoantigens have since been 
identified and confirmed, predominantly in RA, by the reactivity of antibodies in patient 
sera and through in vitro T cell proliferation assays (15). Joint-associated autoantigens 
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include human cartilage (HC) gp-39 (298, 299), collagen type 11 (CII) (300) and cartilage 
proteoglycan aggrecan (301). Elevated humoral immunity to proteoglycan decorin has 
also been observed in PsA (302). Autoantigens not associated with the joint include 
endoplasmic reticulum molecular chaperone immunoglobulin binding protein (BiP) (303-
305), heterogeneous nuclear ribonucleoprotein A2 (RA33) (306, 307), glucose-6-
phosphate isomerase (GPI) (308), citrullinated a-enolase (309), citrullinated eukaryotic 
translational initiation factor 4GI (eIF4G 1) (310) and anti-cyclic citrullinated peptide (anti-
CCP) (311). Anti-CCP antibodies may prove a useful serologic indicator for early RA 
diagnosis and prognosis as they are expressed in the inflamed joint, their presence precedes 
disease manifestation, and they are closely linked to PADI and HLA-DR susceptibility 
epitope polymorphisms (175, 312). However, although anti-CCP antibodies are 
considered highly specific markers for RA, they have also been identified in 7.9-12.5% of 
PsA patients with predominantly severe symmetrical arthritis (313, 314). Similarly, anti-
GPI antibodies have been identified in PsA at comparable frequencies (12-25%) to those 
observed in RA (315). A number of studies support an autoantigen driven response in PsA 
(131, 316), however the associations identified to date are not strong. TCR p-chain 
nucleotide sequencing of PsA synovial tissue identified a small population of CD8 T cell 
clones with highly homologous CDR3 amino acid sequences, suggesting a common 
triggering autoantigen (l31). Clearly PsA autoantigenic associations, or otherwise, require 
more resolution. Of interest, a number of strong candidate autoantigens have emerged in 
psoriasis and include keratin 13 (K13), heterogeneous nuclear ribonucleoprotein-AI 
(hnRNP-Al) and rab coupling protein isoform 3 (FLJ00294) (RABllFIP1) (317-319). It 
has been suggested that the lower plasma cell frequency in the PsA synovium as compared 
to the RA synovium may account, in part, for the less consistent autoantigen associations 
(127). 
The role that candidate autoantigens play in the clinical manifestations of disease is, as yet, 
unclear. It has been suggested that in the proinflammatory synovial environment the DC 
phenotype may become skewed, resisting the immunosuppressive effects of IL-10 (295, 
320) resulting in reduced chemotactic motility and an abnormally prolonged life span. 
Thus the persistence of DC-Iymphocyte aggregates in synovium may contribute to the 
perpetuation of the inflammatory response (321). Of note, production of autoantibodies 
against the self-antigen glucose-6-phosphate isomerase (GP!) is believed to initiate 
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synovial inflammation in the KlBxN murine model of arthritis since sera transfer is 
sufficient to induce arthritis in naIve recipients (322-324). This model also supports the 
proposition that joint associated auto antigens may not be a pre-requisite for arthritis 
induction. However, the pathological manifestations of arthritis in the KlBxN model are 
also dependent upon an inflammatory cytokine cascade, particularly IL-l and TNF-a, as 
demonstrated using cytokine knockout mice (325). 
1.1.8 Mechanisms of inflammation 
The myriad inflammatory cells infiltrating the synovial compartment release soluble 
factors including cytokines, chemokines and matrix-metalloproteinases that are directly 
culpable for disease pathology by promoting recruitment and activation of further 
inflammatory cells. 
1.1.8.1 Cytokines 
The underlying aetiology of RA and PsA is not clear, however the critical importance of 
the cytokine cascade in the established phase of disease has been extensively studied. 
Cytokines are small (5 to 50 kDa), non structural proteins or glycoproteins that serve as 
chemical messengers between cells (326) and thus are of critical importance to virtually 
every aspect of innate and adaptive immunity including cell growth, differentiation, 
recruitment and activation, antigen presentation, tissue repair and remodeling and adhesion 
molecule expression. Cytokines are upregulated in inflammatory diseases such as RA and 
PsA, where they regulate the acute and chronic inflammatory response. Although 
cytokines can work in an autocrine fashion (act on the same cell), the proximity of cells in 
the synovium, particularly in the intimal lining layer enhances cytokine mediated 
inflammation by enabling paracrine (neighbouring cell activation) and juxtacrine (cell-to-
cell contact) activity. 
In both RA and PsA numerous pro-inflammatory cytokines including IL-J alP, IL-6, IL-12, 
IL-15, IL-17, IL-18, IL-32, GM-CSF and TNF-(l are elevated in serum, synovial fluid and 
synovium (282, 327-332) (Table 1.2). Thl cytokines, in particular those associated with 
highly activated macrophage frequency, are more prevalent in RA than in other forms of 
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Table 1.2 Major cytokines with a role in inflammatory arthritis* 
Cytokine 
IL-l Superfamily 
IL-I a/lL-I J3 
IL-IRa 
IL-18 
IL-6 Superjamily 
IL-6 
IL-IO superfamily 
ILlO 
TNF Superfamity 
TNF-a 
RANK-L 
LTa 
Type II /IIterjeroll 
IFN-y 
Type I Interferon 
IFN-a/J3 
IL-17 family 
IL-17 
Principal Source 
Monocytes, M~, DC B cells 
Monocytes 
Primary Biological Activity 
f COX-2, iNOS, PGE2 and nitric oxide 
synthesis, adhesion endothelial adhesion-
molecule expression and collagenase by 
fibroblasts and chondrocytes. 
Antagonize effects ofIL-I Cl and IL-I J3 
Monocytes, DC, PMN, endothelial Pleiotropic: + IL-12 f lFN-y production 
cells (Th I), + IL-4 (Th2) 
Fibroblasts, T cells, monocytes, M~, 
B cells 
Monocytes, M~, CD4+ and CD8+ T 
ceIIs, DC, epithelial cells. 
Monocytes, M~, neutrophils, DC, 
activated T cells, NK cells, 
endothelial cells, fibroblasts 
Stromal cells, osteoblasts, T cells 
T ceIIs, monocytes, fibroblasts, 
endothelial cells 
T cells, NK cells 
pDC, B cells 
Th17, activated memory B cells 
Thrombopoiesis, cytotoxicity, 
inflammation, acute-phase reaction, 
haematopoiesis, bone metabolism. 
f B cell proliferation and JgG 1 secretion. 
! IL-12, IFN-y, IL-2, TNF-J3, TNF-a in 
Thl, chemotactic for CD8 T cells; DC 
activation! cytokine release; ! fibroblast 
MMP and collagen release; enhance D 
cell isotype switching. 
f ICAM-I and VCAM-I and E-selectin, 
IL-I, IL-6, IL-8 and GM-CSF; 
neutrophils activation; mediates of toxic 
shock and sepsis. 
Stimulates osteoclast mediated bone 
resorption; modulates T cell-DC 
interaction 
Peripheral lymphoid development; similar 
bioactivities to TNF-a. 
! bone resorption; ! T cell growth; 
opposes Th2; f MHe I and 11 expression; 
M~ activation; t DC and APC function; 
fibroblast coIIagen synthesis; t 
endothelial adhesion molecule; 
Activates naive CD4+ T cells, M~ ; 
enhances CD4+ production of IFN-y and 
IL·IO; f MHC; antiviral 
Bone and cartilage destructive factor; 
enhances leukocyte and fibroblast 
cytokine production. 
APC, antigen-presenting cell; COX-2, cyclo-oxygenase type 2; DC, dendritic cell; GM-CSF, granulocyte 
macrophage colony stimulating factor; ICAM, intracellular adhesion molecule; Ig, immunoglobulin; IL, 
interleukin; IFN, interferon; iNOS, inducible nitric oxide synthase; MBC, major histocompatability complex; 
M~, macrophage; MMP, matrix metalloproteinase; NK, natural killer; PGE2, prostaglandin-E2; VCAM 
vascular adhesion molecule; t increase/enhance; ! decrease/suppress. 
• Adapted from (327-330, 332, 333) 
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Table 1.2 Major cytokines with a role in inflammatory arthritis (continued)* 
Cytokine 
"a-helix /amity 
IL-2 
IL-4 
IL-S 
IL-1S 
!L-ll/amity 
IL-12 
IL-23 
IL-27 
Miscellaneous 
IL-32 
GM-CSF 
HMGBI 
TGF-p 
Principal Source Primary Biological Activity 
Activated Tht cells, NK cells t Proliferation and activation ofT cells, B 
cells and NK cells, t IFN-y and TNF-a. 
Th2 cells, NK cells, mast cells i B cell proliferation, differentiation and 
MHC 11 expression, i IgG I and IgE but ~ 
IgM, IgG2a, IgG2b IgGJ , t IL-t Ra 
expression, ~ IL-I, IL-6 TNF-a and IFN-
y. 
Th2 cells, NK cells, mast cells t proliferation and activation of 
eosinophils. t differentiation of cytotoxic 
T cells from thymocytes; B cell 
differentiation; IgA production. 
T cells, monocytes, Mq,. DC t T cell and NK cell recruitment, 
activation, proliferation, ~ T cell death; t 
neutrophils; + IL-12 t IFN-y production; 
t TNF-a production. 
Monocytes, M~, DC, T cells, B cells tNK cell and cytotoxic T cell activity; 
+IL-IS/IL-IS/lL-27 t IFN-y production, t 
TNF-a production. 
Monocytes, DC, Mcjl T cell proliferation and IFN-y production 
Monocytes, DC, M~, endothelial + IL-12 t IFN-y production; anti-tumour 
cells activity; clonal na'ive CD4+ T cell 
expansion. 
T cells, NK cells, FLS, 
T cells, M~. DC, 
endothelial cells 
t TNF-a, IL-IP, IL-6, IL-S and CXCL-l. 
fibroblasts, Granulocyte and monocyte maturation; 
haemopoietic effects; leuokocyte PG 
release; DC maturation; 
M~, necrotic cells, widespread Necrosis-induced inflammation; smooth 
expression muscle chemotaxis; bacteriocidal; 
disrupts epithelial barrier function; DNA-
binding transcription factor; Mcjl 
activation and delayed proinflammatory 
cytokine. 
Fibroblasts, monocytes, T cells, 
platelets 
Initial activation then suppression of 
inflammation; ~ T cell and NK cell 
proliferation and effector function; early 
phase leukocyte recruitment; wound 
repair and matrix maintenance; ~ M~ 
iNOS. 
APC, antigen-presenting cell; COX-2, cyclo-oxygenase type 2; DC, dendritic cell; GM-CSF, granulocyte 
macrophage colony stimulating factor; Ig, immunoglobulin; IL, interleukin; IFN, interferon; iNOS, inducible 
nitric oxide synthase; MHC, major histocompatability complex; M~, macrophage; MMP, matrix 
metalloproteinase; NK, natural killer; PGE2, prostaglandin-E2; RANK-L, receptor activator of NF-KB 
ligand; TGF, transforming growth factor; t increase/enhance; ~ decrease/suppress. 
*Adapted from (327-330, 332, 333) 
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arthritic diseaese (331, 334, 335), however elevated levels are also observed in PsA (280, 
282). In addition, intracellular factors considered key regulators of cytokine production 
such as nuclear factor (NF)-KB, extra-cellular signal-regulated kinase (ERK), c-Jun N-
terminal kinase (JNK) and p38 are activated and expressed in RA synovial tissue (336, 
337). The critical role of cytokines in the pathogenesis of RA and PsA is exemplified by 
the (varied) success of specific cytokine targeted therapies including anti-TNF-a (338), 
anti-IL-6 (339, 340) and anti-IL-IS (341, 342). 
Of note, anti-inflammatory cytokines such as IL-4 and IL-lO, as well as cytokine-inducible 
suppressor of cytokines (SOCS)-1 and -3 and IL-l receptor antagonist (IL-! Ra) and 
soluble TNF-receptor (sTNFR) are also detectable in the inflamed synovial compartment 
(343). However, the levels of these are thought to be too low to be biologically effective, 
thus disequilibrium exists in the balance of pro- and anti-inflammatory signals. 
Alternatively, and given that cytokines can exert biological effects at picomolar 
concentrations, it may point to an inherent defect in the cells of the immune system to 
respond to anti-inflammatory signals by, for example, receptor deficiency as is the case for 
IL-I0Ra expression by RA derived fibroblasts (344). 
1.1.8.2 Chemokines 
The ingress of leukocytes to the inflamed synovium is mediated by chemokines. 
Chemokines, or chemotactic cytokines, are small molecular weight (8 to 12 kD) 
chemoattractant proteins that primarily promote angiogenesis, leukocyte recruitment and 
activation (345). Over 50 distinct chemokines have been identified and can be classified 
into four sub-families: CXC, which act primarily upon neutrophils but also promote 
angiogenesis (1), CC, which act primarily upon monocytes and T cells (2), C, which 
comprises XCLl (lymphotactin) and XCL2 (single cysteine motif-l P (SCM-I P» (3) and 
CX3C, which consists of the membrane bound fractalkine (CX3CL1) (4). A number of 
pro-inflammatory chemokines and chemokine receptors have been detected at elevated 
levels in both RA and PsA serum, synovial fluid and synovial tissue (Table 1.3), although 
RA levels generally exceed those observed in PsA, and both are higher than those observed 
in OA (346-361). 
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Table 1.3 Major chemokines with a role in inflammatory arthritis* 
Systematic Name Receptor (s) Primary Source 
CC chemokine family 
CCL2 (MCP-IIMCAF) CCR2 Fibroblasts 
CCL3 (MIP-Ia/LD78a) CCRl, CCR5 Mononuclear cells, fibroblasts 
CCL4 (MIP-ll3) 
CCLS (RANTES) 
CCR5 
CCRl, 
CCR5 
CCR7 
Monocytes, B cells, DC 
CCR3, Fibroblasts, T cells, M~ 
CCLl9 (MIP-3bIELC) 
CCL20 (MIP-3cx1LARC) 
CCL21 (6Ckine.SLC) 
C Chemokine family 
XCLl (Lymphotactin) 
XCL2 (SCMI-a) 
CXC chemokinefamily 
CXCLl (MGSA-a) 
CXCLS (ENA-7S) 
CXCLS (lL-8) 
CXCLlO (IP-IO) 
CXJC chemokltle family 
CXC3CLI (Fractalkine) 
CCR6 
CCR7 
XCRl 
XCRI 
CXCR2, CXCRI 
CXCR2 
CXCRI, CXCR2 
CXCR3 
CXC3CRI 
M<jl, neutrophils 
M<jl and fibroblasts 
Endothelial cells 
activated CD8+ T cells, NK 
cells, )'0 T cells, mast cells 
Mononuclear cells 
Fibroblasts 
Fibroblasts 
Widespread 
Monocytes, DC, epithelial cells, 
endothelial cells 
Monocytes, M~, fibroblasts, 
endothelial cells, DC 
Physiological Features 
Inflammation 
Inflammation 
Inflammation 
Inflammation 
homeostatic 
Inflammation; 
homeostatic 
homeostatic 
Inflammation; 
I1omeostatic ('1) 
Inflammation; 
homeostatic (?) 
Inflammation 
Inflammation 
Inflammation 
Inflammation 
Inflammation 
CCL, CC chemokine ligand; CCR, CC chemokine receptor; CXCL, CXC chemokine ligand; CXCR, CXC 
chemokine receptor; DC, dendritic cell; ELC, Epstein-Barr virus-induced receptor ligand; LARe, liver and 
activation-related chemokine; M<jl, macrophages; MCAF, Monocyte Chemotactic and Activating Factor; 
MCP, monocyte chemoattactant protein; MIP, macrophage inflammatory protein; NK, natural killer; 
RANTES, regulated on activation normal T cell expressed and secreted; XCL, C ligand; 6Ckine.SLC, 
6Ckine-secondary lymphoid tissue chemokine. 
* Adapted from (346-362) 
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1.1.9 Current therapies in PsA and RA 
Current biologic response modifying therapies represent significant advances, combining 
improved efficacy with reduced toxicity, as compared to traditional drugs such as 
sulphasalazine, cyclosporine, methotrexate, NSAIDS and corticosteroids (363). In 
particular the effects of blocking TNF-a using adalimumab (a human anti-TNF-a 
monoclonal antibody), infliximab (a chimeric anti-TNF-a monoclonal antibody) or 
etanercept (soluble TNF-a receptor-IgG\ fusion protein) have been dramatic in reducing 
disease activity, retarding or halting radiographic erosions and inhibiting subsequent joint 
damage hence improving functional disability, particularly when used in combination with 
methotrexate (364-368). In addition, adalimumab has been shown to reduce rheumatoid 
factor and anti-CCP antibody titres (369). Numerous adverse medical side effects 
including exacerbation of multiple sclerosis (370), inducement of SLE-like disease (371), 
rapid onset of non-melanoma skin cancer (372) and increased susceptibility to infections 
from, for example, Listeria monocytogenes (373, 374), Salmonella typhimurium and 
Candida albicans (375), have been reported. Such severe adverse side effects are however 
rare, and incidences may not exceed rates expected in the general population (376). 
Nevertheless, many patients do not respond to therapy and in those that do 'true' 
remission, whereby patients are able to discontinue medications with no clinical or 
radiological evidence of damage, is rare. This is most likely because current treatment 
strategies target the cytokines and enzymes directly culpable for disease pathology, 
therefore focusing on disease management rather than cure. 
Several lines of research have implicated the participation ofT cells in the pathogenesis of 
arthritis. These include the recruitment of autoreactive T cells to the inflamed synovium 
(377, 378), the strong genetic association of selected HLA-DR (MHC class 11) haplotypes 
with disease susceptibility (160, 379, 380) and the T cell dependency of several animal 
models of arthritis, including collagen induced arthritis (CIA) and adjuvant arthritis (15). 
The mechanisms triggering the aberrant T cell activity have, however, been only partially 
characterised and include cytokine bystander activities. The critical challenge in 
therapeutics now is to uncover the underlying immunological processes responsible for the 
generation and perpetuation of inflammatory arthritis such that peripheral tolerance can be 
re-established and therapeutic remission can be maintained. The recent advent of anti-
CD20 (Rituximab) and CTLA4-Ig (Abatacept), which inhibits the costimulation between 
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B7 on antigen presenting cells (APC) and CD28 on naive T cells, as a treatment for 
rheumatoid arthritis (RA) (381) suggest that such effects may be achievable. 
Of particular interest are the co-stimulatory interactions bridging the innate and adaptive 
immune response, notably those initiated by dendritic cell (DC) interactions with T cell 
subsets, as the evolution of the latter is profoundly influenced by these cognate 
interactions. Because DC are the only APC recognised to date as capable of provoking 
autoimmune disease (382), they represent an important line of investigation in determining 
the initial triggers that generate and potentially maintain chronic inflammatory arthritis. 
1.2 Dendritic Cells 
Arising from CD34+ haematopoetic progenitors, DC were first described in the 1970s by 
Ralph M. Steinman and Zanvil A. Cohn, who characterised a novel mononuclear leukocyte 
with distinctive dendritic cytoplasmic extensions (383-386). Termed dendritic cells, they 
have since been identified in blood, all lymphoid tissues and the majority of non-lymphoid 
tissues (384, 387-394). DC are a highly motile complex network of professional antigen-
presenting cells (APC) critical to the initiation and regulation of adaptive immunity against 
pathogens and tumours, as well as the maintenance of both central and peripheral tolerance 
(395). Morphologically, DC have a characteristic pattern of cell processes, including spiny 
dendrites, bulbous pseudopods and lamellipodiae or veils (396). There is however, 
considerable phenotypic, morphologic and functional variation betwecn the DC subsets 
related to lineage, state of maturation and tissue localisation. 
1.2.1 Dendritic Cell Lineage 
Three distinct stages of DC development have been identified. The first stage, generated 
from CD34+ bone marrow progenitors, are the circulating precursor peripheral blood (PB) 
DC, of which six distinct subsets of lineage negative (CD3, CD14, CD20 and CD56) and 
HLA-DR+ DC have been delineated in humans. Four of these subscts, CDlb/c+, CDI6+, 
CD141 (BDCA-3t and CD34+, are myeloid derived, while the remaining two, 
CDI23+/CD303 (BDCA-2)+, have a lymphoid phenotype, and are described as 
plasmacytoid DC (pDC) (397, 398) (Table 1.4). Recently, pDC have been delineated into 
two distinct subsets based on the differential expression ofCD2. The more common, CD2-
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Table 1.4 Phenotype of human DC subsets· 
Myeloid DC 
Phenotype 
HLA + 
CD 1 a/b/c/d +/-
CD2 
CD4 + 
CDllb + 
CDlIc ++ 
CD 13 + 
CD14 
CD16 +/-
CD33 + 
CD45RA 
CD45RO + 
CD123 + 
CD141 (BDCA-3) +/-
CD303 (BDCA-2) 
CD304 (BDCA-4) 
IgA-like 14.1 
Pre-Ta 
Spi-B 
... Adapted from (395, 397, 399, 400) 
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Plasmacytoid DC 
+ 
-/+ 
++ 
+ 
+++ 
+ 
+ 
+ 
+ 
+ 
pDC comprise 75% of all circulating pDC. It is thought that the less frequent, CD2+ pDC, 
are able to kill target cells (K562) and express lysozyme. Both subsets however are 
capable of potent type I interferon (IFN) release and induce proliferation of memory T 
cells (400). 
It is important to note that in addition to the six 'classical' circulating DC progenitors, a 
number of other cell types have been identified that are capable of differentiating into DC-
like cells. Prominent amongst these are the CD14+ monocytes, which when matured with 
GM-CSF and IL-4 or TNF-a are able to differentiate into mDC, down-regulating CD14 
and up-regUlating CDllc (395). Monocyte-derived (mo) DC also attain the majority of 
described mDC functions and as such, due to their greater frequency in blood and ease of 
culture in bulk, are commonly utilised as substitutes for "true" mDC. Cautionary to this 
use is a report by Osada et al., who observed that peripheral blood DC enhanced NK cell 
activity in assays of anti-tumour cytotoxicity, but monocyte-derived DC did not (401). 
Moreover, monocytes do not express endosomal toll-like receptor (TLR) 3 whereas mDC 
do, allowing recognition of double-stranded (ds) RNA virus (402). Monocyte 
differentiated DC therefore represent a pragmatic, but flawed, substitute for analysing DC 
function. Other cells may also acquire or possess APC activity. 
It has been demonstrated that isopentenyl pyrophosphate (IPP) or Escherichia coli 
stimulation induces yl'O T cells to acquire not only antigen presenting phenotype, with up-
regulation of MHC-II, CD40, CD80 and CD86, but more significantly function, with the 
ability to process and present soluble protein antigen to CD4+ up T cells (403). Moreover, 
the level of antigen presentation and co-stimulation receptor expression was at directly 
comparable levels to LPS stimulated monocyte-derived DC. 
In addition to yl'O T cells it has recently been reported that in a pro-inflammatory 
environment NK cells can become antigen-presenting cells (404), with up-regUlation of 
MHC-II and T cell costimulatory molecule expression, and acquisition of the functional 
ability to present target cell-derived antigens following cytotoxic killing. It is probable that 
the recently described interferon-producing killer dendritic cells (IKDC), which are 
B220+/Ly6c·INK1.1+/GR-I-IPDCA-rlCD122+/MHC-If, are the murine equivalent of 
these cells, although this is yet to be formerly established. Possessing the molecular profile 
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of both NK cells and DCs, they produce type I interferons and IL-12 or IFN-y (stimuli 
dependent). IKDC have the same cytolytic capacity of regular NK cells but rapidly lose 
this ability along with the loss ofNKG2D receptor, and concomitant gain in DC-like APC 
activity and up-regulation of MHC-II and co-stimulatory molecules, features which 
distinguish them from regular NK cells (405-407). Furthermore, IKDC have been 
proposed to constitute a third distinct DC lineage, as although (in the murine system) they 
display MHC-II at comparable levels to pDC, they do not display the pDC receptor mouse 
plasmacytoid dendritic cell antigen (mPDCA)-l. 
The extent to which y/o T cells and NK cells can differentiate into DC, similar to 
monocytes, or purely gain aspects of DC-like function, requires further resolution. 
Nevertheless, these studies may indicate an intriguing system of circulating pre-cursor DC 
comprising not only mDC and pDC, but also monocytes, y/o T cells and NK cells (Figure 
1.3) (400). Significantly, these are all cells of integral importance to maintaining innate 
immunity. I will now focus on the well-established, defined 'classical' DC subsets, mDC 
and pDC respectively. 
1.2.1.1 Myeloid Dendritic Cells 
Myeloid DC (mDC) are phenotypically characterised as CDlc+/CDl1c+/CD45RO+/HLA-
DR+/CDI23 (IL-3Ra)10 (408). Comprising 0.5-1.0% of all circulating mononuclear cells, 
mDC express the myeloid markers CD 13 and CD33 reflecting a lineage relationship in 
common with both monocytes and macrophages (395). Capable of IL-12p70, IL-23, IL-
lS, IL-18, IL-I, IL-6, TNF-a and IL-IQ production as well as antigen capture and 
presentation (409). mDC require GM-CSF for survival in vitro and can differentiate into 
CDla' interstitial DC and CDla+ Langerhans cells in the presence of GM-CSF, IL-4 and 
TGF -p (410). Triggering by dsRNA viruses also triggers the production of a small amount 
of type I interferons (399). 
1.2.1.2 Plasmacytoid Dendritic Cells 
Lymphoid lineage plasmacytoid DC (pDC) have been variously described as plasmacytoid 
T cells (1983). plasmacytoid monocytes (1988) and type I interferon (lFN) producing cells 
(1970s), based upon their plasma cell-like ultrastructural features. including a round 
nucleus and basophilic cytoplasm, expression of MHC 11 and propensity to secrete large 
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Figure 1.3 Human dendritic cell subsets* 
Bone marrow CD34+ progenitors differentiate into blood CD2+1- plasmacytoid (p) DC, 
myeloid (m) DC, CD14+ monocytes, y8 T cells and NK cells. In the presence of growth 
factors such as GM-CSF and IL-4 monocytes can differentiate into Langerhans cells, 
which reside in the epidermis, or monocytes-derived (Mo) DC. pDC preferentially migrate 
direct from the peripheral blood to the lymph nodes. mDC migrate from the blood to the 
tissues, where they act as the body's sentinels, from there migrating to the lymph nodes 
through the afferent lymphatics. y8 T cells and NK cells may acquire antigen-presenting 
functions following antigen insult such as from E. coli. 
• Adapted from (401) 
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amounts of the type I interferons (IFN), 70-1000 times that of other cells, upon viral 
stimulation (399, 411, 412). The low frequency of pDC in PB, less than 0.3% of all 
circulating mononuclear cells (29) (33, 34), has confounded their classification. It was not 
until the late 1990's that pDC were formally defined as a distinct and unique dendritic cell 
subset, identified as CD303 (BDCA-2)+/CD304 (BDCA-4t/CDI23 (IL-3Ra)high/CD11c-
IHLA-DR+/CD45RA+, lacking both CD13 and CD33 but expressing the lymphoid specific 
transcripts preT-cell receptor a, immunoglobulin (Ig) A-like 14.1 and Spi-B (412-415). 
Requiring IL-3 for growth and survival in vitro, pDC can secrete, in addition to the type I 
IFNs, TNF-a, IL-6, IL-lO and IL-15 (411,412). 
1.2.1.3 Murine DC subsets 
In the mouse, up to six DC subtypes have been identified and can be distinguished by CD4 
and CD8 expression (Table 1.5). Three distinct myeloid CD11chi DC subtypes have been 
delineated in spleen, CD4-/CDS+, CD4+CDS-, CD4-/CDS-. Lymph nodes contain two extra 
subtypes thought to have migrated from the tissue to the lymph nodes, CD4-/CDS-
/CD2051°/CDllb+ interstitial DC and CD4-/CDS1o/CD20Shi/langerin+ langerhans cells (416-
41S). In recent years a CD4-1+/CDS-1+ plasmacytoid DC subset has been identified and can 
be distinguished from myeloid DC by CDllc10IMHC n1o/B220 hi /120GS+ /mPDCA-l+ 
expression (419-422). Murine DC subsets are remarkably phenotypically similar to their 
human counterparts, with the exception of CD8, although no evidcnce suggests this is 
functionally significant. In addition murine, but not human, pDC express CDllc, albeit at 
low levels. 
Murine DC subsets share the majority of their functional features with human DC subsets, 
in particular type I IFN secretion from pDC and IL-12 secretion predominantly by mDC. 
The remainder of this review will focus upon the human DC subsets only, in particular 
their function with regard to maturation status. 
1.2.2 Immature Dendritic Cells 
1.2.2.1 Tissue Localisation 
Migration of precursor DC from PB into tissue induces differentiation to an immature 
state. Immature tissue mDC can be further classified according to anatomic location and 
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Table 1.5 Phenotype of murine DC subsets* 
CD4-CDS+ CD4-CDS- CD4+CDS- CD4-CDShi CD4-CDS10 pDC 
Phenotype 
CDS + hi 10 +/-
CD4 + +/-
CD11b + + + + 
CD11c hi hi hi hi hi 10 
B220 + 
Ly6c + 
CD45RB + + + + + +++ 
DEC-205 + +/- hi 10 
1200S + 
mPDCA-l + 
• Adapted from (399, 423, 424) 
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subsequent functional niche (Figure 1.2). Langerhans cells, identified by the expression of 
the lectin langerin (CD207) (425) and presence of Birbeck granules (426) reside in the 
epidennal layer of the skin, while interstitial DC expressing intracytoplasmic 
transglutaminase clotting factor XIIIa (427) and the lectin DC-SIGN (428) reside in the 
dennallayer (383). Interstitial DC are also located in the interstitial connective tissues of 
non-lymphoid organs (429), while follicular DC are found in the B cell areas of the spleen 
and Peyer's patches (430). 
Originally Langerhans cells were thought to be the DC subset responsible for 
communicating antigen from the skin to na"ive T cells in the cutaneous lymph nodes (LN). 
Recent advances however have revealed that interstitial DC residing in the dennis precede 
Langerhans cells to the cutaneous LN following exposure to antigen, migrating within 
hours as compared to 3 days for Langerhans cells (431). It has subsequently been 
suggested that Langerhans cells have evolved to present antigen in situ to effector or 
memory T cells, or alternatively, to respond to pathogens for which a delayed migratory 
response is beneficial (432). 
While circulating PB mDC enter peripheral tissues, migrating to the lymph nodes via the 
afferent lymphatics (395, 433, 434), circulating PB pDC are recruited directly to lymphoid 
tissues through high endothelial venules (HEV) in a CD62L, CXCL9 and CD62E 
dependent manner (435, 436). To date pDC have been identified in the spleen and T cell 
areas of the secondary lymphoid tissues (395, 412). In the steady-state pDC are 
predominantly absent from sites of pathogenic entry to the body, however they have been 
identified infiltrating sites of inflammation including the dennal layer of the skin in such 
conditions as psoriasis (437), cutaneous lupus erythematosus lesions (438) and lesional 
Lichen planus (439). The contrasting migratory properties of the precursor DC subsets 
result from differential CC chemokine receptor (CCR) expression. 
1.2.2.2 Chemokine Receptor Expression 
The ability of immature DC to home to sites of inflammation and antigen is an integral 
component to their function as APC. This migratory capacity is enabled by high 
expression of the proinflammatory chemokine receptors CCRI, CCR2, CCR5, CCR6 
(Langerhans cells only), and CXCRl which respond to inflammatory chemokines such as 
macrophage inflammatory protein-la (MIP-Ia), monocyte chemotactic protein-l (MCP-I) 
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and regulated on activation normal T cell expressed and secreted (RANTES) (440, 441). 
Although pDC and mDC display many of the same CCRs, their distinct patterns of 
migration can be attributed to differing expressions of key receptors (Table 1.6). 
Compared to precursor mDC, precursor pDC express higher levels of CCR5, CXCR3 and 
significantly, the pivotal chemokine receptor driving DC migration to the lymph node, 
CCR7 (442). It is consequently thought that in the steady state, pDC comprise the most 
abundant DC population in lymphoid organs. Moreover, pDC have been identified as the 
dominant cytokine producing DC subset within the human lymph node (443). The rapid 
infiltration of pDC to sites of inflammation is also directed by the expression of serpentine 
chemokine-like receptor 1 (CMKRlIChemR23), the ligand for the chemotactic agent 
chemerin, which is activated during blood coagulation (444), and expressed selectively by 
HEV in secondary lymphoid organs and inflamed endothelium (445). 
The migratory capacity of DC, coupled with their propensity for antigenic capture make 
immature DC vital sentinels of the periphery. 
1.2.2.3 Antigen Capture 
Immature mDC are able to efficiently capture and process antigens at ambient picomolar 
and nanomolar concentrations via macropinocytosis (446), receptor-mediated endocytosis 
via C-type lectin receptors (mannose receptor, DC-SIGN, DEC-205, langerin) or Fcy type I 
(CD64) and II (CD32) receptors, and phagocytosis of particles such as apoptotic and 
necrotic cell fragments via CD91, U vP3, uvPs integrins and the thrombospondin reccptor 
CD36 (447, 448). Furthermore, immature DC can internalise peptide loaded heat shock 
proteins (Hsp) gp96 and Hsp70 (395). 
While the ability ofmDC to uptake antigen has been convincingly established, the antigen-
capturing competence of pDC is in debate. In vitro studies comparing the capacity of 
mDC and pDC subsets to phagocytose apoptotic and necrotic K562 leukaemia cells 
revealed no evidence of phagocytosis by pDC (449). However other studies have 
suggested that the capacity for phagocytosis and pinocytosis is intact in pDC, albeit weak 
in comparison to mDC (450, 451). Furthermore, pDC express a unique C-type lectin 
receptor, CD303 (BDCA-2), which may act as an antigen-capturing molecule (413). In 
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Table 1.6 CC Chemokine Receptor expression on mDC and pDC* 
Immature 
Mature 
Myeloid 
CCR2 high CXCR4 high 
CCR3 10 CCR4 10 CXCRl lo CXCR2 10 
CCR5 10 CCR7 10 CXCRJ lo 
CCR6 (Langerhans cells only) 
CCR2 10 CCR5 10 CXCR3 10 CXCR4 10 
CCR7 high 
Plasmacytoid 
CCR2 high CXCR4 high 
CCR3 10 CCR4 10 CXCRl lo CXCR2 10 
CCR5 high CCR7 hlllh CXCRJ hleh 
CMKRl (ChemR23) high 
CCRI lo 
CCR2 10 CCR5 10 CXCR3 10 CXCR4 10 
CCR7 high 
CCR, CC chemokine receptor; CXCL, CXCR, CXC chemokine receptor; CMKRl, serpentine chemokines-
like receptor I. 
• (395, 442-444) 
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addition to this, CpG oligodeoxynucleotide (ODN) and influenza virus matured pDC are 
capable of stimulating antigen-specific memory recall T cell expansion and, in the case of 
influenza virus, antigen-specific primary and secondary CD4+ and CD8+ T cell expansion 
and differentiation in vitro (422, 452-456). Thus pDC function may be antigen and context 
dependent such that comparable studies with mDC in vitro are rendered meaningless. 
1.2.2.4 Antigen Processing 
Immature mDC and pDC produce large amounts of MHC class 11 molecules, localised to 
MHC class II-rich late-endosomal compartments, that can be loaded with captured 
antigenic peptide ready for transport to the cell surface for presentation (457-462). MBC 
II gene expression is controlled by the non-DNA binding coactivator MHC class 11 
transactivator (CIIT A), which in turn is regulated by three independent promoters pI, pIli 
and plV (463). The promoter pI regulates CIITA expression in all myeloid lineage APC, 
including mDC, whereas the promoter pIlI strictly regulates APC of lymphoid origin 
including pDC (464). It is likely that these differences impact fundamentally on the 
antigen presentation capabilities of the two subsets, particularly as cellular maturation and 
up-regulation of surface MHC II triggers pI mediates shutdown of MHC II biosynthesis in 
mDC but not pDC maturation (464). 
In the steady state, antigen engulfment is thought to induce a tolerogenic immature DC 
phenotype characterised by low CD86 and HLA-DR expression, but increased expression 
of the lymph node homing CCR7. It is in the lymph node that these immature DC can 
induce tolerance. In contrast, a pro-inflammatory microenvironment, characterised by 
cytokines such as TNF-a and IL-I p and toll-like receptor (TLR) triggering ligands such as 
LPS and bacterial DNA, induces en masse DC migration and differentiation (465). 
Whether immature DC, encountering antigen in the absence of danger signals, or non-
activated mature DC are responsible for the induction of tolerance - and hence represent a 
tolerogenic DC phenotype is a matter requiring clarification. 
1.2.2.5 Differential Pattern-Recognition Receptor Expression 
DC express germ-line-encoded receptors known as pattern-recognition receptors, which 
include toll-like receptors (TLR), C-type lectins (for example DC-SIGN), NOD (for 
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example NOD2) and Mannose receptors. Pattern-recognition receptors recognise different 
pathogen-associated molecular patterns (P AMPS) associated with (for example) bacterial, 
viral, protozoan or fungal infection, playing a crucial role in the early phase of antigen 
uptake and subsequent immune response. It has been suggested that pDC and mDC may 
have evolved to combat different types of pathogens based upon their differential 
expression of pathogen-recognition receptors (Table 1.7). Similar subset propensity for 
antigen may be based on physiochemical properties. Thus the preferential expression by 
mDC of TLRl, 2, 4 and 6 makes them particularly suited for stimulation by lipid-based 
P AMPs. Similarly, numerous reports indicating that pDC have an aptitude for the 
presentation of endogenous antigens and viral antigens may be explained by their selective 
expression of intracellular TLR7 and TLR9. 
1.2.3 Mature Dendritic Cells 
TLR, NOD or lectin signalling modulates pleiotropic effects on immature DC evolved to 
best facilitate the translation from innate recognition to an adaptive immune response and 
as such constitutes one of the pivotal control points of immunity and potentially 
autoimmunity. Cytoskeletal re-modelling is accompanied by down-regulation of the 
inflammatory chemokine receptors, but upregulation of the lymphoid homing receptors 
CCR4, CXCR4 and CCR7 (466) (Fig. 1.4). The maturing DC then migrate to lymphoid 
tissue via the lymphatics in response to secondary lymphoid tissue chemokine (SLC), 
produced by lymphatic endothelial cells, and Epstein-Barr virus-induced ligand chemokine 
(ELC), produced by stromal cells and DCs in T cell aggregates (395, 408, 466). 
Macrophage-derived chemokine (MDC), thymus and activation-regulated chemokine 
(T ARC), pulmonary and activation-regulated chemokine (PARC) and IFN-,,(-inducible 
protein (IP-I 0) produced by mature DC in the lymph nodes, further enhance migration and 
promote DC to interdigitate to T cell areas of the lymph node (396). During this 
differentiation process, DC down-regulate the ability to capture and process antigen, but 
up-regulate the molecules required for efficient antigen presentation including peptide-
loaded MHC I and 11 molecules, the costimulatory molecules CD80, CD86 and CD58 and 
signalling molecules CD40 and TRANCE/RANK-L (395). Thus mature DC are efficiently 
equipped to present antigen to T cells, generating antigen-specific effector lymphocytes 
that migrate back to the site of inflammation, hence initiating the adaptive immune 
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Table 1.7 Toll-like Receptor expression by DC and their specific agonists. 
roDC 
TLRl + 
TLR2 + 
TLR3 + 
TLR4 + 
TLRS 
TLR6 + 
TLR7 + 
TLR8 + 
TLR9 
TLRIO 
pDC 
+ 
+ 
+ 
+ 
+ 
Ligand 
Forms heterodimers with TLR2 to detect pam3cys(467) 
Peptidoglycan (PGN)( 468), mycoplasma lipoprotein (MALP)( 469), 
HMGB 1 (470) 
DsRNA, polyriboinosinic:polyribocytidylic acid (poly(l:C)( 4 71) 
Lipopolysaccharide (LPS)(472), Lipid A analogs(473), 
mycobacterial components( 474), fibrinogen( 4 7S), surgactant( 476) 
protein-A(477), heparan sulphate(478), soluble hyaluronan(479), p-
defensin 2(480), highmobility group box 1 protein (IIMGBl)(470), 
Hsp60(481), Hsp70(482) Gp96(483) 
Bacterial flagel1in( 484) 
Lipid based P AMPs( 48S), required for TLR2 signalling recognition 
ofPGN(486) 
lmidazaquino}ines (imiquimod, R848) and guanosine analogs 
(Loxoribin)(487), ss RNA, GV-rich ssRNA (488, 489) 
ss RNA, GV-rich ssRNA, R848 (488, 489) 
Bacterial unmethylated deoxy-cytidylate-phosphate-deoxy (epG) 
DNA (490) 
?? 
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Figure 1.4 Dendritic cell maturation 
Signalling immature dendritic cells (DC) through pattern-recognition receptors, CD40L or 
soluble factors such as TNF-a induces maturation. Maturation is accompanied by 
cytoskeletal re-modelling, down-regulation of antigen up-take but up-regulation of antigen 
presentation and MHC II expression. In addition mature DC up-regulate co-stimulation 
and maturation receptor expression and pro-inflammatory cytokine release as well up-
regulating lymph node homing chemokines receptor expression. As such maturation best 
facilitates the translation from innate recognition to adaptive immunity. 
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response. The direction in which the response is skewed is, however, dependent upon DC 
lineage, the maturation stimulus and the inflammatory mediators present at the site of 
infection (491). 
1.2.3.1 Interactions between DC and T cells 
The traditional paradigm for T cell activation by DC is based upon a bimodal model. 
Interaction of antigen-specific TCR with the MHC 11 peptide complex on DC induces T 
cell anergy (Signal 1). In order to generate T cell activation, IL-2 production and 
immunity, additional sustained co-stimulation by CD28/CDSO/CD86 is required (Signal 2) 
(492) (Fig. 1.5). Optimal T cell activation is achieved by fonnation of an immunological 
synapse composed ofa ring ofLFA-lIICAM-l interactions that stabilises the TCRlMHC 11 
and CD28/CDSO/CD86 complex (493). Of note, CTLA-4 (CDI52), expressed by activated 
T cells, has 10-20 times greater affinity to CD80/S6 binding than does CD28. As such 
CTLA-4/CD80/CD86 is one critical mechanism by which the T cell response is modulated, 
exemplified by lethal lymphoproliferative disease in CTLA-4 knockout mice (494, 495). 
Additional modulation is likely provided by DC expression of the B7 family members 
ICOS-L and the inhibitory receptor programmed cell death receptor-l (PDCD-l) (496, 
497). 
The differentiation and expansion of activated CD4+ T cells into Th 1 or Th2 cells is 
dependent upon additional DC signalling and soluble factors in the micro-environment. 
Thl cells release pro-inflammatory cytokines including IFN-y, enhance macrophage 
cytokine release (IL-6, TNF-a) and are important for cellular immunity. In contrast Th2 
cells release anti-inflammatory cytokines, IL-4 and IL-5, and promote humoral immunity. 
Initial investigations suggested that mDCs and pDCs possessed an intrinsic ability to 
polarise naive T cells towards a Thl or Th2 phenotype respectively. This observation was 
largely based upon the mDC secretion of IL-12, but pOC secretion of IFN-a, following 
C040L stimulation (412). However, it is now recognised that while pOC prime T cells to 
secrete IL-4 (type 2) following incubation with IL-3 and C040-L, they can also induce T 
cells to produce IFN-y (type I) and IL-IQ (regulatory T cells) when given a viral stimulus 
(498). Moreover, pDC can (in common with mDC), produce high levels of IL-12p70 in 
response to CD40 ligation when accompanied by bacterial CpG motif stimulation (402, 
499). 
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Figure 1.5 The two signal model of T cell activation by dendritic cells 
According to the traditional paradigm of T cell activation by dendritic cells (DC), antigen-
specific T cell receptor (TCR) interacts with the MHC II peptide complex (Signal 1), 
which alone induces T cell anergy. T cell activation is generated by additional sustained 
signalling by CD281 CD80/CD86 (Signal 2). 
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Signal 1 only Signal 1 + 2 
DC 
MHC III CD80/CD86 
Na'ive T cell Na'ive T cell 
Anergy 1,L-2 
Thus the capacity of DC to initiate a given immune response does not appear to be an 
intrinsic quality, but rather a consequence oflocal environmental pressure. 
1.2.4 Tolerogenic DC 
The development of central tolerance in the thymus, whereby self-reactive T cells and B 
cells are eliminated through clonal deletion is an imperfect process, allowing some self-
reactive lymphocytes to escape to the extra-thymic regions. Self-reactive lymphocytes are 
consequently present in the normal immune repertoire (500). The maintenance of 
peripheral tolerance by dendritic cells (DC), through cell-contact and cytokine mediated 
modulation of the immune response, is therefore critical in preventing pathological self-
reactivity. Traditionally, tolerance has been considered a paradigm of maturation, whereby 
immature DC induce T cell anergy or Treg cells, but mature DC exclusively induce 
immunogenic primary T cell response. However, this is an over-simplistic model, 
particularly as processing and presentation of antigen, requires at least some DC 
maturation. 
Evidence now indicates a role for semi-mature DC, loaded with tissue antigen, migrating 
to lymph nodes (501, 502). In the absence of additional 'danger' stimuli, such as Hsp60 or 
LPS, these DC are arrested in a semi-mature state and do not produce the pro-
inflammatory stimuli required for T cell activation (503, 504). IL-lO and TGF-p are 
classically associated with 'licensing' DC tolerogenicity by inhibiting DC maturation 
(505), although additional emerging tolerogenic inducing factors include vasoactive 
intestinal peptide (VIP), thymic stromal lymphopoeitin (TLSLP) and G-CSF (506-509). 
Of note, self-antigen may be cross-presented to tolerising lymph node resident DC by 
short-lived DC that migrate through the afferent lymph from peripheral tissues (510). It is 
now generally accepted that DC induction of tolerance or immunogenicity relies on a 
combination of factors including DC lineage and maturation status (immature/semi-
mature/mature), local cytokine milieu and antigen dose (Fig. 1.6). The expression of 
inhibitory receptors such as PDCD-I, DEC-205 and immunoglobulin-like transcript 3 and 
4 (ILT3/ ILT4), as well as low NF-KB activation, are associated with semi-mature DC 
(511-513). However DC tolerogenicity is more a functional, as opposed to a lineage 
specific phenotype. Functional features include modulation of peripheral tolerance by 
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Figure 1.6 Anergy, tolerance or activation is dependent upon dendritic cell 
maturation 
The current model of dendritic cell (DC) induction of anergy, tolerance or activation, 
whereby immature DC induct T cell anergy, but semi-mature DC can stimulate conversion 
of naIve T cells by a combination of co-stimulatory molecule expression and IL-I 0 release. 
Fully mature DC can promote T cell activation and clonal expansion, according to the 
traditional 2-signal model of T cell activation. However, in addition to this mature DC 
may also expand pre-existing Treg, which can in turn modulate the DC directed adaptive 
Immune response. 
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1.2.4.1 Indoleamine 2,3-dioxygnease 
Indoleamine 2,3-dioxygenase (IDO) mediates T cell homeostasis and self-tolerance by 
catabolism of the essential amino acid tryptophan to kynurenines in the local tissue 
environment which physiologically regulates T cell proliferation and survival (514). In 
chronic immune activation, tryptophan availability is reduced, leading to inhibition of cell 
proliferation. As such, IDO has a complex role in immunoregulation in infection, 
pregnancy, transplantation, neoplasia and auto immunity. DC are distinct in their 
expression oflDO functional activity and in the modulation of this activity by IFN-y. This 
may represent a self-limiting feedback mechanism whereby autocrine or paracrine IFN-y, 
from Thl and Treg cells, NK cells or NK T cells, induces DC mo thus inhibiting T cell 
proliferation and triggering T cell apoptosis by depletion of tryptophan (515). Indeed, 
IFN-y ablates the disease-promoting potential of DC from NOD mice, and renders these 
cells protective in diabetic recipients (516). Furthermore, DC tolerogenic function can be 
restricted by CD40 ligation and IL-6 down-regulation of IFN-yR expression (517) and may 
represent a key mechanism of autoimmunity. 
1.2.4.2 DC induction of Treg 
Induction and expansion of CD4+/CD25+/Foxp3+ Treg by semi-mature mDC and pDC 
triggered by treatment with tolerogenic 'licensing' factors, has been demonstrated in a 
number of models including G-CSF treatment in spontaneous type I diabetes in NOD mice 
(508, 509) and VIP differentiated DC transfer to murine EAE (507). The exact cellular 
mechanisms by which Treg are induced are not well defined. However, whether Treg are 
induced by pDC or mDC appears to be a function of TLR stimulation, and as such may 
indicate a pivotal collaborative point whereby one DC subset provides regulation of the 
immune response induced by the other. 
While DC function is undoubtedly critical to maintenance of the immune system it may 
also carry inherent immunological risks. It has been hypothesised that maturing DC may 
present peptides from dying self-tissue and environmental proteins as wen as from 
pathogens, when encountered in a highly inflamed environment. While immature DC 
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induced antigen-specific peripheral tolerance in the steady state should account for this 
risk, in susceptible individuals chronic inflammatory and autoimmune disease may ensue. 
1.3 Dendritic Cells and Autoimmune Disease 
Autoimmune disorders are characterised by the abolition of self-tolerance and subsequent 
emergence of self-reactive lymphocytes. As the only professional APC recognised to date 
as capable of provoking an auto immune disease, DC have been implicated in the initiation 
and perpetuation of systemic lupus erythematosus (SLE) (518), experimental auto immune 
encephelomyelitis (EAE) (519), thyroiditis (520), diabetes (521), Sjogrens Syndrome 
(522), multiple sclerosis (523), psoriasis (524), psoriatic arthritis (525), juvenile idiopathic 
arthritis and rheumatoid arthritis (273). Numerous animal models of spontaneous 
auto immune disease have identified DC as amongst the first cells to infiltrate target tissue, 
highlighting the potency with which DC, expressing endogenous self-peptides or pulsed ex 
vivo with immunogenic self-peptide, can prime autoreactive T cells (526) (527-529). 
1.3.1 Evidence for a Role for Dendritic Cells in Inflammatory Arthritis 
1.3.1.3 Dendritic Cells in Inflamed Synovium 
The arthritic synovium, considered an ectopic lymphoid organ, is characterised by a 
complex cellular infiltrate composed of T cells, B cells, monocytes, macrophages, mast 
cells and DC (295). DC are enriched in both synovial fluid (SF) (530-532) and synovial 
membrane (SM) (274, 533-535). SF DC, despite the inflammatory environment, express a 
less mature, CD80-/CD83 10 phenotype most likely resulting from the presence of 
suppressive factors such as TGF-p, which has been shown to inhibit DC-T cell interactions 
in patients with chronic arthritis (536, 537). Conversely, SM DC are found in the 
perivascular area, localised to lymphocytic aggregates and are reported to exhibit a 
predominantly mature phenotype with high expression of T cell costimulatory molecules, 
MHC I and II (535, 538), nuclear RelB (539), adhesion molecules and STAT 4 (540). 
Immunohistochemical analysis of SM chemokine expression has correlated this mature 
CCR7+ DC homing to lymphocyte derived CCL19121 release (534). The DC maturation 
gradient may reflect migration of immature SF DC to the SM and in situ maturation, 
supported by the localisation of immature CCR6+/ CDla+ DC in macrophage inflammatory 
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protein (MIP)-3a (CCL-20) rich areas of the synovial lining layer (534,541). Alternative 
evidence supports a model whereby over-expression of the precursor DC chemoattractants 
MIP-Ia, MCP-I and RANTES, coupled with the TNF-a driven up-regulation of adhesion 
molecules induces the transendothelial migration of PB DC direct to the SM (538). 
According to this model, monocyte shedding to the SF and subsequent differentiation into 
mDC may account for SF DC, supported by the presence of multiple growth and 
differentiation factors including GM-CSF, TNF-a and IL-1 (538,542). However, this does 
not account for the presence of immature pDC in SF (106, 125). 
Clearly, the analysis of DC infiltrates in the inflamed synovium is by no means definitive 
with the complexity inherent in studying such a transient population of cells amplified by a 
paucity of specific DC markers and reliable quantitation. While mDC are enriched in both 
SF and SM, pDC have been only sparsely analysed but are also found in SF and SM (106, 
125). The relatively recent identification of the novel pDC marker CD303 (BDCA-2) 
(397) will facilitate the more thorough characterisation of pDC and their role, if any, in 
disease pathogenesis. Of interest, numerous cases of arthritis triggered by IFN-a. therapy 
of previously non-arthritic patients, which resolved following cessation of treatment, have 
been reported (543-549), implicating this type I interferon in disease pathology and, by 
association, the cells which produce it. Thus the necessity for more thorough 
characterisation of the presence and functional role of different DC subsets in 
inflammatory arthritis is clear. It can be envisaged that greater understanding of the 
involvement of the innate events involved in disease pathology could lead to therapeutic 
strategies inhibiting aberrant perpetual activation 
Clearly, extensive evidence from human studies implicates DC in the pathogenesis of 
inflammatory arthritis. However, elucidation of the direct functional roles that DC play in 
the initiation and perpetuation of the disease has come from exemplary murine studies. 
1.3.1.2 DC involvement in murine models of arthritis 
The early infiltration of (m) DC to the target tissue of inflammation in collagen-induced 
arthritis (CIA), spontaneous arthritis in MRUlpr mice (550) and antigen-induced arthritis 
in rats (551, 552) has been demonstrated. Of particular note, Brewer and Leung have 
clearly demonstrated the capacity for DC in arthritis induction using ex vivo collagen type 
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II-pulsed, bone-marrow differentiated mDC, to induce arthritis in joints adjacent to the site 
of injection (553). Furthermore, administration of TNF antagonists was sufficient to 
inhibit arthritic progression in this model. Similarly, adoptive transfer of T -box expressed 
in T cells (T -bet) expressing DC was sufficient to re-constitute inflammation in RAG2-1-
Tber/- mice, otherwise resistant to collagen antibody-induced arthritis (554). Of particular 
interest, transfer of DC, genetically modified to over-express IL-4, to murine with 
established CIA reduced IFN-y production and collagen type 11 reactivity thus reducing 
disease severity and demonstrating a potential for manipulation of DC as a therapeutic 
vector (555). To date, no analysis of the potential contribution of pDC to murine models 
of arthritis has, as yet, been undertaken. 
1.3.1.3 Pharmacological modification of DC 
Given the central role that DC play in the maintenance of immunity and induction of 
tolerance, in combination with the evidence supporting their integral functional role in 
initiating inflammation, they present an attractive therapeutic target. However, much of 
the evidence - particularly from murine models - concerns their role in the triggering 
stages of arthritis. The majority of therapies are aimed at disrupting the mechanisms 
perpetuating inflammation, as it is at this stage that most patients are diagnosed with 
disease. While a number of drugs have biological effects on DC, the link between these 
effects and the therapeutic efficacy are unclear (Table 1.8). Promisingly, a number of 
studies analysing the efficacy of a variety of therapies, including disease modifying anti-
rheumatic drugs (DMARDs), TNF-blocking therapies and the newer CTLA4Ig have 
observed specific effects on DC, which may be intrinsically associated with the therapeutic 
efficacy of these drugs. 
1.3.1.3.1 DMARDs and DC 
The active metabolite of the potent DMARD, leflunomide, A 77 1726, interferes with mDC 
function by reducing expression of the co-stimulatory molecules CD40 and CD80 and 
subsequently abrogating DC initiated T cell proliferation. Furthermore, both IL-12p70 and 
TNF-a production is impaired and NFKB completely suppressed by A77 1726 and its 
derivative FK778, even in the presence ofLPS or CD40L (556,557). 
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Table 1.8 Biological effects of drugs on DC 
Agent 
Cortocosteroids 
1,25 (OHh vitamin D3 
H ydrochloroquine 
Cyc1osporin 
Mycophenolate 
CD2 binding fusion protein 
(Alefacept) 
Anti-COlla (Efalizumab) 
A77 1726, the active 
metabolite of Leflunomide 
CTLA-4Ig 
Biological Action on DC 
Suppresses number of pDC precursors; restrains monocyte differentiation into 
DC; suppresses IL-12 production; enhances IL-10 production by DC(558-
560) 
Restrains monocyte differentiation into DC; suppresses monocyte derived DC 
maturation; suppresses IL-12 production; enhances IL-IO production by DCs; 
modulates DC responses to chemotactic signals(561, 562) 
Prevents lysosomal vacuole acidification(563) 
Suppresses TNF production(564) 
Retards DC maturation; reduces IL-12 production(565) 
Reduces CD83+ and CD 11 c + expressing DC in psoriatic lesions in psoriasis; 
suppresses IL-23 production(566) 
Reduced infiltration of langerin-/CD 14-/lfLA-DR+CD40+/CD86+ IDC-
LAMP+/CD83+ DC to psoriatic skin lesions in psoriasis(567) 
Suppresses IL-12 production by mDC; reduces expression of co-stimulatory 
molecules; inhibits NFKB, suppresses TNF-a production by mDC(556, 557) 
Activates pDC lOO production(568) 
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1.3.1.3.2 TNF neutralisation and DC 
Analysis of the mode of action of TNF blocking (etanercept) therapy has been assessed in 
psoriasis. Immunohistochemical analyses revealed that TNF blocking led to a gradual 
decrease in CD 11 c + DC infiltration to psoriatic plaques, which was likely attributable to a 
decrease in MIP-3a. Also decreased was both IL-23 mRNA and iNOS mRNA and protein 
commensurate with a decrease in DC activity (569). Consistent with this report, TNF-a 
has been shown to enhance the phenotypic and functional maturation of human Langerhans 
cells, with up-regulation of CD40/CD54/CD86/CD83IDC-LAMP/CCR7 and down-
regulation of langerin, inducing both IL-12p40 and IFN-y-inducible-protein (IP-
lO)/CXCL-IO, a Thl-attracting chemokine (570). Therefore TNF blockade may break the 
potentially self-sustaining cycle of DC activation and maturation. 
1.1.3.1.3 CTLA-4/g and DC 
CTLA-4Ig binds CD80/86 with high affinity, thus blocking CD28 and inhibiting DC-T cell 
contact and T cell activation. CTLA-4 Ig infusion has been shown to reverse the activation 
status of DC in psoriatic plaques as well as their accumulation to psoriatic plaques. (571). 
Furthermore, the study suggested that the specific co-stimulation of T cells through CD28 
is pivotal to creating the inflamed microenvironment in which autoimmune inflammation 
is perpetuated. However, these signals alone are not sufficient to initiate the chronic 
inflammatory cascade - this is likely to occur due to a number of factors including genetic 
pre-disposition of the host, increased levels of autoantigen and autoreactive T cells, 
elevated MHC II antigens and enhanced inflammatory cytokines. In this study B7-
CD28/CTLA4 blockade down-regulated a variety of pro-inflammatory stimuli resulting in 
a longer clinical response than had been observed in other T -cell based therapies. The 
durable response may have been attributable to IFN-y secretion, triggered by CTLA-4 Ig. 
IFN-y has an immediate autocrine effect upon DC that results in IDO secretion (568), 
which was up-regulated in psoriatic plaque infiltrating pDC (discussed 1.2.4.1). Of note, 
CTLA-4Ig was not toxic to DC, thus their depletion in the psoriatic lesions was probably 
attributable to down-regulation of endothelial adhesion molecules thus impairing their 
ability to enter the site. 
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1.4 Summary and Hypothesis 
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory 
arthropathies of heterogeneous aetiology affecting 2-3% of the general population. 
Extensive in vivo and in vitro studies have identified the multiple pro-inflammatory 
cytokines and enzymes implicated in the pathogenesis of these disorders culminating in 
therapeutically beneficial cytokine targeted therapies. Cytokine blockade however exhibits 
variable responses across patient populations and importantly disease activity recurs upon 
cessation of therapy. The critical challenge in therapeutics now is to uncover the 
underlying immunological processes responsible for the generation and perpetuation of 
inflammatory arthritis such that peripheral tolerance can be re-established and therapeutic 
remission can be maintained. Of particular interest are the co-stimulatory molecule and 
cytokine mediated interactions bridging the innate and adaptive immune response, notably 
those initiated by the interaction of dendritic cells (DC) with T cells, as the evolution of the 
latter is profoundly influenced by these cognate and soluble interactions. DC are the only 
APC recognized to date as capable of provoking autoimmune disease. DC biology thus 
embodies an important line of investigation in determining the initial triggers that generate 
and (of therapeutic significance) maintain chronic inflammatory arthritis. However, to 
date there have been very few investigations of the phenotype and function of DC, in 
particular with reference to DC lineage. 
The central hypothesis of this thesis is that the comprehensive characterisation of dendritic 
cell subsets, plasmacytoid (p) DC and myeloid (m) DC, in the blood and primary target 
tissue of chronic inflammatory arthritis patients would clarify their contribution to the 
initiation, modulation and perpetuation of inflammatory arthritis. Accordingly, this thesis 
has utilized a combination of in vitro and in vivo analyses in order to examine the aberrant 
accumulation to, and function within, the inflamed synovium from PsA and RA patients. 
1.4.1 Specific Aims and Objectives 
• Characterise mDC and pDC phenotype and provisional function in inflammatory 
synovitis patients; 
• Explore the effects ofTNF blockade on such DC subsets; 
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• Perform in vitro assays to determine human DC function ex vivo; 
• Explore the regulation of DC subsets in vitro using a novel cell culture model - in 
particular to rationalise the co-expression ofTNF and IL-15 in this context; and 
• Use an in vivo model of inflammatory arthritis to formally test the hypothesis that 
DC subsets perform distinct roles in initiation and perpetuation of inflammatory 
arthritis. 
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Chapter 2: Materials and Methods 
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2.1 Patients and Controls 
Inflammatory arthritis patients fulfilled the American College of Rheumatology (formerly, 
the American Rheumatism Association) criteria for RA (23), or met a diagnostic criteria 
for PsA as previously described (572, 573). All patients and healthy donors gave informed 
consent and the study protocol was approved by the Ethical Committee, Glasgow Royal 
Infirmary, Scotland, and by the Medical Ethics Committee of the Academic Medical 
Center in Amsterdam, The Netherlands. Specific patient details for each study are located 
in the pertinent results chapters (3.2.1, 4.2.1, 5.2.1). 
2.1.1 Clinical assessment 
Full demographic details and list of current medications were recorded for each visit at the 
time that sample (peripheral blood, synovial fluid or synovial membrane) was obtained. 
2.1.2 Parameters of disease activity 
Disease activity was assessed during clinic visit by the clinician using standard hospital 
diagnostic laboratory techniques. 
2.1.2.1 Joint scores 
Clinical assessment was performed at the screening visit for tenderness and swelling of 
each peripheral joint. The Disease Activity Score in 28 joints (DAS28) was calculated. 
2.1.2.2 C-reactive protein 
C-reactive protein (CRP) levels were measured by standard nephelometry and are reported 
in units ofmglL. 
2.1.2.3 Erythrocyte sedimelltatioll rate 
Erythrocyte sedimentation rate (ESR) was measured by standard Westergren method and 
are reported in units ofmmlhour. 
2.1.2.4 Auto-alltibodies: rheumatoid/actor 
Rheumatoid factor (RF) was measured by Enzyme-Linked-ImmunoSorbent Assay 
(ELISA). 
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2.2 Animals 
6-8 week old female BALB/c mice were purchased from Harlan (Bicester, UK) and used 
for in vitro experiments and as Tg CD4+1KJ1.26+ T cell transfer recipients in the OVA TcR 
transgenic model of arthritis. DOl1.10 BALB/c TCR Tg mice containing CD4+T cells 
expressing a TCR that recognizes the chicken OVA peptide 323-339 complexed with the 
MHC class II molecule I-Ad (detected by the clonotypic mAb KJ1.26) (574), were used as 
Tg CD4 T cell donors (bred in-house, Central Research Facility, University of Glasgow, 
Glasgow, UK). 6-8 week old female DBAlI mice were purchased from Harlan (Bicester, 
UK) and used for in vitro experiments and in the collagen-induced arthritis (CIA) model. 
2.3 Antibody Preparation 
2.3.1 F(ab')z fragmentation 
Human anti-IL-15 and human IgG (both were supplied by Gcnmab, Amsterdam) were 
fragmented using an Immunopure® F(ab')2 Preparation Kit according to the 
manufacturer's instructions (Pierce). Briefly, 1.0 mg of antibody was added to a tube 
containing immobilized pepsin and incubated for 4 hours in a shaking water bath at 37°C. 
A resin separator was used to separate digest from the immobilized pepsin, and 1.5 ml of 
Immunopure® IgG Binding Buffer was added. The digest was then added to an 
equilibrated column and throughput collected. The fragmented antibody was dialyzed at 
SOK MWCO, to remove small Fc fragments. 
2.3.2 Antibody purification 
The pDC depleting antibody Rat anti-mouse 120G8 IgG\1C was a generous gift from Dr 
James Brewer, University of Strathclyde, UK. The isotype control YCATE.S5.9.1 rat anti-
dog CD8 IgG\1C was a generous gift from Mark Frewin (Sir William Dunn School of 
Pathology, University of Oxford, UK). Antibody was purified from culture ascites using 
the Montage® Antibody PurificationpRosEP®G Kit (Millipore) according to the 
manufacturer's instructions. Briefly, samples were diluted 1: 1 in binding buffer (1.5 M 
glycinelNaOH buffer, 3 M NaCl, pH 9.0) and added to an equilibrated spin column and 
centrifuged at 100-150 g for 20 minutes. The throughput was collected and added back to 
the spin column as above and repeated 4 times as Rat JgGl has low affinity binding. Spin 
columns were washed in binding buffer by 2 minute centrifugation at 500 g. The bound 
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IgG was then eluted by addition of 10 ml elution buffer (0.2 M glycinelHCI buffer pH 2.5) 
and centrifugation for 5 minutes at 500 g into a tube containing 1.3 ml of neutralization 
buffer (1 M TrislHCl buffer pH 9.0). The antibody preparation was concentrated by 
centrifugation through an Amicon Ultra-IS centrifugal filter device, 30,000 NMWL 
(Millipore). Dialysis tubing was prepared by boiling for 5 minutes (Medicell International 
Ltd). Concentrated antibody preparations were de-salted by dialysis into PBS overnight at 
4°C. 
2.3.3 Protein Concentration Assay 
The final antibody concentration was determined usmg a BCA ™ Protein Assay Kit 
according to the manufacturer's instructions (Pierce). Briefly, 25 ~l of each BSA standard 
or unknown sample was added in triplicate to a 96 well NUNC MaxiSorp microplate 
followed by 200 J..lI of BCA™ working reagent. Plates were incubated at 37°C for 30 
minutes and then absorbance measured at 570 nm. The concentration of antibody in 
solution was proportional to the optical density (OD) of the standards, and concentrations 
were calculated using Microsoft Excel. 
2.4 Cell culture 
All cell culture reagents were purchased from Invitrogen Life Technologies, Sigma-
Aldrich or Gibco unless otherwise stated (see 2.10 for supplier's addresses). All cells were 
cultured at 37°C 5% CO2 in RPMI-1640 complete medium containing L-glutamine (2 mM), 
penicillin (100 IU/ml), streptomycin (100 J..lg/ml), amphotericin B (1.25 J-lg/ml) and 10% 
foetal calf serum (FCS) (all Sigma-Aldrich). For human pDC and mDC cultures, complete 
medium did not contain 10% FCS but was instead supplemented with 5% human AB 
serum (Sigma-Aldrich). 
2.4.1 Cell Lines 
2.4.1.1 BDB2 
BDB2 cells, an IL-15-dependent, human T cell line, were a kind gift of Dr. John Campbell, 
University of Glasgow, UK. BDB2 cells were cultured in complete medium supplemented 
with 10 ng/ml IL-15 (R&D Systems). 
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2.4.1.2 X63 
X63 cells are a GM-CSF transfected myeloma cell line and were a kind gift of Brigitta 
Stockinger, National Institution for Medical Research, London, UK. X63 cells were 
cultured in complete medium and the culture ascite used to differentiate murine bone 
marrow cells into myeloid dendritic cells. 
2.4.1.3 DOll.10 GFP T cell hybridoma 
The DO 11.1 0 GFP T cell hybridoma is a cell line that responds to presentation of OVA 
peptide (323-339) on the MHC Class II molecule (I_Ad) and were a kind gift from Dr 
James Brewer, University of Strathclyde, UK. Cells were cultured for 24 hours before 
adding 100 ~l/10ml Geneticin® (G418) (GIB CO, BRL) and 200 ~l/lOml HEPES buffer 
(Sigma). 
2.4.2 Primary human cell culture 
2.4.2.1 Purification ofmollonuc/ear cells from synovialfluid or peripheral blood 
Synovial fluid (SF) or peripheral blood (PB) mononuclear cells (MC) were purified by 
standard density gradient centrifugation. Briefly, SF or PB was obtained by needle 
effusion of the swollen joint or venepuncture to heparinised tubes (Leo Laboratories Ltd). 
SF or PB was then diluted 1:1 in phosphate buffered saline (PBS) (Gibco) and overlaid on 
Histopaque®-1077 (Sigma) at 3:1 in 15 ml centrifuge tubes. Tubes were centrifuged at 
800 g for 20 minutes at room temperature. The mononuclear cell layer was then harvested 
from each tube and washed three times at 300 g for 10 minutes in PBS, prior to use for cell 
culture, or ice cold PBS containing 2mM ethylene diamine tetra-acetic acid (EDT A) and 
0.5% bovine serum albumin (BSA), for cell purification (both Sigma). 
2.4.2.2 Isolation of myeloid and plasmacytoid dendritic cells 
Plasmacytoid dendritic cells (pDC) and myeloid dendritic cells (mDC) were sequentially 
purified by magnetic cell sorting (MACS; Miltenyi Biotec) using a high gradient Mini-
MACS® device, according to the manufacturer's instructions. Briefly, in the experiments 
described in chapter 3, mononuclear cells (2.4.2.1) were resuspended in 200 ~I PBSIO.5% 
BSAl2mM EDTA containing 100 ~l/107 cells anti-CD304 (BDCA-4) magnetic microbeads 
and 100 ~I FeR block (both Miltenyi Biotec) for 18 minutes at 4°C, followed by 
centrifugation at 300 g for 10 minutes. Cells were then resuspended in 500 J.lI 
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PBS/O.5%BSN2mM EDTA buffer and CD304 (BDCA-4)+ (pDC) purified by positive 
selection over a pre-equilibrated magnetic MS column (Miltenyi Biotec). Unlabelled cells 
were collected and, after washing by centrifugation at 300 g for 10 minutes, resuspended in 
200 III PBS/O.5%BSN2mM EDTA containing 100 III anti-CD19-conjugated magnetic 
microbeads (for B cell depletion) and 100 III ofFeR block and 100 III of biotin-conjugated 
anti-CDlc for 18 minutes at 4°C (all Miltenyi Biotec), followed by centrifugation at 300 g 
for 10 minutes. B cells were then depleted by retention in a magnetic MS column as 
described above. The throughput was collected, and after centrifugation at 300 g for 10 
minutes, resuspended in 200 III PBS/O.5% BSN2mM EDTA containing 100 111/1 a' cells 
anti-biotin-conjugated magnetic microbeads (MiItenyi Biotec) for 18 minutes at 4°C, 
followed by centrifugation at 300 g for 10 minutes. CDlc+mDC were then isolated by 
positive selection over a pre-equilibrated magnetic MS column. 
For the experiments described in chapter 5, CD19+ B cells were first depleted from 
mononuclear cells followed by CDlc+ mDC purification as described above. pDC were 
then isolated by negative selection by incubating the remaining cells in monoclonal biotin 
conjugated antibodies against antigens not expressed by pDC. Thus T cells, B cells, NK 
cells, mDC, monocytes, granulocytes and erythroid cells were labelled by 10 minute 
incubation at 4°C in 100 III of biotin-conjugated non-pDC antibody cocktail (Miltenyi 
Biotec), followed by two washes at 300 g for 10 minutes and incubation with 100 III anti-
biotin-conjugated magnetic microbeads for 15 minutes at 4°C. Non-pDC cells were then 
removed by retention in a magnetic LS column (Miltenyi Biotec). Unlabelled cells in the 
throughput were therefore pDC. Purity and phenotype of pDC and mDC was assessed by 
flow cytometry (as described in 2.6.2) and routinely >95% for PB purifications and >93% 
for SF purifications «10% neutrophil contamination). 
2.4.2.3 Isolation o!CD3+ Tcells and CD14+ MOllocytes 
CD3+ T cells and CDl4+ monocytes were purified by positive selection from mononuclear 
cell suspension by MACS, according to the manufacturer's instructions. Briefly, 
mononuclear cells were incubated in 200 III PBS/O.5% BSN2mM EDT A containing 100 
11111 a' cells anti-CD3-conjugated magnetic microbeads, or 100 1ll/IO' cells anti-CDI4-
conjugated magnetic microbeads (both Miltenyi Biotec) for 18 minutes at 4°C. After 
washing in PBS/O.5% BSN2mM EDTA by centrifugation at 300 g for 10 minutes, CD3+ T 
cells or CDI4+ monocytes were isolated by positive selection over a pre-equilibrated MS 
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column (Miltenyi Biotec). Purity was assessed by flow cytometry (2.6.2) and routinely 
>98%. 
2.4.2.4 mDC and pDC stimulation 
To ascertain function of DC subsets, stimulation using TLR agonists was used. Isolated 
mDC (2.4.2.2) were incubated in triplicate at 1-5xl0slml containing 50 nglml GM-CSF 
(StemCell Technologies) alone or supplemented with the TLR2 agonist Staphylococcus 
aureus peptidoglycan (PGN) at 10 J.1g1ml or the irrelevant control, TLR9 agonist CpG 
oligodeoxynucleotide (OON) 2216 (ggGGTCAAGCTTGAgggggG) at 3.2 J.1g1ml (both 
In Vivogen). Isolated pDC (2.4.2.2) were incubated in triplicate at 1-5x 1 OSlml containing 
20 nglml IL-3 (StemCell Technologies) alone or supplemented with CpG OON 2216 at 3.2 
J.1g1ml or ODN 2216c (control for CpG ODN 2216) (ggGGGAGCATGCTCgggggG) at 3.2 
J.1g1ml (both InVivogen). After 24 hours at 37°C 5% CO2, cultures were centrifuged, 
supematants collected and stored at -20°C until analysis by mUltiplex (2.7.2) and 
phenotypical analysis of mDC and pDC was performed by flow cytometry methods 
(2.6.2). 
2.4.2.5 mDCIT cell contact and pDCIT cell contact assays 
CD3+ T cells were purified by positive selection (2.4.2.3) from PB and blasted by 48 hour 
culture in complete medium containing 5 J.1g1ml phytohaemagglutinin (PHA), in order to 
produce an activated phenotype similar to that displayed in synovium. At 48 hours, mDC 
and pDC were sequentially purified by positive (mDC) and negative (pDC) selection from 
autologous PB donors (2.4.2.2). Isolated mDC were plated in flat-bottom 96 well plates in 
triplicate aliquots at 0.5-IxlOslwell in complete media containing 50 nglml GM-CSF 
(StemCell Technologies). Isolated pDC were plated in flat-bottom 96 well plates in 
triplicate aIiquots at 0.2-0.8xl0slwell containing 20 nglml IL-3 (StemCell Technologies). 
The blasted T cells were either fixed in PBS/2% paraformaldehyde on ice for 2 hours, or 
not (as indicated), and added back to mDC and pDC cultures at a ratio of 3: 1. T cells were 
separated from mDC and pDC by cell membrane inserts where indicated (Nunc). After 24 
hours of incubation at 37°C 5% CO2, supematants were harvested and cytokines measured 
via multiplex analysis (2.7.2). 
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2.4.2.6 Differentiation of monocyte derived dendritic cells 
CD14+ monocytes were purified from PBMC by positive selection (2.4.2.3) and cultured in 
12 well plates at 2xl06 cells/well in complete medium supplemented with 20 nglml IL-4 
and 50 nglml GM-CSF (both StemCell Technologies), or by addition of 10% cell free 
osteoarthritis (OA), systemic-lupus erythematosus (SLE), psoriatic arthritis (PsA) or 
rheumatoid arthritis (RA) synovial fluid (SF) for 5 days. The cell free SF from each 
diagnostic group was composed of a cocktail of SF taken from 5 separate patients. 
Monocyte-derived DC (moD C) phenotype was assessed by flow cytometry analysis of 
surface CDlc and CDllc and maturation marker expression (2.6.2). 
2.4.3 Murine cell culture 
2.4.3.1 mDC generation from bone marrow 
Bone marrow was isolated from mouse femurs and a cell suspension prepared and filtered 
through Nytex to minimize clumps. To generate mDC, bone marrow cells were cultured at 
5x 1 05 cells/well, in a 6 well culture plate (Coming Costar), in complete medium 
supplemented with 10% conditioned medium generated by the GM-CSF-transfcctcd X63 
myeloma cell line for 6 days at 37°C/5%C02• On day 6, immature mDC were harvested 
by gentle scraping and used as a source of DC. 
2.4.3.2 pDC generation from bone marrow and purification 
Bone marrow was isolated as described above. To generate pDC, bone marrow cells were 
cultured at 2xl06/well, in a 6 well culture plate (Coming costar), in complete medium 
supplemented with 100ng/ml human Flt-3L (generous gift from Professor A Mowat, 
University of Glasgow, UK) for 8 days at 37°C 5% CO2• pDC were then purified by 
positive magnetic cell sorting (MACS, Miltenyi Biotec), according to the manufacturer's 
instructions. Briefly, cells were harvested by gentle scraping and then incubated in 200 III 
PBS/0.5% BSN2mM EDT A containing 100 III anti-mouse plasmacytoid dendritic cell 
antigen (mPDCA)-I-conjugated magnetic microbeads for 18 minutes at 4°C (Miltenyi 
Biotec). After washing in PBS/0.5% BSN2mM EDTA by centrifugation at 300 g for 10 
minutes, mPDCA-I + pDC were isolated by positive selection over a pre-equilibrated MS 
column. mPDCA-l + pDC were harvested from one column and immediately added to a 
fresh pre-equilibrated column to enhance purity. Purity was assessed by flow cytometry 
and routinely >95% (2.6.4). 
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2.4.3.3 Isolation of CD,(" T cells from lymph nodes and spleen 
Lymph nodes were harvested from DBA-l mice undergoing collagen-induced arthritis 
(CIA), and lymph nodes and spleen were harvested from naive DBA-! mice. Single cell 
suspensions were prepared from spleen by crushing under Nytex (Cadisch Precision 
Meshes), followed by red cell lysis in 5 ml water for injection for 10 seconds, rapidly 
followed by addition of 5 ml of two times concentrated PBS. Single cell suspension was 
prepared from lymph nodes by crushing under Nytex. After washing, all cells were pushed 
through nytex to minimise clumping. CD4+ T cells were purified by positive magnetic cell 
sorting (MACS, Miltenyi Biotec), according to the manufacturer's instructions. Briefly, 
cells were incubated in 200 III PBS/O.5% BSN2mM EDTA containing 100 f.ll anti-CD4-
(L3T4) conjugated magnetic microbeads for 18 minutes at 4°C (Miltenyi Biotec). After 
washing in PBS/O.5% BSN2mM EDT A by centrifugation at 300 g for 10 minutes, CD4+ T 
cells were isolated by positive selection over a pre-equilibrated MS column. Purity was 
assessed by flow cytometry (2.6.5) and routinely >98%. 
2.4.3.4 Antigen-specific proliferation by mDCI T cell and pDCIT cell co-culture 
Antigen-specific responses were assessed by tritiated thymidine uptake proliferation assay 
to evaluate DNA synthesis. Bone-marrow differentiated mDC (2.4.3.1) and pDC (2.4.3.2) 
were cultured in triplicate in complete medium at 0.5x 1 05/ well, in a flat-bottomed 96 well 
culture plate (Coming Costar). Cells were cultured as indicated with or without 50 f.lglml 
bovine tracheal collagen type Il (CIl; Sigma-Aldrich), for at least 6 hours. To some of the 
pDC cultures was added 3.2 f.lg/ml epG ODN 1826 (mouse) 
(TCCATGACGTTCCTGACGTT) (InVivogen) 2 hours prior to addition of CD4+T cells. 
CD4+ T cells were purified from DBN! mice, either naive or undergoing collagen-induced 
arthritis (2.4.3.3) and added to the DC cultures at a ratio of 3:1. At 48 hours 0.5 f.lCi/well 
[6)H]-thymidine (Amersham Pharmacia Biotech) was added to each well and allowed to 
incorporate into cellular DNA for 8-12 hours. Cells were harvested onto glass fibre filter 
mats (Perkin Elmer) using a Betaplate 96-well harvester (Amersham Pharmacia Biotech). 
Incorporated label was assessed by liquid scintillation counting and results are expressed as 
the Index of Stimulation, calculated as the proliferation in triplicate wells supplemented 
with CII divided by the proliferation in matched triplicate cultures in media alone. 
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2.4.3.5 mDC and pDC presentation o/OVA peptide to DOll.10 GFP trallsgellic T cells 
The DO 11.10 GFP T cell hybridoma is a cell line that responds to presentation of OVA 
peptide (323-339) on the MHC Class II molecule (I-Ad). When the T cell hybridoma 
receives this stimulation, it induces transcription of Nuclear Factor of activation of T cells 
(NF AT). Modification of the hybridoma by the addition of a NF AT reporter construct 
means that when NF AT is produced, it binds to a NFAT specific binding site, which 
regulates a green fluorescent protein (GFP) inducing promoter (575). In essence, when the 
T cell hybridoma sees MHC/peptide complex, it fluoresces. Bone marrow differentiated 
mDC (2.4.3.1) at day 5 of culture, and pDC (2.4.3.2) at day 8 of culture, were harvested by 
gentle scraping and then plated into a 24 well plate (Greiner) in 1 ml complete medium at 
5x 1 05 cells/ml after washing by centrifugation at 300 g for 5 minutes. After 24 hours 5 
mg/ml OV A323-339 (Worthington) was added to half of the wells. After 6 hours 5x 1 05 
DOll.I0 GFP T cell hybridoma was added to all wells and cultures incubated overnight at 
37°C 5% C02 (v/v). Non-adherent cells were then harvested from wells, and washed in 
PBS at 300 g for 5 minutes. The cells were resuspended in PBS/0.5%BSAlO.l %NaN3 and 
counter-stained in CD4 (L3T4)-PE or Rat IgG2a-PE isotype control (both R&D Systems) 
for 20 minutes on ice. Cells were then washed three times in PBS/O.5% BSNO.l % NaN3, 
resuspended in PBS and fluorescence measured by flow cytometry on a F ACScalibur 
(Becton Dickinson). 
2.5 Murine models of arthritis 
2.5.1 Collagen-Induced Arthritis 
Collagen-induced arthritis (CIA) was elicited in 6-8 week old DBAll mice (2.2). Mice 
were immunized by intradermal injection of 200 ~g of acidified bovine type II collagen 
(CII) (Chondrex Inc) emulsified in Complete Freunds Adjuvant (CFA) (BD Biosciences). 
Mice were boosted intra-peritoneal (Lp) with CII (200 J-lg in PBS) on day 21. Mice were 
monitored for signs of arthritis based on erythema, swelling or loss of function present in 
each paw on a scale of 0-3, giving a maximum score of 12 per mouse. After onset of 
arthritis, mice were sacrificed and lymph nodes harvested for in vitro analysis (2.4.3). CIA 
was administered by Dr Michelle lema (MD Biosciences, UK). 
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2.5.2 Induction of experimental arthritis by breaking self-tolerance 
1.5.1.1 Preparation of cell suspension for adoptive transfer 
This system produces a peptidelMHC-specific DOll.10 TCR-transgenic T cell population 
within a syngeneic recipient. The T cells from DO 11.10 mice contain rearranged TCR-Vu 
and TCR-VP genes that encode a TCR specific for the chicken ovalbumin (OVA) peptide 
323-339 (OVA323-339) bound to I_Ad MHC class 11 molecules (574). These cells can be 
detected by flow cytometry using the clonotypic KJ1.26 monoclonal antibody (mAb) 
conjugated to fluorescent fluorochrome (576). Since KJ1.26+ T cells are not produced in 
BALB/c at detectable levels, BALB/c are ideal transfer recipients allowing tracking of the 
transferred cells (577). 
1.5.1.1 Purification ofCD4+ T cells from D011.10 BALBlc 
Axillary, brachial, inguinal, cervical, mesenteric and popliteal lymph nodes from DO 11.1 0 
BALB/c mice were pooled and single cell suspensions prepared by forcing through Nytex 
(Cadisch Precision Meshes) with a syringe plunger. Cells were washed in complete 
medium at 400 g for 5 minutes. Cell pellets were resuspended in PBS/O.5% BSN2 mM 
EDTA containing anti-CDI9, anti-CDllc, anti-CDl6 and anti-CD8 mAbs (Serotec) and 
incubated for 18 minutes at 4°C. After washing by centrifugation at 300 g for 10 minutes, 
anti-IgG magnetic beads (Miltenyi Biotec) were added to cell suspensions and binding 
allowed to take place for 18 minutes at 4°C. B cells, monocytes, NK cells and CD8+T cells 
were therefore depleted by positive selection over LS columns (Miltenyi Biotec). The flow 
through was collected and contained only CD4+ T cells. The % KJ1.26+/CD4+ T cells in 
cell suspension was determined by flow cytometry methods. Briefly, cells were 
resuspended in PBS/O.5% BSNO.l % NaN3 and KJ 1.26-FITC (BD Pharmingen) and 
counter-stained in CD4 (L3T4)-PE or Rat IgG2a-PE isotype control (both BD Biosciences) 
for 20 minutes on ice. Cells were then washed three times in PBS/O.5% BSNO.l % NaN3, 
resuspended in PBS and fluorescence measured by flow cytometry on a FACScalibur 
(Becton Dickinson). 
1.5.1.3 Th1 differentiation ofCD4+ T cells 
Spleens were taken from 0011.10 BALB/c and single cell suspensions prepared and 
treated with mitomycin C (Sigma-Aldrich). Th 1 differentiation of T cells was induced by 
culturing at 2 x lOS/m! CD4+ T cells with 2 x 106/ml mitomycin C treated APC and DJ IlM 
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OVA323-339 (Genosys) in complete medium supplemented with 5 nglml IL-12 (PeproTech 
EC Ltd) and 10 J.lglml anti-IL-4 mAb (R&D Systems). After 3 days of culture, cells were 
harvested and washed by centrifugation at 400 g for 5 minutes. The % KJ1.26+/CD4+ T 
cells in cell suspension and intracellular IFN-y (to confirm Thl) was determined by flow 
cytometry methods (2.6.5). 
2.5.2.4 Adoptive trallsfer 
A total of 2 X 106 naive, Th 1 KJ 1.26+ DO 11.1 0 T cells were transferred by intravenous 
(i.v) injection into BALB/c recipients (n=42). One day following adoptive transfer all 
recipients were immunized s.c with 100 J.lg of OVA in CF A (Sigma-Aldrich). One day 
prior to, the day of, and on each of two days following, adoptive transfer, some of the 
recipients were injected s.C with 200 J.lg of 120G8 pDC depleting antibody (n=6) or 200 J.lg 
of the irrelevant isotype control YCATE.SS.9.l rat anti-dog CDS IgG\K (n==6). These mice 
did not receive further injections of 120G8 depleting antibody or isotype control for the 
remainder of the model. 
2.5.2.5 Arthritis illductioll alld mOllitor 
Ten days after immunisation with DV A in CF A, all animals were challenged by s.c. 
injection close to the left ankle joint with 100 J.lg of heat-attenuated OVA (HAO) in 50 J.lI 
of saline. One day prior to, the day of, and on each of two days following, challenge, some 
of the recipients were injected s.c with 200 J.lg of 120G8 pDC depIcting antibody (n=lO), 
200 J.lg of the isotype control YCATE.55.9.1 rat anti-dog CD8 IgG\K (n=10) or 200 J.lI PBS 
(n=lO). pDC depletion was measured in one animal from each group by harvesting lymph 
nodes and spleen, and analyzing mPDCA-l (Miltenyi Biotec), B220 and CD11c (both 
R&D) cell expression by flow cytometry. Mice were subsequently monitored for signs of 
arthritis. Footpad thickness was measured daily with a dial caliper (Kroeplin). At day 7 
following challenge mice were sacrificed and for histological assessment hind limbs were 
removed and fixed in 10% neutral-buffered formalin and 6-J.lm sections were stained with 
haematoxylin and eosin (H&E) or toluidine blue (both from Sigma-Aldrich). 
Immunohistochemical analysis was carried out by Colin Hughes, University of Glasgow. 
For ex vivo antigen-specific assays and analysis of Foxp3+ Tregs, draining popliteal lymph 
nodes were harvested from each mouse and processed immediately (2.4.3.3). To 
determine serum antibody levels, blood was also taken from each mouse and centrifuged at 
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800 g for 20 minutes. Serum was then taken and placed in a fresh tube at -20°C until 
analysis (2.5.2.7). 
2.5.2.6 Measurement of antigen-specific response ex vivo 
Antigen-specific responses were assessed by proliferation and cytokine production. 
Proliferation of Ag-specific T cells was assessed by the tritiated thymidine uptake assay to 
evaluate DNA synthesis. Briefly, at the times indicated, lymph nodes were removed and 
single cell suspensions prepared and plated in triplicate at Ix 105 cells/well in round bottom 
96 well plates in complete medium. Cells were stimulated, as indicated, with or without 
OVA (1 mg/ml) (Worthington) or bovine collagen type 1I (ClI) (50 J.lg/ml) (Sigma). The 
final volume in wells was 200 J.ll. Cultures were incubated at 37°C 5% (v/v) C02 
atmosphere at 95% humidity. At 72 hours 100 J.lI of supernatant was removed from each 
well and stored at -20°C for later cytokine analysis by multiplex (2.7.2). To the cultures 
was added 100 J.lI of complete medium (as above) supplemented with 0.5 J.lCi/well [6_3H]_ 
thymidine (Amersham Pharmacia Biotech) for the last 8 hours of culture to allow 
incorporation into cellular DNA. Cells were harvested onto glass fibre filter mats (Perkin 
Elmer) using a Betaplate 96-well harvester (Amersham Pharmacia Biotech). Incorporated 
label was assessed by liquid scintillation counting and results are expressed as the Index of 
Stimulation, calculated as the proliferation in triplicate wells supplemented with OVA or 
ClI divided by the proliferation in triplicate cultures in media alone. 
2.5.2.7 Detection ofserum antibodies/rom adoptive trails/er recipiellts 
To detect B cell derived anti-OVA, anti-collagen and anti-IgG2a in serum, Nunc-Immuno 
plates (Nalge Nunc International) were coated with 100 J.lI of20 J.lglml OVA, 2 J.lglml CII 
or I J.lglml IgG 1 (BD Pharmingen) in carbonate buffer (Sigma-Aldrich) overnight at 4°C. 
Plates were then washed in PBS/0.5% Tween20 three times prior to blocking PBS/] 0% 
FCS for 1 hour at 37°C. Plates were washed once again before incubation with serially 
diluted samples (in PBS) for 2 hour at 37°C. After further washing, plates were incubated 
in goat anti-mouse IgG2a-HRP (1110000; Southern Biotech) for 1 hour at 37°C. Plates 
were washed once again and 100 J.lI tetramethylbenzidine (TMB) added to each well 
(Biosource). Colour reaction was stopped using 100 J.lI Stop solution (Biosource), and 
optical density (OD) analysed read on a plate reader at 570 nm. 
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2.6 Flow Cytometry Methods 
2.6.1 Enumeration of DC subsets in PB and SF 
Circulating DC populations were identified by flow cytometry using a FACScalibur 
(Becton Dickinson) and using a circulating DC enumeration kit (Miltenyi Biotech) 
according to manufacturer's instructions (Blood Dendritic Cell Enumeration Kit, Miltenyi 
Biotech). Briefly, a white blood cell (WBC) count was calculated from PB and SF 
samples using a Coulter Counter (Beckman Coulter). Aliquots of whole blood were 
labelled with a cocktail of antibodies including anti-CDI4-phycoerythrin (PE).Cy5 and 
anti-CDI9-PE.Cy5 plus or minus anti-CDlc-PE (mDC marker) and CD303 (BDCA-2)-
fluorescein isothiocyanate (FITC) (pDC marker) or mouse IgG2a-PE and mouse IgG(-FITC 
antibodies. A proprietary dead cell discriminator was also included. After incubation, red 
cell lysis and wash, cells were fixed and examined using a F ACScalibur and analysed 
using Cellquest software (both Becton Dickinson). Results were expressed as % mDC or 
pDC in WBC or as absolute numbers per ml of PB/SF calculatcd as (% positive - % 
negative cells) x WBC per ml (x 10611 00). 
2.6.2 Analysis of mDC and pDC phenotype and maturation 
Isolated DC were phenotyped by four colour flow cytometry usmg the following 
monoclonal antibodies against: CDlc-FITC (IgG2a) (mDC only), CD303 (BDCA-2)-FITC 
(IgG() (pDC only) (both Miltenyi Biotec), CDl23 (IL-3Ra)-PE (IgG() (pDC only) (Becton 
Dickinson), CDIIc-PE (IgG() (m DC only), CD14-PE (lgG2a) (mDC only), CD40-APC 
(IgG(), CD62L-FITC (IgG(), CD80-FITC (lgG(), CD83 (B7-1)-APC (JgG(), CD86 
(B70/B7-2)-APC (IgG(), CCR7-PE (IgG2a) or the relevant isotype controls as indicated 
(all BD Biosciences Pharmingen). Isolated T cells were phenotyped by using CD3-FITC 
(IgG)) and CD4-PE (IgG); both BD Biosciences Pharmingen). Isolated monocytes were 
phenotyped by using CD14-FITC (IgG2a; BD Biosciences Pharmingen). A proprictary 
dead cell discriminator (Viaprobe; BD Bioscences Pharmingen) was also included. 
Briefly, pDC or mDC were washed in PBS/O.I % NaN3/O.2% BSA, followed by incubation 
in the above monoc1onal antibodies, as indicated, for 20 minutes on ice. Cells were then 
washed 3 times in buffer, resuspended and analysed for surface expression of the indicated 
phenotype and maturation markers by flow cytometry. 
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2.6.3 Analysis of IL-15 on BDB2 
2.6.3.1 11-15Ra expression 
The expression ofIL-l5Ra was first determined on BDB2 cells by incubation with the IL-
15Ra specific Ml6I (Genmab). Briefly, BDB2 cells were washed in PBS/O.l% NaNJ/2% 
goat serum and resuspended cells incubated in 10 Ilg/ml MI6I or isotype control for 30 
minutes on ice. After centrifugation at 300 g for 5 minutes, cells were resuspended in 
PBS/O.l % NaNJ/2% goat serum and PE-conjugated goat anti-mouse IgG for a further 30 
minutes on ice. After further centrifugation, the cells were resuspended and surface 
expression of IL-I5Ra determined by flow cytometry. 
2.6.3.2 Surface-bound IL-15 detection 
Surface-bound IL-I5 was detected on BDB2 cells by flow cytometry. Briefly, BDB2 cells 
were incubate in 100 ng/ml IL-I5 (R&D) for 30 minutes at 37°C. Cells were then 
immediately washed in ice-cold PBS. Cells were blocked by incubation in PBS/O.I % 
NaNJ/2% goat serum for 30 minutes on ice. After washing at 4°C, cells were incubated in 
7 Ilg/ml F(ab'h anti-IL-15 or 7 Ilg/ml F(ab')z human IgG isotype control for 30 minutes on 
ice. Cells were washed once again followed by incubation with FITC-conjugated goat 
anti-human IgG (Fab) (Sigma-Aldrich). After further centrifugation, the cells were 
resuspended and surface expression of IL-15 determined by flow cytometry. 
2.6.4 pDC depletion from BALB/c 
Depletion of pDC from BALB/c after 120G8 s.c injection (2.5.2.4) was assessed by flow 
cytometry methods. Briefly, lymph nodes and spleen were harvested from animals and 
processed as described (2.4.2.3). Single cell suspensions were resuspended in PBS/O.I % 
NaNJ/O.2% BSA and stained with mPDCA-I-FITC (Rat IgG\; Miltenyi Biotec) or CDllc-
FITC (Ham IgG2a)/B220-PE (Rat IgG\) or appropriate isotype control (all BD Biosciences) 
for 20 minutes on ice. After washing in PBS three times, cells were resuspended in FACS 
buffer and fluorescence measured on a FACScalibur (Becton Dickinson). 
2.6.5 Intracellular cytokine staining of Thl differentiated Tg OVA323-3J9 TcR D011.10 
CD4+ T cells 
Intracellular cytokine analysis for IFN-y production in Tg OVA32J-339 TcR DOI1.l 0 CD4+ 
T cells was carried out prior to transfer to Balb/c recipients. Cells were harvested from 
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culture and centrifuged at 1500 rpm for 5 min and washed 3 times in F ACS buffer. They 
were then stained with FITC labeled KJ.126 antibody for 20 min at 4°C and washed 3 
times with F ACS buffer. The cells were then resuspended in 100 III Cytofix/Cytoperm 
(BD Pharmingen) for 20 min at 4°C and washed twice with Perm Wash (BD Pharmingen). 
Permeable cells were subsequently stained with PE labeled anti-IFN- y (BD Phanningen) 
for 30 min at 4°C. Control cells were incubated with relevant isotype control antibodies. 
Cells were finally washed 3 times in F ACS buffer, resuspended and analysed for 
intracellular IFN- y by flow cytometry, using a F ACScalibur. 
2.6.6 Identification of Foxp3+T regs 
Intracellular analysis of Foxp3 in CD4+ T cells was carried out after harvesting lymph 
nodes from BALB/c undergoing transient arthritis. Single cell suspension were prepared 
from lymph nodes and centrifuged at 1500 rpm for 5 min and washed 3 times in F ACS 
buffer. They were then stained with FITC-conjugated CD4 antibody for 20 min at 4°C and 
washed 3 times with F ACS buffer. The cells were then resuspendcd in 100 III 
Cytofix/Cytoperm (BD Pharmingen) for 20 min at 4°C and washed twice with Perm Wash 
(BD Pharmingen). Permeable cells were subsequently stained with PE labeled anti-FoxP3 
(eBioscience) for 30 min at 4°C. Cells were finally washed 3 times in FACS buffer, 
resuspended and analysed for intracellular Foxp3 expression by flow cytomctry. 
2.7 Cytokine analysis 
2.7.1 Enzyme-Linked-ImmunoSorbent Assay (ELISA) 
Cytokine levels in culture supernatants were analyzed by sandwich ELISA. Sandwich 
ELISA involves attachment of a capture antibody to a 96 well plate followed by culture 
samples in a buffer, which minimizes sample attachment to the 96 well plate. An enzyme-
labeled antibody is then added for detection. Levels of IFN-a. in pDC culture supernatants 
and SF samples were measured using a human IFN-a. Matched Antibodies Module Set 
(Bender MedSystems®) according to the manufacturer's instructions. Levels of IFN-y and 
TNF-a. in PBMC, SFMC, mDC and pDC culture supernatants were assessed using a 
human IFN-y Cytoset™ and Human TNF-a. Cytoset™, respectively. Briefly, 96 well 
NUNC MaxiSorp microplates were coated in 100 III per well PBS/coating antibody (IFN-a 
10 Ilglml; IFN-y 4 Ilglml; TNF-a 2 J-lglml) for 12-18 hours at 4°C. Wells were then 
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aspirated and blocked in 300 JlI per well PBS/O.5%BSA for one hour at room temperature 
on an orbital shaker. Following vigorous washing in PBS/O.5%polyoxyethylene sorbitan 
monolaurate (Tween20) (Sigma-Aldrich), to each well was then added 100 JlI of either the 
sample of interest, or standards as supplied, followed by 50 JlI of biotinylated detection 
antibody (IFN-y, 0.4 Jlglml; TNF-a, O.S Jlglml) or horse-radish peroxidase (HRP)-
conjugate for IFN-a detection only, and incubated for 2 hours at room temperature with 
shaking. After 4 washes in PBS/O.5%Tween20, 100 JlVwell ofStreptavidin-HRP at 1/5000 
in PBS was added (not IFN-a detection plates) and incubated for 30 minutes at room 
temperature. After washing, 100 JlI of chromogen tetramethylbenzidine (TMB) 
(Biosource) was added to all wells. Colour change was monitored and stopped by addition 
of lOO JlVwell stop solution (Biosource). The optical density of plates was measured at 
450 nm (reference filter 650 nm). 
2.7.2 Multiplex Bead Assay 
Cytokine production was analysed by using Multiplex Bead Assay (Biosource, UK) 
according to the manufacturer's instructions. In human cell cultures a 20-plex was used 
containing the chemokines and cytokines CCL2 (MCP-I), CCL3 (MIP-Ia), CCL4 (MIP-
I~), CCL5 (RANTES), CXCLS (IL-S), CXCL9 (MIG), CXCLlO (lP-lO), IL-7, IL-I~, IL-
6, TNF-a, GM-CSF, IFN-y, IL-lO, IL-17, IL-lRa, IL-2, IL-2R, IL-4, IL-5, IL-12p40, IL-
13, IL-15, IFN-y. In murine cell cultures a 10-plex was used containing the cytokines GM-
CSF, IFN-y, IL-l p, IL-2, IL-4, IL-5, IL-6, IL-lO, IL-12p40, TNF-a. The principle of this 
method is a sandwich immunoassay where specific antibodies have been coated to the 
surface of fluorescently encoded microspheres. Each microsphere is labeled with a 
distinguishable fluorophore that allows it to be assigned or gated to a particular region by 
the scanner. Cytokine capture microspheres are first incubated with the culture supernatant 
under investigation followed by biotinylated detection antibody. Relevant standards are 
also used to enable quantitative analysis. Finally, Streptavidin-RPE is added and the 
fluorescence bound to the microspheres analysed using a Luminex XMAp™ system. The 
fluorescence intensity is proportional to the concentration of cytokine/chemokines present 
in the sample. 
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2.8 Immunohistochemical Methods 
2.8.1 Antibodies 
The following primary mouse monoc1onal antibodies (mAbs) were used: anti-CDIc 
(IgG2a; BD Beckman Coulter), biotin-conjugated anti-CDlc (BDCAl; IgG2a, Miltenyi 
Biotec, Bergisch, Gladbach, Germany), biotin-conjugated anti-CD304 (BDCA4; IgG\, 
Miltenyi Biotec), anti-CDIc (BDCAI; IgG2a, Miltenyi Biotec), anti-CD304 (BDCA4; 
IgG\, Miltenyi Biotec), FITC-conjugated anti-CDIc (BDCAl; IgG2a, Miltenyi Biotec), 
FITC-conjugated anti-BDCA2 (IgG\, Miltenyi Biotec), anti-CDllc (IgG\, BD 
Pharmingen, San Diego, CA), anti-CD123 (lgG\; BD Biosciences Pharmingen), PE-
conjugated anti-CD123 (IgG It BD Biosciences), anti-CD83 (IgG\, BD Pharmingen), anti-
CD3 (IgG\, BD Biosciences), anti-CD8 (IgG\, BO Biosciences), anti-IL-12p70 (IgG\, 
R&D Systems, Minneapolis, MN), anti-IL-15 (IgG\, Diaclone SAS), anti-IL-18 (lgG\, MD 
Biosciences, St. Paul, MN), and anti-IFN-a and IFN-P (both IgG1, PBL Biomedical 
Laboratories, Florence, Italy). Polyc1onal rabbit anti-human IL-23p 19 subunit was kindly 
provided by Dr. J. Pirhonen (Department of Microbiology, National Public Health 
Institute, Helsinki, Finland). 
2.8.2 Single Immunohistochemical Staining 
Acetone-fixed cryosections were incubated with mAbs against CDlc (BOCAl) or CD304 
(BDCA4) for 1 h at room temperature after blocking endogenous peroxidase activity with 
H202 and sodium azide (NaN3). As negative controls, the primary antibodies were omitted 
or irrelevant isotype-matched antibodies were applied. After incubation with goat anti-
mouse horseradish peroxidase (HRP)-conjugated (DakoCytomation) for 30 min at room 
temperature, sections were incubated for 15 min with biotinylated tyramine (Perkin 
Elmer), followed by an incubation with streptavidin-HRP (strcp-HRP; DakoCytomation). 
Peroxidase activity was revealed using amino-ethylcarbazole (AEC) substrate kit (SK-
4200, Vector laboratories). With this procedure COIc (BDCAlt mDC and C0304 
(BDCA4)+ pDC stained red. Other cellular elements were counterstained with 
hematoxylin (Sigma-Aldrich), dried and mounted with glycerol/gelatine. 
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2.8.3 Double Immunohistochemical Staining 
The double staining of CDIc or CD304 with CD3, CD8, CD83 and DC-LAMP was 
undertaken by Dr M.C.Lebre, AMC, Amsterdam, The Netherlands. 
For double immunohistochemical stainings with CDIc (BDCAI) or CD304 (BDCA4) in 
combination with CD3 or CD8 respectively, the sections were incubated overnight at 4°C 
with either biotin-conjugated anti-CDIc or with biotin-conjugated anti-CD304 as primary 
mAbs. After incubation with strep-HRP for 30 min at room temperature sections were 
incubated for 15 min with biotinylated tyramine, followed by incubation with strep-HRP 
for 30 min. Following a 15 min incubation with 10% normal mouse serum, anti-CD3 or 
anti-CD8 were applied to the sections and incubated for 1 h at room temperatute followed 
an incubation with alkaline phosphatase (AP)-conjugated goat anti-mouse for 30 min. 
Peroxidase activity was revealed as stated above and AP activity was revealed using 
alkaline phosphatase substrate III kit (Vector laboratories). 
For double immunohistochemistry of CD304 in combination with CD123, acetone-fixed 
cryosections were incubated in 0.5% l-h02/methanol for 30 minutes followed by blocking 
in 20%horse serurnl20%human serumIPBS (Sigma-Aldrich) for 30 minutes at room 
temperature. Sections were then incubated with mAb against CD123 (lL-3Ro) for 90 
minutes at room temperature. As negative controls mouse IgG\ was applied. After 
washing, slides were incubated with biotimylated horse anti-mouse IgG (H+L) 
(Dakocytomation). Slides were then incubated with Vectastain ABC (Vector) for 30 
minutes followed by 5 minute incubation with DAB Ni (Vector). CD123+ cells stain grey. 
Sections were then incubated for 90 minutes at room temperature with CD304. 
Immunohistochemistry was then carried out as above, but NovaRED ™ (Vector) was used 
for visualization. Other cellular elements were counterstained with Harris modified 
haematoxylin solution (Sigma-Aldrich), followed by alcohol dehydration and mounting in 
DPX mountant for microscopy (BDH Laboratory Supplies). By this procedure CD304+ 
cells stain red, whereas CD304+/CDI23+ cells are black. 
2.8.4 Immunofluorescent Staining 
For double immunofluorescence staining, sections were first incubated with FITC-
conjugated primary mAbs against CD 1 c or CD303 (BDCA2) followed by incubation with 
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rabbit anti-FITC (DakoCytomation) and with Alexa-488 conjugated goat anti-rabbit 
(Molecular Probes Europe). After blocking with normal mouse serum, the sections were 
incubated with the mouse monoc1onal antibodies against CD83, IL-12p70, IL-15, IL-18, 
IFN-a. or IFN-P, or with the rabbit polyc1onal against IL-23p 19. After incubation with 
Alexa-594-conjugated goat anti-mouse or with Alexa-594-conjugated goat anti-rabbit 
(Molecular Probes Europe), the slides were analyzed using a fluorescence microscope 
(Leica DMRA) coupled to a CCD camera and Image-Pro Plus software (Media 
Cybernetics, Dutch Vision Components). For coexpression of CDS3 or DC-LAMP and 
mDC or pDC 12 patients with RA, 5 patients with OA and 7 patients with PsA were 
analyzed. For the expression of cytokines by mDC and pDC 5 patients with RA were 
analyzed. To quantify the data, the numbers of double positive staining cells were counted 
in a minimum of 6 microscopic fields and the percentage of double positive cells was 
calculated. The selection of these patients was based on the presence of mDC and/or pDC 
in the synovium. 
2.S.5 Digital Image Analysis 
All sections were coded and randomly analyzed by computer-assisted image analysis. For 
all markers, 18 high-power fields were analyzed. The high-power field images were 
acquired on an Olympus microscope (Olympus), captured using a charged coupled device 
video camera (Sony), and digitized using a PVl 00 multimedia 16-bit colour video digitizer 
card, using a standardized macro program to simplify as well as to standardize the 
acquisition process. The resultant colour images were in a 640x480 pixel RGB format with 
a 24-bit resolution, enabling the use of 16581375 colours. For each acquisition session, the 
microscope, camera and computer were calibrated according to a standardized procedure. 
The images obtained were stored as hitmaps without compression using a Zip disk and 
portable driver (lomega, Roy, UT, USA). The images of the high-power fields were 
analyzed using the Qwin Pro V2.2 analysis system (Leica Microsystems), which consists 
of of a personal computer (PC) with software (lntel Pentium 200 MHz processor and 
Windows ™ NT 4.0 environment). 
2.9 Statistical analysis 
Data are expressed as the median and interquartile range or mean ± standard error of the 
mean (SEM) as indicated. Where presented statistical significance was determined using 
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the nonparametric Mann-Whitney U test between disease groups and healthy controls. 
CRP correlation to PB DC numbers was analysed by Pearson Correlation. 
Ap value <0.05 was considered significant. 
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2.10 Suppliers addresses 
Amsersham Pharmacia Biotech 
Amersham Place 
Little Chalfont 
Buckinghamsire HP7 9NA 
BD Biosciences 
21 Between Towns Road 
Cowley 
Oxford OX4 3L Y 
Bender MedSystems® 
C/o Catlag-MedSystems 
Botyl Rd 
Botolph Clayton 
Buckingham MK18 2LR 
Cadisch Precision Meshes Ltd 
Unit 1 Finchley Industrial Centre 
879 High Rd 
Finchley 
London Nl2 8QA 
Calbiochem 
c/o CN Biosciences 
Boulevard Industrial Park 
Padge Road 
Beeston 
Nottingham NG9 2JR 
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Chondrex Inc 
C/o MD Biosciences 
Morwell Diagnostics GmbH 
Gewerbestrasse 9 
Postfach 8132 
ZUrich Switzerland 
Corning Incorporated 
Coming NY 14881 
USA 
Dako UK Ltd 
Denmark House 
Angel Drive, Ely 
Cambridgeshire CB7 4ET 
Diaclone SAS 
C/o I.D.S 
Boldon Business Park 
Boldon 
Tyne and Wear NE35 9PD 
eBiosciences 
C/o Insight Biotechnology Ltd 
Wembley Commercial Centre 
East Lane 
Wembley HA9 7XX 
Genosys 
Cambridge 
UK 
Gibco 
Paisley P A4 9RF 
Scotland 
Harlan UK Ltd 
Shaw's Farm, Blackthome 
Bicester 
Oxon OX25 1 TP 
Invitrogen Life Technologies 
3 Fountain Drive 
Inchinnan Business Park 
Paisley 
InvivoGen 
C/o Autogen Bioclear UK Ltd 
Holly Ditch Farm, Mile Elm 
Calne, Wiltshire SNII DPY 
Kroeplin 
C/o Newman Tools Ine 
3422 Notre Dame West 
Montreal H4CIP2 
Canada 
Leica Microsystems (UK) Ltd 
Davy Avenue 
Knowhill 
Milton Keynes MK5 8LB 
Leo Laboratories Ltd 
Pmces Risborough 
Bucks HP27 9RR 
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Medicell International Ltd 
239 Liverpool Rd 
London NI ILX 
Miltenyi Biotec 
Almac House 
Church Lane 
Bisley 
Surrey GU24 9DR 
Millipore 
Billencia 
MA 01821 
USA 
PeproTech EC Ltd 
29 Margravine Rd 
London W6 8LL 
Perkin Elmer 
549 Albany St 
Boston MA 02118 
USA 
Pierce 
C/o Perbio Science UK Ltd 
Unit 9, Atley Way 
North Nelson Industrial Estate 
Cramlington 
Northumberland NE231 W A 
Promega 
Delta-House 
Chilworth Science Park 
Southampton SO 16 7NS 
R&D Systems Europe Ltd 
19 Barton Lane 
Abingdon Science Park 
Abingdon 
Ox on OXI4 3NB 
Serotec UK 
22 Bankside 
Kidlington 
Oxford OX5 13E 
Sigma-Aldrich Company Ltd 
Fancy Road 
Poole 
Dorset BH12 4QH 
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StemCell Technologies SARL 
London 
UK 
Vector Laboratories Ltd 
3 Accent Park 
Bakewell Road 
Orton South gate 
Peterborough PE2 XS 
VWR International 
Haasrode Researchpark Zone 3 
Geldenaaksebaan 464 
Leuven B309 
Worthington Biochemical Corporation 
Clo Lome Laboratories Ltd 
Ruscombe Business Park 
Twyford, Reading 
Berkshire RG I 0 9NJ 
Chapter 3: Enumeration, phenotype and functional analysis of distinct 
dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis 
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3.1 Introduction 
The inflammatory arthritides, including rheumatoid arthritis (RA) and psoriatic arthritis 
(PsA), comprise auto immune disorders characterised by chronic joint inflammation, 
immune cell infiltration to the synovium, fibroblast-like synoviocyte expansion and 
destruction of cartilage and bone. Extensive in vivo and in vitro studies have identified 
multiple pro-inflammatory cytokines and enzymes implicated in the pathogenesis of both 
of these disorders. Targeting cytokines has proven therapeutically useful exemplified 
particularly in tumour necrosis factor (TNF) blockade and more recently in targeting 
interleukin (IL)-6, and IL-15 (339, 340, 342, 578). Cytokine blockade however exhibits 
variable responses across patient populations and importantly disease activity recurs upon 
cessation of therapy. A major challenge in therapeutics now is to develop strategies that 
re-establish immune tolerance such that amelioration of inflammation is accompanied by 
long-term disease suppression. Early evidence that such responses may be feasible is 
derived from clinical studies utilising CTLA-4Ig (381) and anti-CD20 (289, 579) in RA 
and co-stimulatory blockade in psoriasis (571, 580, 581). 
Many data indicate the presence and significance of autoimmune processes in articular 
inflammation. In RA, recent results implicate citruIIinated peptidcs in disease progression 
and response to TNF blockade (311). Additional auto-specific antigens include type 11 
collagen (300) and cartilage derived gp39 (298, 299). Although in PsA few autoimmune 
targets have been identified, perhaps reflecting the absence thus far of defined 
autoantibodies, analysis of PsA synovial and skin T cell subsets clearly indicate 
oligoclonal responses that may be self targeted (582, 583). Critically, in both diseases, 
upstream immunological processes have been poorly characterised ex vivo, particularly 
with respect to the site and nature of antigen presentation. Antigen presenting 
macrophages and B cells play a potential role in synovial inflammation, especially in 
mediating cartilage degradation (584, 585). However, the role played by various subsets of 
dendritic cells (DC) is less clear (295). Although enrichment of DC in RA synovial tissue 
and fluid and in seronegative synovial fluid has been reported (274, 530-535), the 
considerable phenotypic, morphologic and functional variations between DC subsets 
related to lineage, stage of maturation and tissue localisation remains less well understood. 
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This partly reflects difficulty in adequately identifying DC subsets in peripheral blood and 
tissues where most methodologies rely on complex combinations of surface markers. 
Recently, novel markers useful in human DC studies have been defined that resolve these 
issues (397). Five distinct subsets of lineage negative, HLA-DR+ DC have been classified 
in humans. Four subsets, CDlb/c+, CD16+, CD141 (blood dendritic cell antigen (BDCA)-
3t and CD34+ are myeloid-lineage derived, while the fifth, CDl23 (IL-3Ra+)/ CD303 
(BDCA-2t, has a lymphoid phenotype and is described as plasmacytoid DC (pDC) (397, 
398). Comprising 0.5-1.0% of all circulating mononuclear cells, myeloid DC (mDC) are 
characterised as CDlc+/ CDllc+/ CD45RO+/ HLA-DR+/ CD123 (lL-3Ra)lo. Capable of 
IL-12-p70, IL-6, TNF-a and IL-lO production in response to bacterial or CD40L 
stimulation as well as antigen capture and presentation (409). mDC require GM-CSF for 
survival in vitro and can differentiate into interstitial DC (int DC) and Langerhans cells 
(LC) in the presence ofGM-CSF, IL-4 and TGF-p (410). Conversely pDC, characterised 
as CD303 (BDCA-2t/ CD304 (BDCA-4t/ CD123 (lL-3Ra) high/ CDllc-/ HLA-DR+/ 
CD45RA+, comprise less than 0.3% of all circulating mononuclear cells and secrete large 
amounts of type I interferons in response to virus mediated stimulation (411, 412). 
It has been suggested that DC play a role in the initiation and perpetuation of inflammatory 
arthritis by presentation of arthritogenie antigens to autoreactive T cells (273, 294-296). 
This presentation may drive aberrant memory T cell responses, promoting B cell activation 
and immunoglobulin class switching. DC infiltration into the synovium occurs early in 
disease pathology (295, 550, 552). DC could represent important cellular targets in 
inflammatory synovitis, by virtue of their potent antigen presentation potential and 
capacity to promote local inflammation via TLR expression (491, 586) and cytokine 
release (402, 412, 465, 498,587). 
3.2 Aims and Objectives 
Recent advances in identifying DC subsets have improved resolution of subset 
heterogeneity. It was therefore the aim of this chapter to undertake a comprehensive 
enumeration and characterisation of the phenotype and function of pDC and mDC in 
peripheral circulation as well as synovial effusions in the context of inflammatory arthritis. 
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Specifically, I planned to address: 
• Whether total peripheral circulating numbers of pDC and mDC are altered in 
inflammatory arthritis in comparison to OA patients and healthy donors, by use of a robust 
and sensitive assay system utilising specific receptors. 
• Whether peripheral circulating pDC and mDC express a nonnal or abnonnal phenotype 
compared to healthy donor derived pDC and mDC. 
• Whether pDC and mDC are detectable in synovial effusion from RA and PsA and if so, 
the total number by volume of each. 
• Whether pDC and mDC in synovial fluid from RA and PsA patients display an immature 
or mature phenotype. 
• Whether an assay system could be established in order to detennine if pDC and mDC in 
synovial fluid are hyper or hypo-responsive to TLR stimulation in comparison to healthy 
donor derived pDC and mDC, as assessed by cytokine release and maturation marker 
expressIon. 
• Finally, whether there exist any identifiable and specific differences in the number, 
phenotype and function of pDC and mDC from RA blood and synovial fluid in comparison 
to PsA blood and synovial fluid, thus indicating a disease specific phenomenon. 
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3.3 Results 
3.3.1 Patients 
Inflammatory arthritis patients attending Glasgow Royal Infirmary (GRI) fulfilled the 
American College of Rheumatology criteria for RA (23), or met diagnostic criteria for PsA 
as previously described (572, 573). All patients and healthy donors gave informed consent 
and the study protocol was approved by the Ethical Committee, GRI. Peripheral blood 
(PB) was obtained from patients with RA (n=12), PsA (n=13) and OA (n=ll) and 
compared to healthy controls (n=12). Matched synovial fluid (SF) was obtained from a 
subset of these donors (RA=6, PsA=6) (Table 3.1). All cell analysis was undertaken on 
freshly isolated cells. For cytokine investigation, cell free SF and supernatants from cell 
culture were stored in the Centre for Rheumatic Disease (CRD) Biobank at -70°C until 
analysed. At the time of study, RA patients were receiving methotrexate (n=7), 
sulphasalazine (n=8) or hydroxychloroquine (n=4) or a combination of these agents (n=5). 
PsA patients were receiving either methotrexate (n=ll) or sulphasalazine (n=4) or a 
combination of these agents (n=2). OA patients did not receive any immune modulatory 
therapy, but were taking atenolol (n=3), omeprazole (n=3), simvastatin (n=2), arthrotec 
(n=I), zopiclone (n=l) or a combination of these agents (n=3). Patients on oral steroids 
were excluded from the study. 
3.3.2 Whole blood enumeration of circulating peripheral blood pDC and mDe 
We first chose to examine systemic circulating and local levels of DC subsets In 
inflammatory arthritis. Changes in circulating DC subpopulations have been identified in 
other autoimmune disease, particularly systemic lupus erythematosus (SLE) (498, 588-
590). Until recently however, the quantitative analysis of DC subsets has been hindered by 
complex methodologies, a lack of specific surface markers and low absolute DC levels 
eluding reliable detection. We therefore utilised the novel DC markers CDlc (mDC) and 
CD303 (pDC), within a unique whole blood three colour F ACS assay system allowing 
enumeration of DC numbers with high sensitivity. Fresh PB was obtained, a white blood 
cell (WBC) count performed, and the PB processed (as described in 2.6.1). The first step 
of analysis was to exclude dead cells and cellular debris by gating on the leukocyte fraction 
as delineated by forward scatter (FSC) and side scatter (SSC) (Fig. 3.1 a). The CD 1 c 
expressing monocytes and B cells were excluded based upon CD 14 expression 
(monocytes) or CD19 expression (B cells). Any remaining dead cells were excluded using 
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Table 3.1. Patient data 
Characteristic PB study group SF study group 
RA Age, Mean ± SD 58 ± 12 (24-80) 59 ± 15 (33-70) 
Female:Male 10:2 5: 1 
WBC, Mean ± SEM 6.4xl06/ml ± 1.2x104/ml 
CRP (mg/liter) 26 ± 6 (6-100) 22 ± 7 (6-41) 
PsA Age, Mean ± SD 42 ± 14 (24-81) 41 ± 15 (25-50) 
Fernale:Male 10:3 5: 1 
WBC, Mean ± SEM 8.0xI06/ml* ± 4.5xlOslml 
CRP (mg/liter) 14±4(6-73) 30 ± 15 (6-73) 
OA Age, Mean ± SD 63 ± 12 (52-82) 
Female:Male 4:6 
WBC, Mean ± SEM 6.0 xl06/ml ± 8.9xlOslml 
CRP (mglliter) 10 ± 3 (6-14) 
Healthy Age, Mean ± SD 44 ± 11 
Female:Male 6:6 
WBC, Mean ± SEM 6.4xl06/ml ± 4.7xlOslmJ 
Mean ± standard error of the mean (range) is shown, CRP (ClReactive Protein), *p<0.05 compared to 
healthy control PB 
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Figure 3.1 Assay to enumerate mDe and pDC from whole blood. 
Whole blood was stained with an antibody cocktail containing CDI4/CDI9-PE-Cy5 and 
dead cell discriminator (DCD) with either CDlc-PE/CD303-FITC or mouse IgG2a-
PE/mouse IgGl-FITC and analysed by FACS following lysis of red blood cells. White 
blood cells (WBC) were selected (a), monocytes, B cells, neutrophils and dead cells 
eliminated (b) and CDlc+ mDC and CD303+ pDC identifed (d) as compared to the isotype 
control (c). Analysis shown is representative of a typical experiment, in this case using a 
healthy control. 
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a dead cell discriminating (DCD) nuclear stain, and neutrophils were excluded based upon 
SSC profile. The gate to encompass remaining cells was set routinely high towards the 
CD 14+ monocytes as PB mDC sometimes express CD 14 at low levels. PB mDC and pDC 
were identified as discrete CDlc+ (mDC) or CD303+ (pDC) expressing populations (Fig. 
3.1d) as compared to the isotype controls (Fig. 3.1c). By using this method we were able 
to calculate the number of mDC and pDC as a percentage of WBC and the total number of 
mDC and pDC/ml of PB. This was considered a vital step in order to account for 
variations in other cell populations, hence unmasking any 'false' differences. 
3.3.3 Number and proportion of circulating pDC are reduced in PsA and RA PH and 
mDC are reduced in RA PH. 
In RA PB, mDC were significantly decreased compared to healthy controls, as expressed 
as total numbers/ml PB (Fig. 3.2a) (p=0.0086) and as a percentage of WBC (Fig. 3.2b) 
(p=0.0262). In PsA PB, mDC were not significantly decreased compared to healthy 
controls when expressed as total numbers/ml in PB (p=0.1147), but were significantly 
decreased when adjusted to percentage of WBC (p=O,OI8) most likely reflecting an 
elevation in another cell population as indicated by a significantly increased WBC count in 
PsA PB compared to healthy controls (Table 3.1, p=O.0470). In contrast, circulating pDC 
were significantly decreased in both RA and PsA PB compared to healthy controls 
expressed either as total numbers/m I PB (Fig. 3.2c) (RA, p=0.0194, Ps A, p=O.0098) or 
indeed as a percentage of WBC (Fig. 3.2d) (RA, p=O,O 180, PsA, p=0.0051). In OA PB, 
although there was a trend towards a decrease in pDC numbers/ml ofPB, neither mDC nor 
pDC numbers were significantly reduced compared to healthy controls whether data were 
expressed as a percentage of total WBC or as total cell numbers/ml PB. 
To determine if the observed reduction in circulating PB DC subsets was a cell specific 
phenomenon, or a pattern common to other myeloid or lymphoid lineage cells we also 
analysed the proportion and percentage of WBC of circulating CD14+ monocytes 
(myeloid) and CDI9+ B cells (lymphoid). In RA and OA CD14+ monocytes were not 
significantly decreased compared to healthy controls when expressed as total numbers/m I 
PB (Fig. 3.3a, p=O.3348 and p=O.0756 respectively) or when adjusted to percentage WBC 
(Fig. 3.3b, p=0.2318 and p=0.0828 respectively). Similarly, in PsA CD14+ monocytes 
were not significantly decreased compared to healthy control when expressed as 
numbers/ml PB (Fig. 3.3a, p=O.3348) but were significantly decreased when adjusted to 
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Figure 3.2 Circulating pDC and mDC are significantly decreased in RA PB and pDC 
are significantly decreased in PsA PB. 
Total number ofmDC (a) and pDC (c) per ml ofPB and percentage ofmDC (b) and pDC 
(d) ofWBC in healthy (n=12), RA (n=12), PsA (n=13) and OA (n=U) sUbjects. Squares 
indicate individual samples, - = median, *p<O.05, **p<O.Ol. Statistical analysis was 
carried out using Mann Whitney. 
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Figure 3.3 Circulating monocytes and B cells are not significantly decreased in RA, or 
OA PB but monocytes are decreased in PsA. 
Total number ofCD14+ monocytes (a) and CD19+ B cells (b) per ml ofPB and percentage 
of CD14+ monocytes (c) and CD19+ B cells (d) of WBC in healthy (n=12), RA (n=12), 
PsA (n=13) and OA (n=l1) subjects. Squares indicate individual samples, - = median, 
**p<O.Ol. Statistical analysis was carried out using Mann Whitney. 
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percentage WBC (Fig. 3.3b, p=0.0020). Consistent with our previous observations, this 
significant decrease was once again most probably reflecting an elevation in another cell 
population. In RA, PsA and OA CD 19+ B cells were not significantly decreased compared 
to healthy control when expressed as total numbers/m I in PB (Fig. 3.3c, p=0.2l4, p=Ol571 
and p=0.2707 respectively) or when adjusted to percentage of WBC (Fig. 3.3 d, p=0.0885, 
p=0.5444 and p=0.4887 respectively). 
3.3.4 Reduced PB DC subset numbers are inversely correlated to CRP 
The significant decrease of pDC and mDC in RA PB and pDC in PsA PB, as well as the 
trend towards a decrease in pDC in OA PB was intriguing and led us to investigate a 
possible correlation to the magnitude of inflammatory disease activity. Accordingly, we 
correlated pDC and mDC numbers from PB of RA, PsA and OA patients with serum CRP 
concentrations. Pooled analysis of the disease subsets combined indicated a significant 
inverse correlation between mDC and pDC numbers/m I PB and serum CRP (mDC r=-
0.346, p=0.045 and pDC r=-0.407, p=0.017), indicating a link between circulating DC 
subsets and inflammation. Disease subset analysis revealed that mDC numbers/ml PB 
(p=0.021 and r=-0.45233), but not pDC numbers/ml (p=0.228 and r=-.04001), were 
significantly and inversely correlated to CRP levels from RA patients (Fig. 3.4a and 3.4d). 
However, neither mDC nor pDC numbers/m I PB were significantly inversely correlated to 
CRP levels from PsA patients (r=-0.20574, p=0.496 and r=-0.2753, p=0.434) (Fig. 3.4b 
and 3.4e) or OA patients (r=-0.4293, p=0.238 and r=-0.0998, p=0.806) (Fig 3.4c and 3.4f), 
indicating that RA dominates the analysis, most likely as CRP levels are lower in PsA 
patients. 
3.3.5 CD62L is ab errantly expressed on RA and PsA circulating PB DC. 
To further study the phenotype of PB mDC and pDC, these cells were isolated by 
sequential positive selection in a subset of RA (n=5) and PsA (n=5) PB and compared to 
healthy controls (n=5). The purity of the isolated DC was confirmed by double staining 
with CDlc and CDllc (mDC) (Fig. 3.5a) and CD303 and CD123 (pDC) (Fig. 3.5b) and 
was routinely >99% mDC and >95% pDC. Thereafter a panel of maturation markers was 
examined using FACS analysis. Both CDlc+/CDllc+ mDC and CD303+/CD123+ pDC 
from PsA and RA PB displayed an immature phenotype similar to mDC and pDC isolated 
from healthy controls (Fig. 3.Sa and 3.Sb respectively) with absent expression of the 
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Figure 3.4 Circulating mDC numbers are significantly inversely correlated to CRP 
levels in RA PB. 
The CRP levels of RA (blue), PsA (green) and OA (orange) patients compared to total 
numbers ofmDC (a), (b) and (c) and pDC (d), (e) and (I) respectively per ml ofPB. CRP 
levels are calculated on a logarithmic scale and squares indicate individual samples. CRP 
correlation to PB DC numbers was analysed by Pearson Correlation. *p<O.OS. 
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Figure 3.5 RA and PsA PB pDC and mDC have an immature phenotype and 
significantly decreased CD62L expression. 
Migration and maturation markers on CDlc+/CDllc+ mDC purified from RA PB (n=5) 
and PsA PB (n=5) compared to healthy control PB (n=5) (a) and CD303+/CD123+ pDC 
purified from RA PB (n=5) and PsA PB (n=5) compared to healthy control PB (n=5) (b). 
Values are calculated as the mean fluorescent intensity (MFI) fold of increase over the 
isotype control. The box and leaf plots depict median and interquartile range (50% of the 
data), flanked by whiskers indicating the extent of the data. *p<0.05. Typical examples of 
F ACS histograms analysing CD62L fluorescence intensity on pDC and mDC, compared to 
their respective controls, for one healthy donor PB sample and one RA PB sample are 
shown (c). Statistical analysis was carried out using Mann Whitney. 
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maturation marker CD83 and low to absent expression of CD40, CDSO and CDS6 and the 
chemokine receptor CCR7. However, expression of the adhesion molecule CD62L (L-
selectin) was significantly reduced on inflammatory arthritis derived mDC (RA p=0.0371, 
PsA p= 0.0122) and pDC (RA p=0.0367, PsA p=0.0373) compared to healthy control PH 
mDC and pDC respectively (Fig. 3.Sc). In order to account for inter-individual variability 
the F ACS analysis results were calculated as the fold increase of the mean fluorescence 
intensity (MFI) over each individual isotype control, thus enabling comparative analysis 
across separate donors. 
3.3.6 RA and PsA SF contain mDe and pDC. 
The foregoing data strongly suggest that DC subset distribution in inflammatory arthritis is 
abnormal and commensurate with either enhanced migration to the synovial compartment 
or reduced release from bone marrow. To investigate the former possibility, we chose to 
evaluate DC subsets freshly isolated from SF. To this end, we enumerated mDC and pDC 
in SF and matched PH obtained from 6 patients with RA and 6 patients with PsA. 
Magnetic sorting and flow cytometry revealed that whereas absolute mDC and pDC 
numbers varied greatly between individual patients, both subsets were consistently present 
in RA and PsA SF (Table 3.2). The ratio of mDC: pDC in PH was approximately 2: 1 in 
both RA and PsA patients and was similar to that seen in OA patients and healthy controls 
(Fig. 3.6a). In contrast, this ratio was significantly increased in both RA (median 9.4: I, 
p=0.00S2) and PsA (median 6.05:1, p=0.0453) SF (Fig 3.6b) compared with matched PB, 
suggesting enrichment of these poputations in tissue. 
3.3.7 SF mDC have a semi-mature phenotype but pDC are immature. 
To investigate the phenotype ofmDC and pDC in SF, cells were isolated from a subset of 
RA SF (n=3) and PsA SF (n=4), as stated above, and analysed by FACS analysis using a 
range of cell surface markers. Isolated DC subsets were routinely >90% pure. Phenotype 
was determined by gating specifically on CDlc+/COllc+ cells (mDC) and 
C0303+/CDI23+ cells (pDC). Once again the FACS analysis results were interpreted as 
the fold increase of the MFI above each individual isotype control to allow comparative 
analysis. In both RA SF (Fig. 3.7a) and PsA SF (Fig. 3.7b) the phenotype of mOC was 
similar, with increased expression ofCD40, CD80 (significant in PsA p=0.037), C083 and 
CD86 (significant in PsA, p=O.036) in comparison to their RA and PsA PH counterparts 
respectively, indicating a semi-mature phenotype. In contrast, RA SF (Fig. 3.7c) and PsA 
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Table 3.2. Absolute number of cells in RA and PsA PB matched SF. 
WBC (x104/ml) mDC (x104/ml) pDC (xl04/ml) 
RA PB 652 ± 93.7 1.36 ± 0.641 0.582 ± 0.211 
n=6 
SF 1020 ± 235 11.6±3.12 3.24 ± 1.71 
PsA PB 969 ± 240 1.39 ± 0.420 0.761 ± 0.220 
n=6 
SF 2860 ± 351 37.5 ± 8.72 7.20 ± 2.23 
Data are mean ± SEM. 
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Figure 3.6 mDC:pDC ratios in SF are significantly increased when compared to 
matched PB. 
The ratio ofmDC: pDC in PB from RA (dark blue, n=12), PsA (dark green, n=13) and OA 
(orange, n=l1) subjects was not significantly altered compared to healthy control subjects 
(red, n=12) (a), median and interquartile range is shown. The ratio of mDC: pDC in SF 
from RA (n=6) and PsA (n=6) subjects was significantly increased compared to matched 
PB samples (b). Squares indicate individual matched samples. The ratio was calculated 
from total number of cells/m!. The scale is the same for both graphs to allow comparison. 
*p<O.05, **p<O.Ol. Statistical analysis was carried out using Mann Whitney. 
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Figure 3.7 RA and PsA SF pDC have an immature phenotype but mDe have a semi-
mature phenotype. 
Migration and maturation markers on CDlc+/CDllc+ mDC purified from RASF (n=3) 
compared to RA PB (n=5) (4) (a) and PsA SF (n=3) compared to PsA PB (n=5) (b) and 
CD303+/CD123+ pDC purified from RASF (n=3) compared to RA PB (n=5) (c) and PsA 
SF (n=3) compared to PsA PB (n=5) (d). Values are calculated as the mean fluorescent 
intensity (MFI) fold of increase above the isotype control. The box and leaf plots depict 
median and interquartile range (50% of the data), flanked by whiskers indicating the extent 
of the data. *p<0.05. Statistical analysis was carried out using Mann Whitney. 
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SF (Fig. 3.7d) pDC displayed an immature phenotype, generally comparable to that of 
circulating PB pDC, with low to absent expression of CD40, CD80 and CD83. The only 
difference observed was an increase of CD86 expression on PsA SF pDC compared to PsA 
PB pDC (p=0.046), although this was not observed on RA SF pDC. Since CD62L was 
significantly reduced compared with healthy volunteers but not absent, on mDC and pDC 
from RA and PsA PB, we also evaluated expression on SF derived cell subsets. CD62L 
was further decreased on mDC and pDC from both RA and PsA SF DC subsets compared 
to RA and PsA PB (significant in PsA SF mDC, p=0.049). 
The presence of relatively large numbers of immature pDC in SF was intriguing, since 
immature pDC characteristically produce high levels of IFN-a (591). The level of IFN-a 
expression in inflammatory synovial fluids has rarely been characterised, and if sought 
declared absent in previous publications (125). We therefore analysed SF from RA 
(n=18), PsA (n=14) and OA (n=7) for the presence oflFN-a by ELISA (Fig. 3.8). By this 
methodology, IFN-a was detectable in many synovial fluids, derived not only from RA and 
PsA but also from a small number of OA SF. However, there were no significant 
differences when disease states were compared. 
3.3.8 SF can differentiate monocytes into mDe 
I next considered whether SF itself contained factors that drive mDC semi-maturation. It 
has previously been reported that SLE serum is sufficient to differentiate monocytes into 
monocyte-derived DC (moDe) due to its high IFN-(l content (498). Monocytes were 
purified from healthy volunteer PB and cultured in granulocyte-macrophage-colony 
stimulating factor (GM-CSF) and IL-4 supplemented media as a positive control (Fig. 
3.9b) or media alone as a negative control (Fig. 3.9a). The remaining monocytes were 
cultured in media supplemented with either 10% cell free SLE SF (Fig. 3.9c), 10% cell free 
OASF (Fig. 3.9d), 10% cell free PsA SF (Fig. 3.ge) or 10% cell free RA SF (Fig. 3.91). 
All SF was sterile filtered. Light microscopic images of morphological alterations and 
F ACS analysis of cell phenotype were used to assess cellular conversion. 
After 5 days of culture the monocytes in media alone did not have good viability and 
showed no proliferative capacity. The monocytes cultured in SF supplemented media were 
viable and proliferating and morphologically, were comparable to moDe driven by the 
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Figure 3.8 RA, PsA and OA SF contain IFN-a.. 
The level of IFN-~ in SF from RA (n=18), PsA (n=15) and OA (n=8) was measured by 
ELISA. Squares indicate individual samples expressed on a log scale. - = median. 
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Figure 3.9 The SF mediated conversion of PB monocytes to mDe. 
Light microscopic phase contrast images and phenotype pre and post 24 h incubation with 
S.aureus PGN (10Jlglml) of monocytes purified from healthy PB and cultured in GM-
CSF/IL-4 (a and g), media alone (b and h), 10% SLE SF (c and i), 10% OA SF (d and j), 
lO% PsA SF (e and k) or 10% RA SF (f and I). Arrows indicate mature DC with typical 
dendrite extensions. 
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traditional culture system using GM-CSF and IL-4. F ACS analysis of cellular phenotype 
indicated that all SF supplemented media cultures had up-regulated CDllc expression to 
comparable levels with that driven by GM-CSF and IL-4, consistent with moDC 
conversion. Expression of CDlc was also upregulated on SF supplemented cultures, but 
not to levels as high as that observed in GM-CSF/IL-4 supplemented cultures. 
Furthermore, CD14 persisted on the cell surface of SF cultured cells at levels higher than 
that observed on GM-CSF/IL-4 cultured cells. Expression of CD40, CD80 and CD83 was 
low to absent, while CD86 was expressed on cells consistent with a predominantly 
immature phenotype. 
3.3.9 SF inhibits TLR2 stimulated TNF-a release from moDe 
A number of classical animal models of arthritis, such as streptococcal cell wall induced 
arthritis, are dependent upon the engagement of the innate immune system via TLR 
signalling. TLR2 deficient animals display significantly reduced severity of arthritis (592). 
Moreover, bacterial peptidoglycans (PGN) capable of acting as agonists to TLR2, have 
been detected in the joints of patients with inflammatory arthropathies (593) and APC 
(otherwise poorly characterised) containing PGN have been identified in inflamed 
synovium (594). It is now recognised that DC are activated via TLRs (491). Thus TLR 
induced phenotypic changes and cytokine production were evaluated in order to assess the 
functional capacity of SF converted moDC using the TLR2 agonist S.aureus PGN 
(10Jlg/ml). 
Upon exposure to PGN, GM-CSF/IL-4 cultured moDC matured both morphologically, 
phenotypically and functionally as expected. Dendrite expression and up-regulation of 
CD80, CD83 and CD86 and slight down-regulation ofCDlc and CDllc (Fig. 3.9g) were 
observed and release of TNF-a to agonist was increased (Fig. 3.10). Media cultured 
monocytes did not alter dramatically (Fig. 3.9h), nor did they release TNF-a. Surprisingly, 
while many moDC in both SLE and OA SF culture matured morphologically with evident 
dendritic expression, CD80, CD83 and CD86 were not upregulated on the cell surface, 
indicating aberrant maturation (Fig. 3.9i and 3.9j respectively). Consistent with this 
observation, SLE and OA SF cultured moDC were capable of only low level TNF-a. 
release (Fig. 3.10). Furthermore, only a small percentage of PsA and RA SF cultured 
moDC attained mature morphology, but like SLE and OA SF cultured moDC, did not 
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Figure 3.10 SF cultured moDe release only low levels ofTNF-a. 
TNF-a levels in GM-CSF/IL-4 cultured moDC (red), media cultured monocytes (purple), 
SLE SF cultured moDC (pink), OA SF cultured moDC (orange), PsA SF cultured moDC 
(green) and RA SF cultured moDC were analysed by ELISA following 24 h stimulation 
with (filled bars) or without (levels too low to appear) s'aureus PGN (10 Ilg/ml) and 
expressed as pg/mt. One representative example from each of thrice replicated 
experiments is shown. 
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attain a mature phenotype (Fig. 3.9k and 3.91 respectively). Again, consistent with this 
observation, PsA and RA SF cultured moDC were capable of only low levels of TNF-a 
release following TLR2 stimulation (Fig. 3.10). Together these data indicate a number of 
possibilities. Firstly, whereas SF from RA, PsA and OA is sufficient to drive conversion 
of monocytes to moDC this process is incomplete resulting in the presence of intrinsic 
cellular defects. Alternatively, factors in the SF itself may directly inhibit the function of 
moDC. 
In order to assess the latter possibility, monocytes were cultured into moDC using GM-
CSF/IL-4 and at day 5 of culture were incubated in the presence or absence of either 10% 
cell free RA SF, or 10% cell free PsA SF. The SF in both cases was composed of a pooled 
cocktail of SF from 5 separate donors. After 24 hours, S. aureus PGN (1 OJ.tglml) was 
added to wells and incubated for a further 24 hours before supernatants were analysed for 
TNF -a levels by ELISA. All cultures released TNF -a in response to TLR2 stimulation, 
however cells in the presence of either RA SF or PsA SF released significantly less TNF-
a than those cells in media alone (p=0.016 and p=0.024 respectively) (Fig. 3.11b). Both 
RA SF and PsA SF contained negligible levels of TNF-a a priori (Fig. 3.11a). The data 
indicate that factors in SF, irrespective of diagnostic criteria, may either partially inhibit 
TLR2 mediated activation or may inhibit TNF-a release through anti-inflammatory 
activity. Alternatively soluble (s) TNF-receptor 1 (TNFRI) in SF may bind to some of the 
TNF-a released thus resulting in a lower measurement on ELISA. To assess this 
possibility IL-6 release was also measured. Both RA SF and PsA SF contained substantial 
levels of IL-6 (Fig. 3.IIc), thus culture supernatants were calculated as the concentration 
ofIL-6 above the background. Analysis revealed that both RA and PsA SF were sufficient 
in themselves to elicit IL-6 release from moDC (Fig. 3.11 d). IL-6 levels were further 
increased after TLR2 activation in all cultures, indicating that SF is neither inhibiting 
TLR2 activation nor moDC activity. The data are instead consistent with sTNFRI present 
in SF binding TNF-a released by DC. However, as background IL-6 levels were high, 
additional experiments analysing intracellular mechanisms of activation such as NF-KB 
phosphorylation and transcriptional IL-6 mRNA are required in order to investigate this 
finding further. 
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Figure 3.11 SF inhibits TNF-a. release from GM-CSF/IL-4 cultured moDC. 
TNF-a. (b) and IL-6 (d) levels in GM-CSF/IL-4 monocyte differentiated moDC incubated 
for 24 h in media alone (red), 10%PsA SF (green) or lO%RA SF (blue) were analysed by 
ELISA pre and post 24 h stimulation with s'aureus PGN (10 Jlg/ml) and expressed as 
pg/ml. The background levels of TNF-a. (a) and IL-6 (c) in cell free media containing 
lO%PsA SF or 10%RA SF alone was also analysed. Levels of TNF-a. and IL-6 were 
corrected for the background levels as measured in the SF alone. 
*p<0.05 Statistical analysis was carried out using Student's T test. 
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3.3.10 SF mDe and pDC mature and release cytokines upon TLR stimulation. 
In order to detennine if DC subsets within SF have an intrinsic defect preventing nonnal 
function both subsets were purified from SF and response to TLR stimulation analysed. It 
is recognised that DC are activated via TLRs (491). Thus TLR induced cytokine 
production was evaluated in disease compared with healthy PB derived DC in order to 
detennine if DC subsets within SF have an intrinsic defect. 
We purified mDC and pDC as previously described and evaluated addition of the TLR2 
agonist S.aureus PGN (for mDC) or the TLR9 agonist CpG ODN 2216 (for pDC) over 
24h. For control purposes, mDC were also incubated with GM-CSF alone or the irrelevant 
TLR agonist CpG ODN 2216 (mDC do not express TLR9). pDC were incubated with IL-3 
alone or with control ODN 2216c. Phenotypic changes in DC subsets were measured by 
F ACS analysis and cytokine release by multiplex assay or ELISA. Irrelevant TLR agonists 
did not induce cytokine production in any culture conditions tested, nor had they any effect 
on in vitro maturation of DC subsets (data not shown). Distinct patterns of cytokine 
production emerged on comparison of PB versus SF derived mDC and pDC. In PGN-
stimulated cultures mDC from both PB and SF produced comparable levels ofTNF-q (Fig. 
3.12a). In contrast, SF mDC produced considerably higher levels of IL-l ° following PGN 
stimulation than did PB comparators. IL-12p70, IL-2 and IL-4 levels were below the limit 
of sensitivity of the assay in cultures. Furthennore, coincident addition of PGN with GM-
CSF produced considerably higher levels of maturation marker expression (compared with 
GM-CSF alone), particularly CCR7, CD40, CDSO and CDS3 (Fig. 3.12b). We next 
examined cytokine release by pDC. CpG ODN 2216 stimulated the release of large 
amounts of IFN-a and TNF-a, from PB and SF derived DC. llowever only SF pDC 
produced IL-1O following CpG ODN 2216 stimulation (Fig. 3.13a). Neither IL-2 nor IL-4 
release was detected under these conditions. Upon phenotypic analysis upregulation of 
CCR7, CD80 and CD83 (Fig. 3.13b) after CpG ODN 2216 stimulation was observed. 
Finally, we noted that growth factor alone, namely GM-CSF or IL-3, was sufficient to 
promote maturation marker expression but did not induce cytokine production. Together 
these data indicate that SF DC subsets retain the capacity to upregulate maturation markers 
and respond to TLR agonists and that the latter are necessary to promote optimal 
maturation and cytokine production. They further show no intrinsic specific maturation 
failure or block. 
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Figure 3.12 SF mDC mature and release TNF-a at comparable levels to healthy PB 
mDe, but only SF mDC release IL-10. 
Cytokine release and maturation status of mDe purified from healthy control PB (n=3) or 
inflammatory arthritis SF (RA=2, PsA=l) were assessed after 24 h incubation with GM-
CSF supplemented media alone or containing s'aureus PGN (10 Ilglml). The 
concentrations ofTNF-a and IL-lO (a) in supematant from the cultures was determined by 
multiplex analysis and expressed as release per 5x104 cells. Squares indicate individual 
donors. Maturation and co-stimulation marker expression was determined by flow 
cytometry and one representative example from each of the healthy control PB and 
inflammatory arthritis SF groups are shown (b). 
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Figure 3.13 SF pDC mature and release IFN-a and TNF-a at comparable levels to 
healthy control PB pDC, but only SF pDC release IL-lO. 
Cytokine release and maturation status of pDC purified from healthy control PB (n=3) and 
inflammatory arthritis SF (RA=2, PsA=l) were assessed after 24 h incubation with IL-3 
supplemented media alone or containing the TLR9 agonist CpG ODN 2216 (3.2 J-lg/ml). 
The concentrations of IFN-a, TNF-a and IL-1O (a) in supematant from cultures was 
determined by multiplex and ELISA analysis and expressed as release per 5x 1 04 cells. 
Squares indicate individual donors. Maturation and co-stimulation marker expression was 
determined by flow cytometry and one representative example from each of the healthy 
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3.4 Discussion 
The relative role of innate and adaptive components of the host immune response to 
inflammatory synovitis is of considerable current interest. DC comprise a heterogeneous 
network of professional antigen presenting cells, capable not only of presenting antigen 
and inducing subsequent adaptive immune responses, but also of sensing the inflammatory 
environment and contributing to the cytokine milieu therein. Whilst implicated in the 
pathogenesis of RA and PsA (273, 294-296, 550, 552), prior analysis of DC subsets has 
been hampered by a lack of specific DC markers and reliable quantitation methodologies. 
This study has utilised the pDC specific CD303 and the mDC marker CD 1 c within a 
sensitive assay system to provide enumeration and phenotypic analysis of the DC subsets 
in PB and SF from PsA and RA patients. Thereafter we have utilised novel markers to 
purify DC subpopulations and perform a functional evaluation of their activation potential 
ex vivo. Finally we have for the first time attempted a phenotypic description of DC 
subsets in PsA and compared them with those in RA. 
The first observation was reduction in circulating PB pDC and mDC populations in RA 
and pDC populations in PsA. That this was not observed in prior investigation probably 
reflects less sensitive methodologies (125, 595) and identification of subsets based upon 
CD123 expression, which is also expressed by basophils (596), hcmatopoietic progenitor 
cells (597), endothelial cells (598), monocytes, eosinophils and small subsets of 
lymphocytes (599). The observed decrease in DC numbers is not due to steroid therapy, 
which has been reported to reduce DC numbers (600) and function (601), as patients on 
corticosteroids were excluded. Decreased PB DC numbers most likely reflect DC 
migration from the circulation and accumulation to the inflamed synovial compartment. 
This is consistent with previous studies (106, 125, 595), and with our own data indicating 
comparatively high numbers of mDC and pDC in SF effusions from both PsA and RA. In 
addition, SF DC subset expression of CD62L (normally cleaved from the cell surface after 
leukocyte tethering and rolling across high endothelial venules (602) was lower on both 
PsA and RA SF compared to the peripheral blood compartment further indicative of 
migration. The trend towards decreased PB pDC numbers in the OA patients, although not 
significant, may be indicative of altered DC migration toward the synovial compartment. 
OA is associated with synovial hypertrophy, hyperplasia, local inflammation and recurrent 
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effusions (603). Commensurate with this hypothesis, we have identified a statistically 
significant inverse correlation between acute phase response as a surrogate for disease 
activity and circulating PB DC subsets. 
Other factors however may operate in regulating detectable DC numbers, particularly 
within the bone marrow in which increasingly it is recognised that functional maturation 
defects may exist for leukocyte lineages (604). For example, reduced pDC numbers in 
circulating PB could reflect elevated TNF-a expression (605, 606): TNF-a is known to 
inhibit fms-like tyrosine kinase 3-ligand (FLT -3L) driven differentiation of pDC from bone 
marrow progenitors (591, 607). Future studies will be required to establish the circulating 
half life and tissue destination of DC subsets in the context of inflammatory arthopathies, 
and indeed of the effect of cytokine blockade on such parameters. It should also be noted 
that reduced circulating DC subsets have been demonstrated in several other inflammatory 
disorders including SLE (588) and chronic active hepatitis (608) and regulatory pathways 
in such diseases may also be informative in elucidating DC function in synovitis. 
A further novel observation was reduced CD62L expression on both DC subsets in PsA 
and RA PB. Previous reports of reduced CD62L expression on RA PB CD3+ and CD 19+ 
lymphocytes, monocytes and granulocytes (609) have implicated immunosuppressive 
therapies including methotrexate (610) and a similar mechanism could explain our 
observations. However down-regulation of adhesion molecules such as CD62L is 
necessary for the release of CD34+ progenitors to the PB (611), and it is possible that a 
CD62L1o PB DC population may indicate altered recirculation, or modified release of bone 
marrow DC precursors. In addition, after migration across HEV, CD62L is rapidly shed 
from the cell surface via proteolytic cleavage producing a soluble (s) CD62L isoform, a 
process considered essential in order to limit the inflammatory process. A number of 
groups have reported elevated levels of sCD62L in RA serum (612, 613), consistent with 
intact CD62L mediated leukocyte migration. Certainly, the accumulation of pDC and 
mDC in the SF indicates that migration towards the inflamed compartment is not impeded. 
However, as DC comprise fewer than 1 % of all leukocytes it is doubtful that migration of 
these cells alone would alter serum sCD62L significantly. 
SF purified pDC were recently reported to exhibit a relatively immature phenotype given 
their inflammatory environment (125, 595). Similar observations have been made for 
109 
mDC (106, 535). We now confinn these observations in RA and extend the data to include 
PsA derived cells indicating that the inflamed synovial compartment per se can sustain 
immature DC capable, by inference, of antigen sensing, capture and ultimately 
presentation. Both mDC and pDC upon removal from the synovial fluid were capable of 
. increased maturation markers expression and provided with TLR agonist activation were 
capable of cytokine release. There does not therefore appear to be an intrinsic functional 
defect of DCs. Whereas TLR2 or TLR9 stimulation was not sufficient to induce 
substantial IL-I0 release from healthy PB mDC and pDC, it was sufficient for IL-I0 
release from PsA and RA SF purified cells. The functional implications of this observation 
are unclear and require further examination to include other TLR agonists and DC 
activation conditions. 
We wished to examine the cross regulation of mDC and pDC subsets in the context of 
inflammatory synovitis. That said the technical demands of isolating primary DC from an 
inflamed compartment (particularly pDC) are not insignificant and placed limitations on 
the extent of functional analyses that were feasible. Very few groups have thus far 
attempted fonnal functional evaluation of purified DC subsets from any inflamed tissue. 
Other groups have utilised monocyte derived DC (moDC), generated from RA PB, to 
assess by inference DC function in arthritis. In particular these analyses have suggested 
that DC in inflammatory arthritis are hyper-responsive to TLR2 and TLR4 stimulation, 
releasing more IL-l, IL-6, TNF-a. and IL-lO (614, 615). However, Iwahashi et al have 
reported that not only are CD 16+ monocytes elevated in peripheral circulation of patients 
with RA, but they also express higher levels of TLR2 than CD 16" monocytes producing 
increased amounts ofIL-I, IL-6, TNF-a. and IL-8 in response to TLR2 stimulation (616). 
Thus it can be argued that the approach utilised in the earlier studies, although pragmatic, 
was inherently flawed by the use ofmonocytes to infer 'classical' DC function. In addition 
5 days of culture in growth factors are required to drive monocyte differentiation into 
moDC, thus culture artefact cannot be discounted in these studies. Thus in order to gain 
insight into DC function in disease we chose to purify DC directly as, although this 
presented major difficulties in obtaining sufficient numbers, we believed it was necessary 
in order to identify differences in DC function and discount starting cell population or 
culture artefact. Our approach combines a broad but pragmatic approach to start to 
examine DC function ex vivo. Future technical refinements will be required to perform the 
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desired extensive in vitro analyses of DC function that will more comprehensively address 
their functional role. 
These are the first data to investigate purified DC subsets in PsA patients. Prior studies 
have identified pDC in cutaneous psoriasis and increased type I IFN expression in psoriatic 
plaques after application of a TLR agonist (617). Numerous data indicate a role ofT cells 
in PsA pathogenesis (233) and as such determining the functional role of both pDC and 
mDC in PsA synovium should be informative. The present study provides the essential 
pre-requisite for such studies in determining the presence, enumeration and function of 
each subset in PB and SF. 
IFN-a was detected in SF in both RA and PsA patients. The role for this cytokine in 
synovial pathogenesis is indicated by numerous reports linking IFN-a therapy to induction 
of RA and PsA in patients with no pre-existing clinical arthritis (545, 618, 619). 
Moreover, IFN-a is sufficient to drive monocyte differentiation to mDC in SLE patients 
(518). The significantly increased ratio ofmDC:pDC identified in SF, may indicate in situ 
differentiation ofmonocytes shed from the synovial lining layer to mDC, driven in part by 
IFN-a in fluid. It is therefore intriguing to consider a local cytokine mediated feedback 
loop whereby pDC IFN-a release promotes local mDC maturation. Consistent with this we 
observed that PsA and RA synovial fluid is capable of inducing differentiation of De from 
PB derived monocytes (moDC). Unexpectedly however, SF differentiated moDe released 
only low levels ofTNF-a in response to TLR2 stimulation as compared with GM-CSF/IL-
4 differentiated moDe and this occurred irrespective of SF origin (RAlPsAlOAlSLE). 
Considering that both mDC and pDC purified directly from SF responded normally to TLR 
stimulation, indicating no intrinsic defect, it is likely that a soluble factor present in SF 
inhibited either the TLR stimulation or the release of TNF-a. It has been proposed that the 
intracellular signalling initiated by a major regulator of DC function, the inhibitory Fc 
gamma receptor lib (FcyRIIb), is defective in RA thus enabling chronic inflammation 
(620). Since FcyRIIb stimulating immune complexes are abundant in SF, the decreased 
TNF-a released following TLR2 stimulation may have resulted from triggering of the 
(presumably) intact inhibitory FcyRIIb pathway in moDe generated from healthy 
volunteer PB. In order to assess this possibility in future, analysis of this experiment using 
moDe generated from RA and PsA PB is necessary. 
III 
While only mature DC are able to induce the activation ofT cells and the differentiation of 
B-cells into antibody-producing plasma cells, immature DC are able to capture antigen at 
picomolar and nanomolar concentrations (446). In the steady state, presentation of these 
self-antigens should sustain tolerance. However the presentation of these antigens within 
an inflammatory context, such as the inflamed synovial compartment in susceptible 
individuals, may lead to chronic inflammation and autoimmune disease. SF apparently 
contains a pool of immature DC subsets of both mDC and pDC lineage. It is likely that SF 
DC are not only crucial for (auto) antigen capture, but thereafter migrate into the synovial 
membrane leading to perpetuation, and perhaps initiation (neoepitopes) of autoimmunity. 
In order to assess this possibility, it was necessary to analyse the phenotype and 
distribution, particularly in relation to other leukocytes, of mDC and pDC in situ in 
inflamed synovial membrane. The results of these analyses will be discussed in Chapter 4. 
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Chapter 4: Analysis of the localisation, maturation and cytokine profile 
of plasmacytoid dendritic cells and myeloid dendritic cells in 
inflammatory synovitis 
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4.1 Introduction 
A characteristic of the inflamed synovium In RA and PsA is the rapid influx of 
mononuclear cells including CD4+ and CD8+ T cells, plasma cells, B cells, NK cells, 
monocytes, mast cells and DC (101-105, 107, 123-125). In 40-50% of Ps A and RA cases 
cellular infiltration progresses towards the development of lymphoid-like structures, with 
HLA-DR expressing CD4+ T cells localised to aggregates in close association with MBC 
expressing macrophages and DC, as well as B cells. The synovium is therefore generally 
considered an ectopic lymphoid organ, even though germinal centre formation occurs in as 
few as 5-23% of cases (132). Moreover, the lack of classical lymphoid topographical 
segregation in the majority of cases may enhance disease pathology, particularly with 
respect to the potential for in situ antigen presentation. 
DC are the most potent professional .APC, critical not only to the initiation and regulation 
of adaptive immunity but also the maintenance of both central and peripheral tolerance. 
As such, DC have been implicated in the initiation and perpetuation of chronic 
autoimmune disease through the abolition of self-tolerance and subsequent emergence of 
self-reactive lymphocytes. Significantly, it has recently been shown that the aberrant 
accumulation of DC in tissue, but not of T cells or B cells, is sufficient in itself to induce 
symptoms of autoimmunity including the production of antinuclear antibodies (621). 
Furthermore, DC infiltration to the inflamed synovial compartment occurs early in disease 
pathology (273). 
A number of previous immunohistochemical analyses of (predominantly) RA synovium 
sought to characterise the presence and nature of (myeloid) DC infiltration. Immature 
CDla+ mDC have been identified in the RA synovial lining layer, while mature MHC lhigh; 
MHC nhigh/ DC-lysosome-associated membrane protein (LAMPt; CD83+ cells have been 
localised predominantly to perivascular regions and lymphocyte aggregates (534). In 
addition, differentiated mDC expressing nuclear RelB as well as co-stimulatory molecules, 
both of which are associated with active APC function, have been identified in RA SM and 
this is consistent with hypotheses of DC driven autoreactive T cell expansion (273). 
However technical restrictions arising from a lack of specific DC surface markers, mean 
that past studies have been limited as they provided no real marker to distinguish mDC 
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from SM infiltrating macrophages, which also express such markers as CD83. Moreover, 
and in consequence, there is poor understanding of how DC phenotype differs within and 
between inflammatory arthropathies. 
The origin of SM localised DC is unclear, although it has been suggested that immature SF 
DC may migrate towards CCL19/21 rich lymphocyte aggregates where they undergo local 
maturation. This hypothesis is supported by the apparent DC maturation 'gradient' 
described by prior studies identifying immature CCR6+ mDC in CCL20 rich areas of the 
synovial lining layer and mature DC localised to ectopic lymphoid-like structures in the 
synovium (133). Alternative theories suggest a model whereby over-expression of 
precursor DC chemoattractants CCL2, CCL5 and CCL20, coupled with TNF-a driven up-
regulation of adhesion molecules induces the transendothelial migration of PB DC direct to 
the synovium. According to this model, monocyte shedding to the SF and in situ 
differentiation to moDC, driven by the presence of multiple growth and differentiation 
factors including GM-CSF, TNF-a and IL-l, may account for SF DC (538). However, this 
model does not account for the presence of immature pDC in SF. Indeed, almost nothing 
is known of the infiltration or phenotype ofpDC to the arthritic synovium. 
A number of reports have recently identified pDC in the target tissue of numerous 
inflammatory disorders including contact dennatitis, psoriasis vulgaris and systemic lupus 
erythematosus (SLE) (437, 622). Furthennore, a critical role has been attributed to pDC in 
the aetiopathology of SLE and is associated with excessive IFN-a production (623). It is 
of note then that a role for this cytokine in synovial pathogenesis is indicated by numerous 
reports linking IFN-a therapy to induction of RA and PsA in patients with no pre-existing 
clinical arthritis (543-549). Critically, IFN-a is increasingly considered important to the 
pathology of psoriasis, a defining extra-articular feature of PsA (437). Clearly then, 
resolution of the pDC profile in inflamed tissue is required, particularly in the context of 
cytokine production as pDC are the primary type I IFN producing cells in the body. 
Cytokines are pivotal players in inflammatory synovitis, as evidenced by the therapeutic 
success of TNF-a blockade. However many patients do not respond to therapy, and in 
those that do, long-tenn remission is rare. Thus in the treatment of RA, the critical 
challenge now is to uncover the underlying immunological processes responsible for its 
generation and perpetuation, such that peripheral tolerance can be re-established and 
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therapeutic remission can be maintained. To this end it is vital to understand what 
cytokines are produced by those cells most involved in the maintenance of self-tolerance, 
namely DC. Indeed, detailed analysis of cytokine expression by DC in the context of 
human inflammatory disease has, to our knowledge, been performed by only one other 
group (125). 
4.2 Aims and Objectives 
As described in Chapter 3, we have identified an increase in the synovial fluid, but 
decrease in the blood, of both pDC and mDC from RA and PsA patients. Considering the 
recent advances in identifying DC subsets by use of specific markers, it was therefore the 
aim of this chapter to undertake a comparative analysis of pDC and mDC in synovium 
from RA and PsA patients in order to address whether the reduction in PB DC subsets 
could be accounted for solely by accumulation to the SF, or whether these subsets also 
migrated to the SM. In addition, it was aimed to provide a more comprehensive 
investigation of the functional phenotype, including maturation status and cytokine profile, 
ofmDC and pDC than has previously been attempted. 
Specifically, it was planned to address: 
• Whether pDC and mDC could be detected in the SM of patients with RA, PsA or OA 
using immunohistochemical techniques. 
• The maturation profile of RA, PsA and OA SM infiltrating pDC and mDC as assessed by 
CD83 and DC-LAMP expression. 
• Whether pDC and mDC within synovium could be localised to Iymphocyte aggregates, 
specifically with reference to CD3+ and CDS+ T cells. 
• Whether pDC and mDC display the same or different cytokine profiles in SM, by 
analysis ofIL-12p70, IL-23p19, IL-15, IL-18, IFN-a and IFN-~. 
• Finally, whether there exist any identifiable and specific differences in the number and 
phenotype ofpDC and mDC from RA SM in comparison to PsA SM. 
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4.3 RESULTS 
4.3.1 Patients and tissue samples 
Inflammatory arthritis patients attending the GRI and the Academic Medical Centre 
(AMC) in Amsterdam fulfilled the American College of Rheumatology criteria for RA 
(Amett), or met diagnostic criteria for PsA as previously described. All patients and 
healthy donors gave informed consent and the study protocol was approved by the GRI 
Ethical Committee and the AMC Medical Ethics Committee. Twenty RA patients, ten 
osteoarthritis (OA) patients and nine psoriatic arthritis (PsA) patients were included in this 
study (Table 4.1). Patients were receiving disease modifying anti-rheumatic drugs 
(DMARDs) such as methotrexate (no more than 15 mg/week), hydroxychloroquine, or 
sulfasalazine, of stable dose for at least two months. Non-steroidal anti-inflammatory 
drugs (NSAIDs) were allowed, provided that the dose and frequency had been stable for 30 
days. Small-bore arthroscopy was performed under local anesthesia and synovial tissue 
samples were obtained from multiple sites in the joint using 2-mm grasping forceps 
(Storz). Synovial tissue matched skin biopsies were taken from one patient with PsA. 
Biopsy samples were collected and snap-frozen in TissueTek OCT (Miles Elkhart). 
Frozen blocks were stored in liquid nitrogen until sectioned for staining. Sections (5 ~lm) 
were cut in a cryostat and mounted on Star Frost adhesive glass slides (KnittelgUlser) that 
were stored at -80°C until use for immunohistochemical analysis. 
4.3.2 mDC and pDC in inflamed synovium. 
Other studies of DC infiltration to the target tissue in inflammatory disease have utilised 
tissue dissociation and FACS analysis to determine DC subset numbers (622). However, 
the enzymatic digestion of synovium is associated with increased cell death and altered CD 
receptor expression, thus compromising the recovery of rare DC subsets and rendering 
phenotype investigation difficult. In addition this method does not allow examination of 
tissue architecture and the distribution of DC subsets therein. Accordingly, we first chose 
to examine the expression and distribution of CDlc+ mDC and CD304+/CD123+ pDC in 
synovial tissue taken at biopsy from RA, PsA and OA patients by immunohistochemical 
methods. 
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Table 4.1. Clinical features of RA, PsA and OA patients included in the study· 
Diagnosis Characteristic Median (range) 
Age (years) (Median, range) 53 (26-73) 
Male:Female 9:11 
RA Disease Duration (months) 46 (4-412) 
n=20 ESR (mmlhour) 50.5 (4.112) 
CRP (mg/liter) 22.5 «3-122) 
RF (+1-) 16 (+), 4 (-) 
Age (years) (Median, range) 49 (34-71) 
Male:Female 5:3 
PsA Disease Duration (months) 198 (12.456) 
n=9 ESR (mmlhour) 44.5 (7-50) 
CRP (mg/liter) 27.5 (7-51) 
RF (+1-) 0(+),9(-) 
Age (years) (Median, range) 69 (54-81) 
Male:Female 1:7 (NA=2) 
OA Disease Duration (months) 39 (6-240) (NA=2) 
n=10 ESR (mmlhour) 18.5 (14-63) (NA=2) 
CRP (mglliter) 7 (2·60) (NA=2) 
RF (+1-) 0(+),8 (-) (NA=2) 
·RA, rheumatoid arthritis; PsA, psoriatic arthritis; OA, osteoarthritis; ESR, erythrocyte sedimentation rate; 
CRP, C reactive protein; RF. rheumatoid factor; NA, not available 
Median and range is given for each characteristic. 
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4.3.2.1 RA mDC alld pDC sYllovial tissue distribution 
CDlc+ mDC and CD304+/CDI23+ pDC were dispersed throughout the synovial sublining, 
but not the superficial lining layer, in RA (n=5) (Fig. 4.1 a). CD 1 c + mDC could be 
identified in close association with other lymphocytes and, to a lesser extent, in peri-
vascular regions. CD304+/CD123+ pDC were also identified in close association with 
other lymphocytes and in peri-vascular regions. 
4.3.2.2 PsA mDC alld pDC synovial tissue distribution 
CDlc+ mDC and CD304+/CD123+ pDC were dispersed throughout the synovial sublining, 
but not the superficial lining layer, in PsA (n=5) (Fig. 4.1 b). CD 1 c + mDC could also be 
identified in peri-vascular regions and in close association with cellular aggregates. 
CD304+/CDI23+ pDC were also identified in close association with other lymphocytes and 
in peri-vascular regions. 
Psoriasis is a significant defining extra-articular characteristic of PsA and pDC have 
previously been identified infiltrating inflamed skin lesions in studies by other groups 
(437, 622). Accordingly, we obtained SM matched inflamed skin biopsies from one 
patient in order to investigate whether both sites could present targets of pDC migration in 
PsA. For this analysis mDC were identified by CDlc staining, while the pDC specific 
CD303 was used to identify pDC infiltration. CD I c + mDC were identified in the dermal 
and epidermal layer of skin (Fig. 4.2a) and in the sub-lining layer of matched SM (Fig. 
4.2c). CD303+pDC were identified in the dermal, but not the epidermal, layer of skin (Fig. 
4.2b) and in the sub-lining layer of matched SM (Fig. 4.2d). This suggests that in the case 
of PsA, inflamed skin also constitutes a target for DC migration. However, analysis of 
additional matched biopsies would be required in order to undertake informative 
quantitation of the number ofmOC and pOC infiltrating either site. 
4.3.2.3 OA ",DC and pDC sYllovial tissue distributioll 
CDlc+ mDC and CD304+/CDI23+ pDC were dispersed throughout the synovial sublining, 
but not the superficial lining layer, in OA (n=5) (Fig. 4.1c). CDlc+ mDC could be 
observed in close association to other lymphocytes. CD304+/C0123+ pDC were also 
identified in close association with other lymphocytes. Neither subset was observed in 
peri-vascular regions, possibly because OA SM did not appear as vascularised as its RA 
and PsA counterparts. 
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Figure 4.1 CDlc+ mDC and CD304+/CDI23+ pDC are present in RA, PsA and OA 
SM. 
DC subset infiltration to the synovium was investigated by immunohistochemical methods. 
CDlc+ mDC were visualized using AEC substrate (stained red). For pDC detection, 
double-staining was used with CD304+ cells visualized using DAB substrate (brown) and 
CD123+ cells visualized using AEC substrate (red). pDC were identified as 
CD304+/CD123+ double positive cells, appearing black using this technique. mDC and 
pDC were identified in the inflammatory cell infiltrate to the sub-lining layer and around 
vessels of synovial membrane of serial sections taken from RA (n=5) (a), PsA (n=5) (b) 
and OA (n=5) (c). Examples of positive cells are indicated by arrows. One example of 
each disease type is shown with isotype control. 
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Figure 4.2 Inflamed psoriatic skin lesions contain CDIc + mDC and CD303+ pDC. 
Single stain CDlc+mDC (a) (red) were identified in the dermal and epidermal layer and 
CD303+ pDC (b) (red) were identified in the dermal layer of an inflamed psoriatic skin 
biopsy taken from one patient with active psoriatic arthritis. Single stain CD 1 c + mDC (c) 
(red) and CD303+pDC (d) (red) were also identified in the inflammatory cell infiltrate to 
the patient matched SM. Examples of positive cells are indicated by arrows. An isotype 
control is also shown (e). 
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4.3.3 Digital image enumeration of pDC and mDC in SM 
Digital image analysis was used to quantify the number ofpDC and mDC in SM from RA, 
PsA and OA SM. Digital imaging allows computer-assisted analysis whereby 6 
consecutive high-power fields are taken from each of 3 random regions, resulting in 18 
high-power fields per section thus providing a representative measurement of the entire 
tissue section. In order to allow comparative digital image analysis, tissue must be stained 
in single session. To enable single session processing of a large number of sections, 
further immunohistochemical identification of pDC in SM was undcrtaken using single 
CD304 staining. Although CD303 is a more specific pDC antibody than CD304, staining 
(as confirmed by use of tonsil sections as positive controls) was inconsistent for light 
microscopic immunohistochemistry. Technical limitations were, therefore, placed on the 
volume of tissue sections that could be stained at one time, a problcm also experienced by 
other groups (125, 595). However, whereas others have instead opted to analyse pDC 
using CD123, which is expressed by numerous cell types (as discussed in Chapter 3), we 
chose the more specific marker CD304. Although CD304 is also expressed at very low 
levels on endothelial cells, we observed that these only appeared with the substrate DAB 
when additive double-staining methods, as utilised for the initial analyses of pDC 
infiltration to the synovium, were used. Furthermore, CD304'/CDI23+ leukocytes, not 
belonging to either DC subset, were identified during double-staining thus highlighting the 
importance of using the more specific CD304 antibodies, and not CD123, to accurately 
identify the respective DC subsets and exclude non-DC leukocytes from digital image 
analysis. 
Digital data image analysis of the number of mDC and pDC infiltrating RA (n=20), PsA 
(n=9) and OA (n=10) SM revealed that although RA and PsA SM contained more pDC 
and mDC than OA SM, there were no significant differences between disease groups (Fig. 
4.3a and Fig. 4.3b). It is likely that the lower total numbers in OA SM could be explained 
by a lower total cellular infiltration to the synovium. Furthermore, the number of pDC 
detected within each diagnostic group was significantly higher compared to the number of 
mDC in comparable tissue areas (RA, P<O.OOI; PsA, P=O.OOII; OA, P=O.0052) (Fig. 4.3c, 
Fig. 4.3d and Fig. 4.3e). These findings are consistent with a common pattern of DC 
infiltration across the three diseases. 
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Figure 4.3 RA, PsA and OA SM contain comparable numbers of pDC and mDC 
between diagnostic groups, but significantly more pDC than mDC within each group. 
The number ofmDC and pDC infiltrating RA (n=20), PsA (n=8) and OA (n=10) SM was 
calculated by CD1c (mDC) and CD304 (pDC) staining and computer assisted digital image 
analysis. No significant differences were observed between the numbers of both mDC (a) 
or pDC (b) present in RA, PsA and OA SM. In RA alone (c), PsA alone (d) and OA alone 
(e) the number of pDC was significantly higher than mDC (all ***<0.001). Results are 
shown as mean numbers of positive cells integrated optical density (IOD)/mm2±SEM. 
Statistical significance was determined by Mann-Whitney U test (***P<0.001). 
123 
(a) mDC (b) pDC 
RA RA 
PsA PsA 
OA OA 
o 5 10 15 o 50 100 150 
Mean Number of Positive Cells IOD/mm 2 
(c) RA (d) PsA (e) OA 
mDC mDC 
Iljll 
*** 
r--
I 
, pDC pDC pDC 
o 40 80 120 o 50 100 150 o 10 20 30 
Mean Number of Positive Cells IOD/mm 2 
4.3.4 Inflamed synovium contains more immature than mature mDC and pDC. 
It has been hypothesised that maturing DC may present peptides from dying self-tissue and 
environmental proteins as well as from pathogens, when encountered in a highly inflamed 
environment, promoting chronic inflammatory and autoimmune events. The maturation 
status of mDC and pDC in RA, PsA and OA SM was assessed using CDlc-FITC and 
CD303-FITC (which works well for immunofluorescence) in combination with the DC 
maturation markers CD83 (Fig. 4.4a and Fig. 4.4c and Fig. 4.4e) and DC-LAMP (Fig. 4.4b 
and Fig. 4.4d). Mature mDC and pDC were identified in RA (n=12), PsA (n=7) and OA 
(n=5) SM with no significant difference in number per area observed between groups. 
However, the mean percentage of mature CD83+ DC, as a proportion of all DC, was low in 
all patient groups (Table 4.2). The low percentage of mature DC was confirmed using DC-
LAMP, with even fewer mDC and pDC staining positive for this marker (RA mDC 
1.1±1.6 and pDC 7.1±4.3, PsA mDC 2.7±2.2 and pDC 16.1±4.S, OA mDC S.9±4.8 and 
pDC 6.2±3.1). These results indicate that over 76% of all mDC and 79% of all pDC in 
membrane retain an immature phenotype. Few disease differences emerged aside from the 
% of CD83+ mDC in RA and PsA compared to OA SM. Of interest, within RA SM only 
the percentage of CD83+ pDC was significantly higher in comparison to CD83+mDC 
(p=O.0418). 
The results of the SM analysis of DC subsets described thus far identified no significant 
differences between RA, PsA and OA, suggesting that we were observing an inflammatory 
phenomenon rather than a disease specific observation. This observation is consistent with 
other studies that identified no significant differences in the inflammatory infiltrate in RA 
and PsA, and no significant differences in the cytokinc profile of either disease (127,624). 
Thus the following analyses focus on RA SM only. 
4.3.5 mDC and pDC are co-localized to T cell areas in RA synovial tissue. 
We next defined the precise tissue location of DC subsets, particularly relating to T cell 
subsets given the ability of the former to present antigen and direct the differentiation of 
the latter. To this end, double immunohistochemistry was performed using antibodies 
against CD3 and CD8. CD4 was not localized since both CDlc+ and CD304+ DC also 
express the CD4 antigen (397). Both mDC and pDC were identified in close proximity to 
clusters of CD3 (Fig. 4.5b and Fig. 4.5c respectively) and CD8 (Fig. 4.5d and Fig. 4.5e 
respectively) positive cells in RA synovial tissue. 
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Figure 4.4 RA, PsA and OA SM contain more immature than mature mDe and pDC. 
The percentage ofCDlc+ mDC and CD303+ pDC coexpressing the DC maturation markers 
CD83 (a and c) or DC-LAMP (b and d) in RA (n=12), PsA (n=7) and OA (n=5) SM was 
low in all patient groups. A representative double immunofluorescence staining of RA SM 
from one patient is shown. CDlc + mDC (t) and CD303+ pDC (g) are green, CD83+ cells 
are red and double positive cells appear yellow. The isotype control is shown (e). Original 
magnification x400. 
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Table 4.2 Coexpression of the DC maturation marker CD83 by CD1c+ mDC and CD303+ 
pDC in ST from patients with RA, OA and PsA 
RA PsA OA 
CDlc+CD83+ (%±SEM) 4.7±2.9 8.9±7.2 23.9±12.l 
CD303+CD83+ (%±SEM) 23.1±S.9 22.6±6.1 12.7±3.S 
P values CDlc vs CD303 0.0418 0.1908 0.2649 
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Figure 4.5 rnDC and pDC are localized to CD4+ and CDS+ lyrnphocyte aggregates in 
RASM. 
DC subset localization to lymphocyte aggregates in RA SM was investigated by 
immunohistochemical methods. CDlc+ mDC and CD304+ pDC (red) were visualized 
using AEC substrate (stained red). For T cell detection, double-staining was used with 
CD3+ and CDS+ lymphocytes visualized using alkaline phosphatase substrate III kit (blue). 
An isotype control is shown (a). Both CDlc+ mDC and CD304+ pDC were identified in 
close proximity to CD3+ (b and c) and CD8+ (d and e) lymphocytes and as 
CD304+/CD123+ double positive cells, appearing black using this technique. A 
representative example of RA SM from one patient is shown. 
127 
(a) 
(b) 
(d) 
" ....  ~ 
," 
.. 
IgG 
CD1c+/CD3+ 
) 
t;J 
I 
~. 
~~ ,." .' r " 
(c) 
' /' 
I. J • 
" • J I 
, : 
(e) 
.. 
-
4.3.6 Differential expression of cytokines by mDC and pDC in RA synovial tissue. 
The propensity of DC subsets to direct the immune system towards either tolerance or 
immunity can largely be assessed by their specific cytokine profile. We therefore utilised 
double immunofluorescent staining techniques to analyse the expression of a number of 
cytokines of interest by CDlc-FITC+ mDC and CD303-FITC+ pDC. 
4.3.6.1 ThllTh17 regulatory cytokines 
RA is considered a predominantly ThllTh17 skewed disorder. We therefore analysed the 
expression of IL-12p70 by DC subsets as its presence in RA SM, coupled with the 
functional ability to induce or enhance IFN-y production and magni fy the Th 1 phenotype 
of disease, has been established by a number of studies (269, 625). We also chose to 
analyse IL-23p 19, a cytokine of particular current interest as it is critical to the local 
expansion of Th 17 T cells, and has been proposed as an essential promoter of end stage 
joint auto immune inflammation (329, 626). The p40 subunit of the IL-23 hcterodimer 
(pI9/p40) was not measured as this is shared with IL-12 (627). Critically, it is known that 
DC are capable of producing both of these cytokincs given the local environmental 
conditions. 
DC subset identification and co-localisation with cytokine expression proved technically 
challenging and has been recognised as such in many laboratories worldwide in the 
rheumatology field and beyond. In our experiments, high levels of background staining for 
IL-12p70, and for type I interferons in particular were observed. New experiments have 
recently been commenced to address these issues however the reagents and technical 
refinements were not available to me during the conduct of my thesis expcrimentation. 
Data obtained in my initial experiments are contained herein and are reported as such. 
Future re-analyses will be necessary to test their reproducibility and thereby detennine how 
robust the findings are in due course. 
In DC, IL-12p70 staining was confined to the mDC subset (Fig. 4.6a) (p<O.OOI). This was 
unsurprising given that mDC are classically considered the dominant IL-12 producing DC 
subset, although pDC derived IL-12 has been shown in vitro following CD40UCpG ODN 
motif stimulation (402, 499). Unlike IL-12p70, IL-23p 19 was not highly expressed in 
synovium. However, IL-23p19 expression was significantly higher in mDC than in pDC 
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Figure 4.6 IL-12p70 and IL-23p19 expression by mDe and pDC in SM. 
The expression ofIL-12p70 (a) and IL-23p19 (b) bymDC and pDC in serial sections from 
RA (n=5) was determined by immunofluorescent staining. CDlc+ mDC and CD303+ pDC 
were visualized by FITC-conjugated staining (green), with IL-12p70 and IL-23p19 
visualized by Alexa-594 conjugated staining (red). DAPI staining in blue indicates the 
nucleus. Using this method, mDC and pDC producing either cytokine and thus double 
positive, appear yellow. One representative section of each stain is shown. Original 
magnification x400, inset xl 000. Statistical significance was assessed by M ann-Whitney 
U test (*P<0.05, **P<O.OI, ***P<O.OOI). 
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(p=O.0273). Interpretation of these data is confounded by the high levels of background 
which are obvious from the photomicrographs reproduced herein (Fig.4.6). The 
proportional expression reported represents the observer manual counts performed together 
by myself and Dr MC Lebre in Amsterdam. The photographs produced were obtained after 
the manual count and the background predominantly reflects the blanching of fluorescent 
signal by then and consequent amplification of the red channel leading to the high signal 
observed. The fluoescent signal was very much clearer at the point of manual counting and 
for this reason the numbers generated are retained here representing the data obtained. 
However, future studies will certainly require to reproduce and confirm these observations 
and quantifications before formal intepretations can be robustly made. Together these data 
suggest that mDC, not pDC, are the dominant DC subset responsible for directing 
inflammation in RA SM towards a Th 11Th 17 phenotype. 
4.3.6.2 Innate inflammatory cytokines 
Two cytokines of particular interest to this laboratory are IL-IS and IL-I8. IL-IS is 
involved in the proliferation, survival and recruitment of activated T cells as well as 
proliferation and immunoglobulin synthesis by B cells (628). Similarly, IL-I8 is also 
involved in T cell recruitment, activation and proliferation in addition to being pro-
angiogenic and an inhibitor of fibroblast cell death (629). Both IL-IS and IL-I8 work 
synergistically with IL-I2 to enhance IFN-y production. We, and others, have previously 
demonstrated the presence and pathogenic role of both of these cytokines in RA SM (629-
631). Given the identification of DC/T cell clusters within synovium, we were particularly 
interested to investigate the possibility that mDC and pDC could enhance T cell activity by 
expression of either of these cytokines. 
IL-IS (previously identified at high levels in the RA SM) could be identified in non-DC 
leukocyte aggregates, as well as by DC (Fig. 4.7a). Within DC, proportionally high 
numbers of mDC and pDC expressed IL-IS. Although a greater percentage of pDC than 
mDC expressed IL-15, this did not attain statistical significance. IL-18 was also observed 
scattered throughout the synovium in non-DC leukocytes at relatively high levels (Fig. 
4.7b). The expression of IL-I8 however was significantly higher by pDC as compared to 
mDC (p=O.002), as almost all pDC identified in SM expressed this cytokine. 
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Figure 4.7 IL-15 and IL-18 expression by mDe and pDC in SM. 
The expression of IL-15 (a) and IL-18 (b) by mDC and pDC in serial sections from RA 
(n=5) was determined by double immunofluorescent staining. CDlc+ mDC and CD303+ 
pDC were visualized by FITC-conjugated staining (green), with IL-15 and ILl8 visualized 
by Alexa-594 conjugated staining (red). DAPI staining in blue indicates the nucleus. 
Using this method, mDC and pDC producing either cytokine and thus double positive, 
appear yellow. One representative section of each stain is shown. Original magnification 
x400, inset xl 000. Statistical significance was assessed by Mann-Whitney U test 
(*P<0.05, **P<O.Ol, ***P<O.OOl). 
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4.3.6.3 Type IIFNs 
The type I IFNs, IFN-a and IFN-~, are pleiotropic cytokines that promote isotype 
switching and have been shown to potently activate autoreactive T cells and contribute to 
the development of Th! cells (632, 633). Since IFN-a in particular has been associated 
with the aetiopathology of other auto immune diseases including SLE and psoriasis, and 
pDC are the dominant type I IFN producing cells in the body, we therefore chose to 
analyse the expression of these cytokines by DC in RA SM. 
As in the case of IL-12p70, the background staining for the type I IFNs appeared high and 
as such this analysis needs to be re-visited in order to draw firm conclusions from this data 
set. 
At present, the staining as it was undertaken and scored may offer only an indication of the 
respective DC type I IFN phenotype within synovium. Analysis suggested the presence of 
both IFN-a (Fig. 4.8a) and IFN-~ (Fig. 4.8b) in RA SM. Consistent with classical 
literature, IFN-a appeared to be expressed by pDC only and not by mDC, with the majority 
of pDC in SM expressing this cytokine. Conversely, IFN-~ appeared to be expressed by 
both DC subsets and although a greater overall percentage of pOC expressed IFN-~ as 
compared to mDC, this did not reach statistical significance (p=O.0813). Of interest, the 
type I IFNs have been linked to the inhibition of IL-12 production (634), commensurate 
with the observation that pDC in synovium do not express IL-12. Subject to the limitations 
of the photo reproduction these data require to be confinned and extended prior to robust 
interpretation - nevertheless the distinct cell subset localisation of IFN-a is consistent with 
that which we would expect and suggests that properly controlled this approach may offer 
utility in due course. 
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Figure 4.8 IFN-a. and IFN-J3 expression by rnDC and pDC in SM. 
The expression of IFN-a. (a) and IFN-J3 (b) by mDC and pDC in serial sections from RA 
(n=5) was determined by double immunofluorescent staining. CDlc+ mDC and CD303+ pDC 
were visualized by FITC-conjugated staining (green), with IFN-a. and IFN-J3 visualized by 
Alexa-594 conjugated staining (red). DAPI staining in blue indicates the nucleus. Using this 
method, mDC and pDC producing either cytokine and thus double positive, appear yellow. 
One representative section of each stain is shown. Original magnification x400, inset xlOOO. 
Statistical significance was assessed by Mann-Whitney U test (*P<O.05, **P<O.OI, 
***P<O.OOI). 
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4.4 DISCUSSION 
Identifying the phenotype, distribution and activation potential of DC subsets in human 
autoimmune conditions is an important pre-requisite to the description of appropriate 
tolerance inducing therapies. We now provide detailed information concerning the 
distribution and phenotype of mDC and pDC within synovial membrane. Moreover such 
expression was compared between, RA, PsA and OA. Furthermore, and for the first time, 
using RA SM as an example we show that mDC and pDC possess distinct and unique 
cytokine profiles. 
We identified mDC and pDC infiltration to the synovial sublining in RA, PsA and 
inflammatory OA SM. The magnitude of this infiltrate did not differ significantly between 
disease entities. Prior studies by other groups have reported the absence of pDC in OA 
SM, however these studies analysed OA SM biopsy from just two patients and this 
limitation may account for the discrepancy (125). It is probable that mDC and pDC are 
recruited from the circulation to the synovial compartment in response to inflammatory 
stimuli. mDC and pDC are significantly decreased in the peripheral blood of RA patients 
and pDC are significantly decreased in the blood of PsA patients (Chapter 3). The 
possibility that in situ differentiation of either subset from a precursor cell lineage driven 
by the diseased microenvironment, contributed to the synovial accumulation of both mDC 
and pDC cannot be discounted. This is supported by studies identifying the bone marrow 
adjacent to the inflamed synovium as an additional disease compartment, particularly as 
proinflammatory cytokines have been shown not only to promote the release of osteoclast 
precursors from the bone marrow, but also mediate their differentiation to various cells, 
including DC (635). 
Of particular interest, we make for the first time the remarkable observation that pDC 
numbers are significantly higher in inflamed synovia than are mDe. The repercussions of 
this observation are as yet unclear, however it has been hypothesised that IFN-a is a major 
cytokine culpable for joint damage. Indeed, IFN-a therapy has been linked to the 
induction of RA and PsA patients with no pre-existing clinical arthritis (545, 619). As 
pDC are the dominant type I IFN producer in the body and, as we have shown, maintain 
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this function in the SM, the enrichment of pDC in SM may be indicative of destructive 
joint disease. 
The coexistence of both immature and mature mDC in RA synovium has been reported 
(274, 534), however there is poor understanding of how DC phenotypes differ between 
inflammatory arthropathies. In addition, analysis of the maturation status of pDC in SM 
has not previously been attempted due to technical difficulties (125). Here we show that 
the majority of the mDC and pDC present in RA, PsA and inflammatory OA SM are 
immature, as established by low expression of the maturation marker CD83 and confirmed 
by DC-LAMP. In vitro studies of DC differentiation have shown that CDS3 up-regulation 
precedes DC-LAMP up-regulation, indicating that the CD83+ DC are less mature than their 
DC-LAMP+ counterparts (636, 637). This would account for the comparatively reduced 
DC-LAMP staining, and may indicate a maturation gradient, commensurate with local DC 
maturation. These findings are consistent with our observation that mDC and pDC 
maturation is incomplete in inflamed SF (638), and present the intriguing possibility that 
the SF embodies a source from which membrane DC are derived. Alternatively, the large 
pool of immature pDC and mDC present in PsA and RA SM might be recruited wholly 
from the blood in order to mature locally and drive synovial inflammation. It is possible 
that these DC subsets perpetuate the immune response in situ via the continuous 
presentation of arthritogenic peptides to T cells since they are both localized to T cell 
lymphocyte aggregates in the RA SM. 
To our knowledge, local (RA synovium) cytokine release by mDC and pDC has not yet 
been investigated. During the acute and chronic inflammatory response, cytokines convey 
pro- and anti-inflammatory signals between and within cells and as such are crucial in the 
pathogenesis of RA, as exemplified by the success of cytokine blockade therapies in the 
clinic. 
Analysis of the cytokine profile of both mDC and pDC in RA SM proved techinically 
difficult, with high levels of background staining confounding conclusive analysis. As 
such, it is acknowledged that this data set requires further examination, in particular as it 
pertains to the clear identification of individual cells within the synovium. Nevertheless, 
the analysis as it stands suggests that mDC and pDC within the inflamed RA SM may 
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display differential cytokine profiles, commensurate with different roles for these cells in 
the context of synovial inflammation. 
IL-23p 19 was not highly expressed in the synovium, but where evident was predominantly 
localised to mDC. IL-12p70 was more abundant in the synovium, although resolution is 
required to differentiate real staining compared to background staining. Within DC 
however, IL-12p70 appeared to be confined to mDC. mDC may have a central role in 
directing the phenotype ofT cell mediated inflammation, driving Thl and IL-17 producing 
Th17 expansion. IL-17 is a pro-inflammatory cytokine associated with a variety of 
auto immune diseases. Its role in arthritic pathology has been shown by murine studies 
(639, 640). Although the production of IL-23 by DC within SM has been hypothesised by 
others (641) this is the first study to actually demonstrate expression. This is particularly 
important given the localisation of mDC within T cell aggregates. However, a number of 
murine studies have indicated divergent roles for IL-12 and IL-23 in inflammation, the 
former inhibiting the expansion ofTh17 cells, the latter promoting it (642). These studies 
have postulated that IL-23 induced IFN-y production, enhances IL-12 thus creating self-
regulating feedback, the balance of which is reliant on the ratio of IL-12: IL-23. Since 
more mDC in SM by our analysis were expressing IL-12 it would suggest a Th 17 limiting 
process. However, IL-17 has been measured at elevated levels in the SM and SF of 
patients with RA suggesting that this negative feedback may not be intact (626, 643, 644). 
Additional studies will be required to determine if SM derived mDC are dysfunctional in 
this respect, but pDC and macrophage driven Thl7 through IL-23 release can also not be 
discounted. 
We previously demonstrated IL-15 and IL-18 on macrophages, lymphocytes, endothelial 
cells, and fibroblast-like synoviocytes in RA SM (629-631). We now extend this analysis 
to include both mDC and pDC. While both DC subsets expressed IL-15 and IL-18 in RA 
SM, pDC represented the dominant DC source of both. As such, pDC may amplify 
synovial inflammation since IL-15 and IL-18 are pro-inflammatory and can work in 
synergy with IL-12 to induce IFN-y production and drive a Thl phenotype. Of interest, IL-
18 has been shown to recruit mDC (645) and pDC (646) to areas of inflammation, in 
particular under Thl cytokine conditions, thus DC may provide a self-driven mechanism 
by which additional DC are recruited to the inflammatory compartment. 
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Targeting IL-15 has proven therapeutically beneficial in RA, however the mechanisms by 
which this may occur are not completely defined (341). It has been demonstrated that DC 
derived IL-2, required to enable T cell contact and proliferation, is tightly co-regulated 
with the expression ofIL-15 (647). Since the majority ofmDC and pDC in SM expressed 
IL-15 and both subsets were localised to T cell aggregates, this cognate interaction may 
constitute one of the targets of IL-15 therapy by limiting DC driven T cell expansion. The 
IL-15 driven conversion of monocytes to moDC may also represent a local cytokine-
mediated feedback loop driven by SM localised DC and this too, may present an additional 
target ofIL-15 therapy (648). 
In addition to IL-15, IFN-a has also been ascribed a functional role in the differentiation of 
monocytes to moDC (498). The analysis reported here suggests that RA synovial pDC are 
the principal producers of IFN-a and also IFN-P, however as in the case ofIL-12p70 this 
data set needs to be re-visited with more refined techniques. Although type I IFN mediated 
suppression of IL-l has been shown to limit inflammation (649) and IFN-P administration 
has been shown to be therapeutically beneficial in CIA (650), type I IFNs have also been 
critically linked to the pathology of various auto immune diseases including SLE and 
psoriasis (437, 498). Type I IFNs are pleiotropic cytokines with dual effects, the ultimate 
function of which is largely determined by the balance of the surrounding cytokine milieu. 
We propose that within RA SM, given their otherwise pro-inflammatory cytokine profile, 
DC derived type I IFN may promote inflammation by inducing the development of (auto) 
antibody-producing plasma cells and activation of autoreactive T cells. In addition, the 
inflammatory chemokines CXCLIO and CXCLll, chemotactic for pDC, CD4+ T cells and 
NK cells, are upregulated in RA SF and SM (349, 651, 652) and the expression of both is 
inducible by type I IFN (653, 654). This may indicate that, in addition to IL-18, type I IFN 
may also facilitate pDC infiltration to the SM. Taken together this offers one explanation 
for the preferential accumulation of pDC to RA SM. Critically, the dominant presence of 
immature pDC in SM may itself have further pathological ramifications given that IFN-a 
production is down regulated only following pDC maturation. 
Based upon our investigations presented in chapter 3 and chapter 4, we propose a model 
whereby mDC and pDC migrate from the blood to, and potentially traffic between, the 
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synovial fluid and synovial membrane (Fig. 4.9). In this model, immature pDC and mDC 
derived release of pro-inflammatory cytokines may not only contribute to synovial 
pathology, but also promote further DC recruitment to, and differentiation within, the 
inflamed synovial compartment. While mature DC of both subsets were detected in SM, 
the preferential accumulation of immature DC to the SM suggests that either an intrinsic, 
or extrinsic factor is inhibiting their differentiation. Given that we have already shown that 
SF purified mDC and pDC are able to mature normally in vitro, indicating no intrinsic 
defect (chapter 3), we propose that as yet unidentified extrinsic factors are responsible for 
retarding these cells. Of note, the identification of an apparent maturation gradient, 
progressing from CD83 expression to DC-LAMP expression, indicates that some DC may 
escape this mechanism and, given via the expression of Th 11Th 17 expanding cytokines, 
lead to sustained lymphocyte activation. The maturation of DC is important to the 
termination of immune responses as it is coupled by up-regulation of the inhibitory 
receptor CD200, which allows down-regulation of DC activity. Down-regulation is an 
active process, an essential requirement for a return to the steady state. It is probable that 
inhibition of this process could create a 'frustrated' DC phenotype, unable to conclude the 
immune response. Furthermore, our results are consistent with in vitro studies 
demonstrating that TNF-a limits the maturation of CD34+ progenitor cultured DC, but also 
enhances their longevity (655, 656). It is likely that within the proinflammatory synovial 
environment, with high local concentrations of TNF-a, the DC phenotype becomes 
skewed, resisting the immunosuppressive effects of IL-lO (458) resulting in reduced 
chemotactic motility and an abnormally prolonged life span. In future, CD200 expression 
by DC subsets in synovium will be required to investigate this possibility. The use of anti-
CD200R in collagen-induced arthritis has already proved therapeutically beneficial by our 
laboratory (unpublished communication, Mclnnes and Gracie) and by others (657), 
suggesting that disruption of DC function may constitute a therapeutic target. Promisingly, 
inhibition of the co-stimulation between B7 on APC and CD28 on T cells using CTLA-4 
Ig has already proven therapeutically beneficial (381). 
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Figure 4.9 Proposed model of mDC and pDC migration from the peripheral 
circulation into inflamed synovium. 
It is proposed that the migration of pDC and mDe from the peripheral circulation into the 
inflamed synovial compartment and (in the case of PsA) inflamed skin lesions accounts at 
least in part for the reduced mDC and pDC numbers in the blood of patients with RA and 
PsA. Due to yet unknown factors, pDC are preferentially accumulated in synovium 
compared to mDC, whereas mDC exceed pDC in the SF. The in situ release of type IIFNs 
by pDC may also add to the mDC population by driving differentiation ofmonocytes (shed 
from the synovial lining layer into SF) into mDC. This process can be enhanced by 
autocrine IL-15 production and may explain the large numbers of mDC in SF. Within 
synovium mDC can direct the immune response through production of IL-12 and IL-15 
and, of pivotal importance, expand Th17 T cells through the production of IL-23. pDC 
production of IL-15 and IL-18 further enhances the synovial inflammation. Since the 
majority of mDC and pDC in synovium are immature, it is proposed that they display a 
'frustrated' phenotype, unable to mature and upregulate inhibitory surface receptors such as 
CD200, resulting in a state of perpetual activation. 
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Chapter 5: Analysis of plasmacytoid dendritic cells and myeloid dendritic 
cells in RA and PsA synovium 48 hours after TNF blockade and 
comparative analysis of IL-15 and TNF-a blockade on pDC and mDC 
cognate interactions with activated T cells in vitro 
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5.1 Introduction 
The treatment of inflammatory arthritis, in particular RA, has evolved dramatically in the 
last 15 years. Improvements in biochemistry and molecular biological techniques have 
allowed the identification of the multiple pro-inflammatory cytokines and enzymes, 
including TNF-a, IL-lP, IL-6, IL-15, IL-17 and matrix metalloproteinases (MMPs), 
directly culpable for disease pathology. These studies have facilitated the development of 
novel cytokine targeted therapies, in particular anti-TNF blockade, that have had enormous 
clinical impact, delaying joint destruction and reducing mortality. Nevertheless, many 
patients remain refractory to current biological interventions and in those that do respond 
true remission is rare. A major challenge in therapeutics now is to develop strategies that 
re-establish immune tolerance such that amelioration of inflammation is accompanied by 
long-term disease suppression. As the only antigen-presenting cell (APC) recognized to 
date as capable of provoking autoimmune disease by abolition of self-tolerance, DC 
therefore represent an attractive therapeutic target. 
Pharmacological modulation of DC activation has been demonstrated to prevent disease 
progression in several T-cell-mediated auto immune diseases, including RA. Notably, 
inhibition of DC function by anti-rheumatic drugs including A 77 1726, the active 
metabolite of the potent DMARD leflunomide (556, 557, 658), corticosteroids (659), gold 
sodium thiomalate (660) and CTLA-4-Ig (571), has been implicated in their therapeutic 
efficacy. TNF antagonists, including etanercept (a soluble TNF-a type 11 receptor-IgG\ 
fusion protein), infliximab (a chimeric [human and mouse] monoclonal antibody against 
TNF-a) and adalimumab (a human anti-TNF monoclonal antibody), are the most efficient 
therapy for inflammatory arthritis thus far described (661). It is surprising then that their 
biological effect on DC subsets within the context of human arthritic disease has not been 
analyzed. Indeed, the broad biological mechanisms of their anti-inflammatory action are 
not completely understood. Several proposed mechanisms include decreased leukocyte 
recruitment to the synovium caused by rapid down-regulation of ICAM-I, VCAM-l, 
CXCL8 and E-selectin (662, 663); decreased local cytokine (664) and MMP (665) 
production; and inhibition of synovial angiogenesis through reduced VEGF (666). 
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As we have demonstrated, immature mDC and pDC are preferentially accumulated to the 
inflamed synovium in active RA and PsA (chapter 4). A number of studies have indicated 
a role for TNF-a in the differentiation and prolongation of DC in culture (655, 656). It is 
conceivable that similar mechanisms may operate in arthritis, thus the accumulation to, and 
apparent static state of development within, the inflamed synovium. Of significance, a 
biological effect of etanercept on mDC has been demonstrated for psoriasis, the defining 
extra-articular feature of PsA. It was found that after subcutaneous etanercept 
administration there was reduced CDllc+ DC infiltration to, and activity within, psoriatic 
plaques (569). It is therefore possible that TNF neutralization may exert some of its anti-
inflammatory effects directly through mDC. The effect of TNF neutralization on pDC has 
not yet been assessed. Elucidating the mechanisms of anti-TNF action is critical to 
advance its optimum use - anti TNF is expensive and not well-tolerated. It may also help 
to identify possible complementary therapies, such as methotrexate which is already 
proving efficacious. 
One such promising biologic is anti-IL-lS. IL-lS is abundant in the inflamed synovium 
(630) and is not decreased by TNF blockade, indicating that it is not down-stream of the 
TNF cascade (667). As we have demonstrated in chapter 4, both pDC and mDC in 
inflamed synovium express relatively high levels ofIL-lS. IL-lS is critical to DCfT cell 
contact, tightly co-regulating the expression of IL-2, which is required to enable clonal T 
cell expansion (647). Because pDC and mDC in the synovium can be co-localized to T 
cell aggregates, inhibition of cell contact may constitute an important point at which IL-lS 
blockade breaks self-perpetuating chronic inflammation. 
5.2 Aims and Objectives 
As described in Chapter 3 and 4, we have identified an accumulation of functionally active, 
but aberrantly matured pDC and mDC to the inflamed synovial compartment. Previous 
studies by other groups have demonstrated a critical role for TNF-a in the differentiation of 
mDC from CD34+ precursors. Moreover, these studies indicated that TNF-a prolonged the 
life of DC, but significantly retarded the ability of the cells to mature normally. Given the 
high concentrations of TNF-a in inflamed SM, and our description of predominantly 
immature DC in SM, TNF-a may have an aberrant effect on DC in SM. In addition we 
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identified DC of both subsets in close proximity to T cell aggregates within synovium. IL-
15 is required to enable DCfT cell contact, and since the majority of cells from both 
subsets were expressing IL-I5 in SM, inhibiting IL-I5 may retard this interaction. It was 
therefore of particular interest to analyse the effects of TNF-a and IL-I5 neutralisation on 
mDC andpDC. 
Specifically, we planned to: 
• Analyse the effect ofTNF blockade (infliximab) on DC subsets in RA and PsA synovium 
48 hours after first infusion by immunohistochemistry on serial synovial biopsy sections. 
• Examine the broad biological mechanisms of IL-15 neutralisation in order to ascertain 
the points in DCfT cell contact at which it may exert its action. 
• Comparatively analyse the effect of TNF and IL-I5 neutralisation on mDe and pDC in 
co-culture with T cells, in order to determine if there are any identifiable and specific 
differences in the cytokine secretion profile after blockade. 
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5.3 Results 
5.3.1 Infliximab study 
5.3.1.1 Patients 
Twenty-two patients with active RA (23), defined as a Disease Activity Score (28 joints; -
DAS28) of at least 4.8 (at the screening visit), despite maximal methotrexate (either 
25mglweek or the maximum tolerable dose) were included in the study. All patients 
fulfilled the ACR criteria for RA and had failed treatment with at least 2 DMARDs. Stable 
prednisolone therapy at a dosage of:::; 10mg/day and nonsteroidal anti-inflammatory drug 
(NSAID) treatment were allowed. Twelve PsA (572, 573) patients with active skin disease 
and active joint inflammation were also evaluated in this study. Active skin disease was 
defined as at least two psoriatic plaques. Active joint disease was defined as at least three 
tender joints (maximum 28 joint count and included both ankles) and physician's 
assessment as moderate or worse, despite maximal methotrexate (either 20mglweek or the 
maximal tolerable dose). In the PsA group stable dose of NSAID was allowed, but 
prednisolone therapy was not. All patients gave informed consent and the study protocol 
was approved by the Medical Ethics Committee of the AMC, University of Amsterdam 
(Patient characteristics, Table 5.1). 
The RA and PsA patients were randomized to receive either 3mglkg infliximab (RA, n=13; 
PsA, n=6) or placebo (RA, n=9; PsA, n=6) intravenously. All patients were subjected to 
small bore arthroscopy performed under local anesthesia of the same swollen index joint 
(knee, wrist or ankle), immediately before initiation of treatment and 48 hours thereafter. 
At least 6 biopsy samples were obtained using 2 mm grasping forceps (Storz,). Tissues 
were snap frozen en bloc in Tissue Tek aCT (Miles Elkhart) and stored in liquid nitrogen 
until sectioning. Sections (5 mm) were cut in a cryostat and mounted on glass slides (Star 
Frost adhesive slides), which were stored at -80°C until immunohistochemical analysis was 
performed. The study was a single centre, double blind, randomised, placebo controlled 
study. 
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Table 5.1. Clinical features of RA and PsA patients included in the study'" 
Characteristic Infliximab Placebo 
Age (years) (Median, range) 52 (24-81) 55.7 (37-69) 
Male:Female 3:10 3:6 
RA Disease Duration (months) 256 (16-765) 22.0 (3-168) 
n=22 DAS 6.5 (5.6-8.0) 6.1 (4.9-8.0) 
CRP (mg/liter) 12.5 (3-150) 16.3 (3-97) 
RF positive % 77 55 
MTX dose (mg/week) 16.2 (5-30) 16(5-30) 
Age (years) (Median, range) 53 (35-70) 45 (26-60) 
Male:Female 3:3 3:3 
PsA Duration of joint disease (years) 9 (5-13) 9 (1-22) 
n=12 Duration of skin disease (years) 24 (10-41) 17 (2-28) (NA=l) 
DAS 6.8 (5.0-7.9) 5.7 (4.8-8.2) 
CRP (mg/liter) 23 (10-36) (NA=I) 28 (7-65) 
MTX dose (mg/week) 10 (5-20) 10 (5-20) 
*RA, rheumatoid arthritis; PsA, psoriatic arthritis; CRP, C reactive protein; RF, rheumatoid factor; MTX, 
methotrexate; NA, not available 
Median and range is given for each characteristic. 
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5.3.1.2 Expression of DC in SM pre and post intliximab infusion 
Previous studies by the AMC have demonstrated reduced leukocyte infiltration to the 
inflamed RA and PsA synovium as early as 48 hours after infliximab infusion (668, 669). 
We therefore investigated the early effects ofTNF-a blockade on DC subsets in synovium 
by immunohistochemical analysis of serial synovial biopsies taken from patients with RA 
(n=22) or PsA (n=12) immediately prior to, and 48 hours after, infusion with 3mglkg 
infliximab or placebo. To enable single session processing of a large number of sections 
followed by comparative data image analysis, mDC were identified by CDlc staining and 
pDC were identified by CD304 staining. The severity of the inflammatory infiltrate in 
synovial tissue at baseline was comparable between RA infliximab and placebo treatment 
groups, and between PsA infliximab and placebo treatment groups. 
5.3.1.3 pDC and mDC in RA SM pre and post intliximab infusion 
The mDe infiltrate in the inflamed synovium was slightly, but not significantly, higher in 
the infliximab group (n=13) compared to the placebo group (n=9). The difference is 
illustrative of the inter-individual variability inherent in this heterogeneous disease (134). 
There was a trend towards reduced mDC number in SM 48 hours after infliximab infusion, 
as compared to baseline, however this did not attain statistical significance (baseline, 
median = 13.5 (3-36.5) cells/mm2; 48 hours, median = 5 (2-10.50) cells/mm2, p=0.272) 
(Fig. 5.1c and 5.1d). The number ofmDC in SM of the placebo group was not reduced 48 
hours after infusion compared to baseline (baseline, median = 5.0 (0.5-12) cells/mm2; 48 
hours, median = 4.0 (3.0-7.0) cells/mm2, p=0.8598) (Fig. 5.le and 5.1f). 
As with ruDC, when the cohort was examined as a whole, the pDC infiltrate to the 
inflamed synovium was slightly greater, but not significantly so, in the infliximab group 
compared to the placebo group at baseline. In contrast to mDC, a trend towards increased 
pDC in SM 48 hours after infliximab infusion, as compared to baseline was observed 
(baseline, median = 2.0 (1-5.0) cells/mm2; 48 hours, median = 4.0 (1.0-7.5) cells/mm2, 
p=0.8375) (Fig. 5.2c and 5.2d). The number ofpDC in SM of the placebo group was not 
altered between baseline and 48 hours after infusion (baseline, median = 2.0 (0.5-3.0) 
cells/mm2; 48 hours, median = 2.0 (0.5-4.0) cells/mm2, p=0.5365) (Fig. 5.2e and 5.2f). We 
note that in this patient cohort the numbers of pDC in RA SM were lower than observed in 
previous studies (chapter 4). 
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Figure 5.1 CD1c+mDC in paired RA synovium before and 48 hours after infliximab 
or placebo infusion. 
The number of CD 1 c + mDC infiltrating paired serial RA SM biopsies taken before and 48 
hours after treatment with infliximab (3mglkg) (n=13) or placebo (n=9) was detected by 
immunohistochemical methods. CDlc +mDC were visualized using DAB substrate 
(stained brown) and infiltration enumerated by computer assisted digital image analysis. 
One example of paired RA SM before infliximab infusion (a), showing CDlc+mDC 
dispersed throughout the synovial sub lining layer, and after 48 hours (b), showing a 
decrease in CD 1 c + mDC, is shown. In the infliximab group the trend was towards an 
overall decrease in the mDC infiltrate to synovium, although this did not attain statistical 
significance (c and d). In the placebo group there was no clear trend towards increase or 
decrease in the mDC infiltrate (e and 1). The graphs on the left show the total CDlc+ 
cells/mm2 in each patient. The box and leaf plots on the right depict the median and 
interquartile range (50% of the data), flanked by whiskers indicating the extent of the 
entire patient group. Circles indicate outliers as determined using MiniTab. 
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Figure 5.2 CD304+pDC in paired RA synovium before and 48 hours after infliximab 
or placebo infusion. 
The number ofCD304+pDC infiltrating paired serial RA SM biopsies taken before and 48 
hours after treatment with infliximab (3mglkg) (n=13) or placebo (n=9) was calculated by 
immunohistochemical methods. CD304+mDC were visualized using DAB substrate 
(stained brown) and infiltration enumerated by computer assisted digital image analysis. 
One example of paired RA SM showing CD304+ pDC localized to the synovial sublining 
layer before (a) and 48 hours after (b) infliximab infusion is shown. In the infliximab 
group the overall trend was towards an increase in the pDC infiltrate to synovium, 
although this did not attain statistical significance (c and d). In the placebo group there 
was no clear trend towards increase or decrease in the pDC infiltrate (e and I). The graphs 
on the left show the total CD304+ cells/mm2 in each patient. The box and Ieafplots on the 
right depict the median and interquartile range (50% of the data), flanked by whiskers 
indicating the extent of the entire patient group. Circles indicate outliers as determined 
using MiniTab. 
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5.3.1.4 pDC and mDC in RA patients responsive to infliximab infusion 
Approximately 50% of patients are refractory to TNF blocking treatment, failing to 
achieve a 50% improvement in disease activity according to the ACR criteria (ACR50) 
(368, 670). Therefore we next chose to investigate if responsiveness to infliximab therapy 
correlated to the mDC and pDC infiltrate in SM 48 hours after infusion. Responsiveness 
was assessed as good (n=l), moderate (n=l1) or poor (n=l) as evaluated at 3 months post 
initial treatment. 
After 48 hours, mDC in the good response patient group were reduced from 69 mDC/mm2 
to 1 mDC/mm2; in the moderate response cohort mean mDC were reduced from 12.7 
mDC/mm2 ± 7.48 mDC/mm2 to 8.5 mDC/mm2 ± 3.58 mDC/mm2; and in the poor response 
patient mDC were reduced from 27 mDC/mm2 to 6 mDC/mm2 (Fig. S.3a). Together the 
data indicate that mDC are reduced in RA SM following infliximab infusion, irrespective 
of patient responsiveness to treatment. Since the majority of patients responded 
moderately to treatment, study on a larger scale would be required to confirm this finding. 
After 48 hours, pDC in the good response patient were unchanged from 2.0 pDC/mm2 to 
2.0 pDC/mm2; in the moderate response cohort mean pDC were increased from 1.5 
pDC/mm2 ± 2.11 pDC/mm2 to 4.4 pDC/mm2 ± 6.97 pDC/mm2; and in the poor response 
patient group pDC were reduced from 20 pDC/mm2 to 6.0 pDC/mm2 (Fig. S.3b). Again, a 
study on a larger scale, including a patient cohort with more varied treatment response, 
would be required to investigate this result further. 
5.3.1.5 pDC and mDe in PsA SM pre and post infliximab infusion 
The mDC infiltrate to the inflamed PsA synovium was comparable between the infliximab 
group (n=6) compared to the placebo group (n=6) at baseline (p = 0.2556). An overall 
trend towards reduced mDC in SM 48 hours after infliximab infusion, as compared to 
baseline was observed, however this did not attain statistical significance (baseline, 
median = 11.9 (1-34) cells/mm2; 48 hours, median = 6.0 (1-35) cells/mm2, p=0.8983) (Fig. 
5Ac and SAd). Surprisingly, the number of mDC in SM of the placebo group also 
indicated an overall trend to reduction 48 hours after infusion compared to baseline 
(baseline, median = 20 (2-43) cells/mm2; 48 hours, median = 604 (1-15) cells/mm2, 
p::::O.2506) (Fig. S.4e and SAt). 
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Figure 5.3 CDlc+mDC and CD304+pDC in paired RA synovium from good, moderate 
and non-responders to infliximab, before and 48 hours after infusion. 
The number of CDlc+mDC (a) and CD304+pDC (b) infiltrating paired serial RA SM 
biopsies taken before and 48 hours after infliximab infusion was compared between good 
(triangle, n=I), moderate (square, n=l1) and non-responder (circle, n=l) to treatment. 
Total cells/mm2 is shown. Line indicates median value. 
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Figure 5.4 CDlc+mDC in paired PsA synovium before and 48 hours after infliximab 
or placebo infusion. 
The number of CD 1 c + mDC infiltrating paired serial PsA SM biopsies taken before and 48 
hours after treatment with infliximab (3mglkg) (n=6) or placebo (n=6) was detected by 
immunohistochemical methods. CDlc +mDC were visualized using DAB substrate 
(stained brown) and infiltration enumerated by computer assisted digital image analysis. 
One example of paired PsA SM before infliximab infusion (a), showing CD 1 c+mDC in the 
synovial sublining layer, and after 48 hours (b), showing a decrease in CD 1 c + mDC, is 
shown. In the infliximab group the trend was towards an overall decrease in the mDC 
infiltrate to synovium, although this did not attain statistical significance (c and d). In the 
placebo group the trend was towards a decrease in the mDC infiltrate (e and f). The graphs 
on the left show the total CD 1 c + cells/mml in each patient. The box and leaf plots on the 
right depict the median and interquartile range (50% of the data), flanked by whiskers 
indicating the extent of the entire patient group. The circle indicates outliers as determined 
using MiniTab. 
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The pDC infiltrate to the inflamed synovium was greater in the placebo group compared to 
the infliximab group at baseline, but this was not statistically significant (p=0.3472). 
Similar to mDC, a trend towards decreased pDC in SM was observed 48 hours after 
infliximab infusion, as compared to baseline, although this was not statistically significant 
(baseline, median = 2.7 (1-8.0) cells/mm2; 48 hours, median = 1.3 (0-3.0) cells/mm2, 
p=O.l1 02) (Fig. S.5c and S.5d). Again, the number of pDC in SM of the placebo group 
also indicated a trend toward reduction at 48 hours after infusion compared to baseline, 
although this was not statistically significant (baseline, median = 7 (1-20) cells/mm2; 48 
hours, median = 1.6 (1-3) cells/mm2, p=0.3472) (Fig. 5.Se and 5.Sf). As we observed in 
the RA study, in the PsA patient cohort the numbers ofpDC in synovium were lower than 
we have observed in previous studies (chapter 4). 
These analyses may suggest that TNF blockade may have differential effects on DC 
subsets. Given the rarity of this heterogeneous popUlation and the relatively scarce number 
of patient samples available for study, identifying significant measurable alterations in SM 
after TNF blockade has proved difficult. As demonstrated in chapter 4, both mDC and 
pDC in synovium can be co-localised to T cell aggregates. We therefore chose to 
investigate the effects of anti-TNF -a on mDC and pDC interactions with T cells through in 
vitro methods. In particular we were interested in examining TNF blockade compared to 
IL-15 blockade as this laboratory has previously indicated a role for IL-15 in supporting 
macrophage/T cell contact induced TNF-a (630). These experiments will be discussed 
later (S.2.4). First however, we decided to elucidate further the broader biological 
mechanisms by which IL-15 neutralisation may operate, since the general effects of TNF 
blockade are comparatively well characterized. Specifically, we sought to characterize 
points by which IL-15 neutralisation may hinder T cell contact with DC. 
5.3.2 IL-15 neutralisation study 
5.3.2.1 Patients and cell lines 
5.3.2.1.1 Patiellts 
Inflammatory arthritis patients attending Glasgow Royal Infirmary (GRI) fulfilled the 
American College of Rheumatology criteria for RA (23), or met diagnostic criteria for PsA 
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Figure 5.5 CD304+ pDC in paired PsA synovium before and 48 hours after infliximab 
or placebo infusion. 
The number of CD304+ pDC infiltrating paired serial PsA SM biopsies taken before and 48 
hours after treatment with infliximab (3mglkg) (n=6) or placebo (n=6) was detected by 
immunohistochemical methods. CD304+ mDC were visualized using DAB substrate 
(stained brown) and infiltration enumerated by computer assisted digital image analysis. 
One example of paired PsA SM showing CD304+ pDC localized to the synovial sublining 
layer before (a) and 48 hours after (b) infliximab infusion is shown. In the infliximab 
group the overall trend was towards a decrease in the pDC infiltrate to synovium, although 
this did not attain statistical significance (c and d). In the placebo group the trend was 
towards a decrease in the pDC infiltrate (e and f). The graphs on the left show the total 
CD304+ cells/mm2 in each patient. The box and leaf plots on the right depict the median 
and interquartile range (50% of the data), flanked by whiskers indicating the extent of the 
entire patient group. Circles indicate outliers as determined using MiniTab. 
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as previously described (572, 573). All patients and healthy donors gave infonned consent 
and the study protocol was approved by the Ethical Committee, GRI. Peripheral blood and 
synovial fluid was obtained from patients with RA (n=3) and peripheral blood was 
obtained from healthy controls (n=4) (Table 5.2). All cell analysis was undertaken on 
freshly isolated cells. For cytokine investigation, cell free SF and supematants from cell 
culture were stored in the Centre for Rheumatic Disease (CRD) Biobank at -70°C until 
analysed. At the time of study, RA patients were receiving methotrexate (n=2) or 
sulphasalazine (n=l) or a combination of these agents (n=2). PsA patients were receiving 
either methotrexate (n=l) or sulphasalazine (n=3) or a combination of these agents (n=l). 
Patients on oral steroids were excluded from the study. 
5.3.2.1.2 BDB2 eellline 
BDB2 cells, an IL-15-dependent, human T cell line, were a kind gift of Dr. John Campbell, 
University of Glasgow. 
5.3.2.2 Biological action of anti-IL-15 antibodies 
The majority of both mDC and pDC localised to the synovial membrane express IL-lS 
(chapter 4). It was therefore of particular interest to investigate the possibility that IL-15 
blockade in inflammatory arthritis may exert some of its therapeutic benefits by directly 
modifying DC. First however, we chose to elucidate the biological effects of anti-IL-lS in 
a panel of in vitro assays. For these analyses the IL-lS-dependent, human T cell line 
BDB2 cells were utilised. Analysis of the bioactivities of anti-IL-lS were undertaken 
using F(ab')2 fragmented anti-IL-lS in order to obviate Fe interactions (prepared as 
described in chapter 2). 
5.3.2.2.1 Assay of BDB2 eell death 
BDB2 cells are highly sensitive to IL-15 and its absence in culture leads to rapid BDB2 
cell death. In order to detennine if F(ab'h fragmented anti-IL-15 retained biological 
activity we analysed its ability to neutralise exogenous IL-15, causing BDB2 cell death. 
BDB2 cells were cultured in the presence or absence of 0.1 ng/ml IL-IS and cell death 
analysed at 24 hours using propidium iodide (PI) (Fig. 5.6a). PI only stains the nucleus of 
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Table 5.2. Clinical features of RA and PsA patients and Healthy donors included in 
the study* 
RA 
PsA 
Characteristic 
Age, Mean ± SD 
Fernale:Male 
WBC, Mean ± SEM 
CRP (mg/liter) 
Age, Mean ± SD 
Female:Male 
WBC, Mean ± SEM 
CRP (mg/liter) 
Healthy Age, Mean ± SD 
Fernale:Male 
WBC, Mean ± SEM 
PB study group 
58 ± 12 (24-80) 
10:2 
6.4xl06/rnl ± 1.2x104/rnl 
26 ± 6 (6-100) 
42 ± 14 (24-81) 
10:3 
8.0x106/rnl* ± 4.5xl0slrnl 
14 ± 4 (6-73) 
44 ± 11 
6:6 
6.4x106/rnl ± 4.7xlOslml 
*RA, rheumatoid arthritis; PsA, psoriatic arthritis; CRP, C reactive protein 
Mean ± standard error of the mean (range) is shown. 
155 
SF study group 
59 ± 15 (33-70) 
5:1 
22 ± 7 (6-41) 
41 ± 15 (25-50) 
5: 1 
30 ± 15 (6-73) 
Figure 5.6 Effects of anti-IL-15 F(ab') 2 on apoptotic rescue and proliferation of 
BDB2 cells. 
BDB2 cells were cultured with or without IL-15 (O.lng/ml), in culture medium alone or 
supplemented with anti-IL-15 F(ab')2 (10~g/ml) or human IgG (hulgG) F(ab')2 (10~g/ml) 
negative control, and the percentage dead cells enumerated after 24 hours by propidium 
iodide staining and FACS analysis (a). In parallel experiments, BDB2 cells were cultured 
for 24 hours and proliferation was measured by determining 3H-labeled thymidine uptake 
in the last 6 hours of culture (b). Values are the mean ± SEM of triplicate cultures. One 
example representative of three experiments is shown. 
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cells with ruptured membranes and therefore undergoing primary or secondary necrosis. 
In the absence of IL-15 over 70% of BDB2 cells were Pt (dead) after 24 hours, whereas 
only 14% of BDB2 were Pt in the presence of O.lng/ml IL-15. Addition of anti-IL-15 
F(ab')2, but not irrelevant isotype IgG F(ab'h, induced cell death in 44.5% ofBDB2 in IL-
15 supplemented culture. The results were confirmed by parallel analysis of proliferation, 
as determined by 3H-Iabeled thymidine uptake in the last 6 hours of culture (Fig 5.6b). 
Anti-IL-15 F(ab'h. but not irrelevant isotype IgG F(ab')2, suppressed BDB2 proliferation 
in 0.1 ng/ml IL-15 supplemented cultures. 
5.3.2.2.2 Inhibitio1l of IL-15 induced IFN-yand TNF-a release 
It has previously been established that IL-15 operates in synergy with IL-12 to promote 
cytokine production from lymphocytes, particularly IFN-y. In order to assess biological 
activity ofanti-IL-15 F(ab')2 in a more relevant cell group - namely synovial fluid derived 
mononuclear cells, we analysed inhibition of IL-12/IL-15 induced IFN-y release. Addition 
of anti-IL-15 F(ab'b but not irrelevant isotype IgG F(ab'b neutralised IL-12IIL-15 
induced IFN-y release from SF derived mononuclear cells (SFMC) as dctennined by 
ELISA (Fig. 5.7a). This assay confirms the bioactivity of anti-IL-15. 
It has previously been shown that RA SFMC are capable of spontaneous TNF-a release, 
which can be enhanced by addition ofIL-15. We therefore chose to examine the effect of 
endogenous IL-15 neutralization on TNF-a release from RA SFMC culture. TNF-a in 
culture supernatants was measured by ELISA after 16 hours. As expected, addition of 
exogenous IL-15 increased TNF-a release and this effect was abrogated by neutralization 
using anti-IL-15 F(ab')2. Of interest, the spontaneous release of TNF-a from the SF 
derived cells was reduced by the addition ofanti-IL-15 F(ab'h (Fig. 5.7b). Isotype control 
did not affect TNF-a levels. Together these data demonstrate that neutralisation ofIL-15 
can have down-stream effects on other inflammatory pathways and TNF in particular. 
Furthermore, the evidence suggests blockade of endogenous IL-15, indicating that 
leukocytes originating from the inflamed synovial environment are sensitive to IL-15 
neutralisation. 
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Figure 5.7 Effects of anti-IL-15 F(ab') 2 on cytokine production from RA synovial 
fluid mononuclear cells. 
Rheumatoid arthritis (RA) synovial fluid mononuclear cells (SFMC) were incubated for 16 
hours in RPMII10% foetal calf serum (FCS) with or without the cytokines as shown 
(2ng/ml IL-12, 10ng/ml IL-15) in the presence or absence ofanti-IL-15 F(ab')z (lO)lg/ml) 
or human IgG (huIgG) F(ab') z (lO)lg/ml) negative control, and interferon-y (IFN-y) levels 
in culture supematant were measured by enzyme-linked immunosorbent assay (ELISA) 
(a). In parallel experiments RA SFMC were cultured for 16 hours in RPMII10% FCS with 
or without IL-15 (10ng/ml), in the presence or absence of anti-IL-15 F(ab')z (10/-lg/ml) or 
human IgG (huIgG) F(ab')2 (lO)lg/ml) negative control, and TNF-a in culture supematant 
measured by ELISA (b). Values are the mean ± SEM of triplicate cultures. Similar data 
was obtained from 4 RA patients. 
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5.3.2.2.3 DowlI-regulation of surface CD69 
We and others have previously shown that IL-15 enhances CD69 expression on PB and SF 
derived T cells. CD69 is, in turn, implicated in the cognate interactions between T cells 
and APC, and has been shown to be upregulated on cells within the context of active 
inflammatory arthritis (631, 671). In order to elucidate the mechanisms by which IL-IS 
blockade may inhibit these cognate interactions, specifically those between T cells and DC, 
we chose to analyse CD69 expression on RA PBMC and RA SFMC. First, to study 
exogenous IL-IS induced up-regulation of surface CD69, cells were rested overnight 
before 24 hour incubation with or without IL-I5 and anti-IL-15 F(ab'h or irrelevant 
isotype IgG F(ab')2. Consistent with the above data, anti-IL-I5 F(ab'h, but not isotype 
IgG F(ab')z, neutralized exogenous IL-I5 induced CD69 upregulation on both RA PB and 
SF derived mononuclear cells (Fig. 5.8a). In addition, parallel experiments examining 
freshly isolated RA PB and SF mononuclear cells (in the absence of added IL-IS) revealed 
that CD69 expression was reduced by addition of anti-IL-I5 F(ab'h, but not isotype IgG 
F(ab'h (Fig. 5.8b). The data therefore confirm neutralisation of endogenous IL-I5 and 
indicate a mechanism by which IL-15 neutralization could inhibit cognate DC/T cell 
contact. 
5.3.2.2.4 Binding of membra lie boulld IL-15 
The initial release of IL-2 by DC (both pDC and mDC) is required to enable DC directed 
clonal expansion of T cells. However, the production of IL-2 by DC is itself initially 
triggered by T -cell mediated stimuli and, importantly, is tightly co-regulated with the 
expression of IL-IS. Indeed, IL-2 production by DC in IL-IS-deficient mice is strongly 
impaired (647). The down-regulation of CD69 on the T cell is one mechanism by which 
this phenomenon could be explained. We sought to examine if anti-IL-I5 could impair 
cell contact directly by binding surface bound IL-I5 as analysed by FACs methodology. 
IL-I5 binds at the cell surface to a heterotrimeric IL-I5 receptor composed of IL-I5Ra, IL-
I512RP and common'Y chain (672,673). Analyses of IL-I5 binding to the IL-I5 receptor 
complex has been challenging as the receptor is expressed at only low levels on primary 
cells. Previous groups have therefore produced IL-I5 transfected cell lines to allow 
detection of surface bound IL-I5 (674). Because BDB2 are particularly sensitive to IL-I5, 
we first analysed expression of IL-15Ra in order to determine if expression was 
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Figure 5.8 Effects of anti-IL-15 F(ab') 2 on 11-15 dependent CD69 expression on RA 
synovial fluid mononuclear cells. 
RA peripheral blood mononuclear cells (PBMC) or synovial fluid mononuclear cells 
(SFMC) were rested overnight after purification, then incubated for 24 hours with or 
without IL-15 (lOng/ml) in the presence of absence of anti-IL-15 F(ab')2 (IO/-tg/ml) or 
human IgG (huIgG) F(ab'h (lO/-tg/ml) negative control, prior to fluorescence-activated cell 
sorting for CD69 expression (percentage of CD69+ cells within the lymphocyte region) (a). 
Data are representative of 6 similar experiments. In parallel experiments to determine the 
activity of anti-IL-15 F(ab')2 without addition of exogenous IL-15, the percentage of 
CD69+ lymphocytes on freshly isolated RA PBMC and RA SFMC after incubation with 
anti-IL-15 F(ab')2 (lO/-tg/ml) or human IgG (huIgG) F(ab')2 (lO/-tg/ml) negative control 
was calculated. The %reduction of CD69+ lymphocytes is shown. Data are representative 
of 6 similar experiments. 
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sufficiently high to enable F ACS detection, and by association, detection of receptor-
bound IL-15. The level of surface IL-15Ra on BDB2 cells was determined by F ACS 
analysis using the IL-15Ra specific antibody M 161. BDB2 cells express a high level of 
surface IL-15Ra, detectable by F ACS anaysis, and consistent with their sensitivity to IL-15 
in culture (Fig. 5.9a). Furthermore, IL-15Ra binding by M161 could be inhibited by pre-
incubating BDB2 cells in exogenous IL-15 for 30 minutes prior to staining (Fig. 5.9b). We 
therefore concluded that BDB2 surface IL-15 receptor expression was sufficiently high for 
FACS and transfection was not required. We next incubated BDB2 cells in IL-15 for 30 
minutes before addition of biotin-conjugated anti-IL-15 F(ab'h for 30 minutes followed by 
streptavidin-FITC. Anti-IL-15 F(ab')2' but not isotype control IgG F(ab'h, bound 
membrane bound IL-15, as determined by FACS analysis (Fig. S.9c). These data suggest 
that IL-15 neutralising antibody has the potential to inhibit cognate cell contact enabled by 
paracrine presentation of surface bound IL-15. 
5.3.3 Dendritic cell-T cell contact 
T cells are in close association with APC in the inflamed synovium (675). This provides 
anatomical rationale whereby in vivo APC/T cell contact could be of importance in disease 
pathogenesis, particularly as in driving the release of pro-inflammatory cytokincs such as 
TNF-a (676). Direct cell-contact-mediated interactions have been the focus of several in 
vitro studies aimed at replicating this in vivo environment. However, the majority of these 
studies have focused on monocyte/macrophage-T cell interactions (677, 678). As 
described in chapter 4, mDC and pDC are in close contact with T cells in synovium, 
commensurate with in situ cell-contact. However no studies thus far have examined, by in 
vitro methods, the interactions of mDC and pDC with pre-activated T cells. 
5.3.3.1 Interactions between DC and T cells 
We first needed to develop an assay by which to study mDC/pDC-T cell contact in vitro 
(Fig. 5.10). The majority of mDC and pDC in the synovium are immature, but T cells 
display an activated phenotype. For pragmatic reasons we chose to examine the effect of 
pre-activated T cells on immature mDC and pDC purified directly from blood. For these 
experiments healthy donor PB was used as RA and PsA PB had insufficient obtainable DC 
numbers (as discussed in chapter 3). CD3+ T cells were purified by positive selection from 
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Figure 5.9 The expression of IL-15Ra on BDB2 cells and the capacity of anti-IL-15 
F(ab') 2 to bind membrane bound IL-15. 
The expression levels of IL-15-Ra on BDB2 cells was detected by incubation with IL-
15Ra specific detection antibody, M161, followed by detection with goat-anti-mouse-IgG-
FITC and fluorescence-activated cells sorting (FACS) analysis (a). The binding of MI6 1 
to IL-15Ra was inhibited by pre-incubating cells with exogenous IL-15 (0.1 - 100nglml) 
for 30 minutes before staining (b). To evaluate ability of anti-IL-15 F(ab'h to bind 
membrane bound IL-15, BDB2 cells were first incubated with or without IL-15 (lOOnglml) 
for 30 minutes, followed by incubation with anti-IL-15 F(ab')2 (lOJlglml) or human IgG 
(huIgG) F(ab')2 (lOJlg/ml) negative control, and detection with goat-anti-human IgG (Fab) 
and F ACS analysis (c). One example of 5 similar experiments is shown. 
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Figure 5.10 Design of an in vitro experimental model of mDe and pDC contact with 
blasted T cells. 
CD3+ T cells were purified by positive magnetic cell sorting from peripheral blood (PB) 
from a healthy donor and blasted by incubation in phytohaemagglutinin (5~g/ml) for 48 
hours, after which time they were either fixed for 2 hours in PBSI2%paraformaldehyde, or 
not. At 48 hours CDlc+/CDllc+ mDC were purified by positive magnetic cell sorting and 
CD303+/CDI23+ pDC were purified by negative magnetic cell sorting from PB from the 
same donor. mDC (culture supplemented with GM-CSF) and pDC (culture supplemented 
with IL-3) were co-cultured with T cells at a ratio of 3:1 (T cells:DC) and supematant 
harvested at 24 hours. 
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PB and blasted by 48 hour culture with phytohaemagglutinin (PHA) (5)lg/ml), in order to 
produce an activated phenotype similar to that displayed in synovium (676). Purity was 
routinely >98% (Fig. 5.11c). At 48 hours, mDC and pDC were sequentially purified by 
positive (mDC) and negative (pDC) selection from freshly obtained autologous PB, with 
purity routinely >98% (pDC) (Fig. 5.11a) and >96% (mDC) (Fig. 5.llb). This was 
important to ensure DC subsets were as immature as possible, since DC mature rapidly 
upon culture. The blast T cells were either fixed in paraformaldehyde (thus only DC 
released cytokines were measured), or not, and added back to mDC and pDC cultures. 
After 24 hours supematants were harvested and cytokines measured via multiplex analysis. 
5.3.3.2 Activated T cells and cell contact are required to enable DCfT cell induced 
TNF-a production 
We first analysed TNF-a release following the addition of paraformaldchyde fixed or live, 
non-PHA blasted T cells (resting), to mDC or pDC cultures. As expected, resting T cells 
induce negligible levels of TNF-a in culture with mDC or pOC, regardless of fixation (Fig. 
5.12a and c) or live cell culture (Fig. 5.12b and d). Activated T cells induced TNF release 
in contact with DC most likely through ligand interactions including CD69/CD69R, 
CD40/CD40L, TcRIHLA-DR and CD28/CD80-CD86. We confirmed that cell contact was 
required to induce appreciable TNF-a release from mOC/pOC in culture with PHA blasted 
T cells. When a cell membrane insert was used to separate T cells from the DC, TNF-a in 
culture was markedly reduced in mDC/T cell culture (Fig. 5.13a) and pDC/T cell culture 
(Fig. 5.13b). Therefore the TNF-a released by the DC subsets could not be attributed to 
soluble factors alone. 
5.3.3.3 Effects of anti-TNF-a and anti-IL-15 on DCfT cell contact cytokine and 
chemokine release 
Since IL-15 could play a role in T cell cognate interactions with mDC and pDC via indirect 
(CD69 regulation) or direct (surface-bound paracrine induced IL-2) mechanisms, we next 
chose to evaluate the effect of anti-IL-15 on mDC/pDC-T cell contact induced cytokine 
release. We were particularly interested to probe the roles of TNF-a and IL-15 in such 
conditions using available biologic agents. 
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Figure 5.11 Purity of isolated pDC, mDC and CD3+ T cell 
The purity of PB isolated mDC, pDC and CD3 was detennined by staining with 
CD303/CD123 (pDC) (a), CDlc/CD11c (mDC) (b), CD3 (T cells) (c) or appropriate 
isotype controls following by fluorescence-activated cells sorting (F ACS) analysis. Purity 
ofmDC was routinely over 96% for mDC, over 98% for pDC and over 97% for CD3. One 
example is shown of each. 
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Figure 5.12 T cell activation is required to enable cell contact dependent TNF-
a release from mDC and pDC. 
TNF-a levels in culture supematants were measured by enzyme-linked immunosorbent 
assay (ELlS A) after 24 hours of mDC co-culture with resting CD3+ T cells that had been 
fixed in PBSI2%paraformaldehyde (Fixed) (a) or not (Live) (b) and pDC co-culture with 
resting CD3+ T cells that had been fixed in PBS/2%paraformaldehyde (Fixed) (c) or not 
(Live) (d). Values are the mean ± SEM of triplicate cultures. Similar data was obtained 
from 2 healthy donors. 
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Figure 5.13 Cell contact is required to allow activated T cell induction ofTNF-a from 
mDCandpDC. 
Prior to co-culture, CD3+ T cells from healthy donor peripheral blood (PB) were incubated 
in the presence of PHA (5).lg/ml) for 48 hours. The activated T cells (Live) were then co-
cultured in direct contact to, or separated by a permeable cell membrane insert with, either 
mDC (a) or pDC (b), freshly isolated by magnetic cell sorting from the same donor. TNF-
a levels in culture supernatant were measured at 24 hours by enzyme-linked 
immunosorbent assay (ELISA) at 24 hours. Values are the mean ± SEM of triplicate 
cultures. Similar data was obtained from 2 healthy donors. 
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For these experiments mouse IgGI anti-human TNF-a and mouse IgOI anti-human IL-15 
were utilised for a number of reasons. First, technical difficulties precluded the F(ab'h 
fragmentation of infliximab or etanercept. Second, due to low total numbers of mDC and 
pDC that could be purified from blood and to aIIow comparative analysis, the same isotype 
control was needed for both anti-TNF-a and anti-IL-15. Because the isotype control for 
infliximab is human IgG, anti-IL-15 (Fab ')2 could therefore not be used. Third, human 
IgG itself is highly anti-inflammatory via the FcyRIIa receptor, so would obscure any 
effects that either anti-TNF-a or anti-IL-15 might have. Therefore murine anti-human 
antibodies were used to obviate these problems. 
5.3.3.3.1 TNF-a 
Multiplex analysis of culture supematants demonstrated, as expected, that anti-TNF-
a neutralised TNF-a released by pDC and mDC co-cultured with either fixed (Fig. S.14a 
and c respectively) or live (Fig. S.14b and d respectively) PHA blasted T ceIIs (p<O.OOOI). 
In contrast, anti-IL-15 did not significantly reduce TNF-a in mDC or pDC cultures with 
fixed T cells. However, anti-IL-15 did significantly reduce TNF-(l levels in live T cell 
cultures (mDC, p=O.008, pDC p=O.009). Mouse IgG I isotype control did not alter TNF-a 
levels in fixed or live cultures. These data are consistent with the model whereby IL-15 
enables/enhances DC-T cell contact driven T cell promotion of DC cytokine release. 
Clearly such a mechanism would not operate in fixed T ceII cultures. 
5.3.3.3.2 CCL3 
CCL3, formerly designated macrophage inflammatory protein-I-a (MIP-la), was 
measurable in supematants of fixed and live mDC/T cell cultures and fixed and two of 
three live pDC/T ceII cultures, although at lower levels. Neither anti-TNF-a, nor anti-IL-
15 significantly reduced CCL3 in mDC or pDC co-cultures with fixed T cells (Fig. 5.15a 
and c). However, in live T cell co-culture with mDC both anti-TNF-a and anti-IL-15 
reduced CCL3 levels (significant for anti-IL-15, p=O.049) (Fig. S.lSb). In contrast, in two 
of three pDC co-cultures with live T cells anti-TNF-a, but not anti-IL-15, increased the 
amount of CCL3 released (p=O.029) (Fig. 5.l5d). CCL3 was not measurable in culture 
supematants from the third donor. Mouse IgG I isotype control did not alter CCL3 levels in 
fixed or live cultures. These results were consistent with the analysis of infliximab effect 
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Figure 5.14 TNF-a production in cultures of mDC and pDC with fixed or live CD3+ T 
cells. 
Prior to co-culture, CD3+ T cells from healthy donor peripheral blood (PB) were incubated 
in the presence of PHA (5Ilglml) for 48 hours. In half of experiments as denoted, T cells 
were then fixed in PBS/2%paraformaldehyde (Fixed) or left alone (Live). At 48 hours 
mDC and pDC were sequentially purified by magnetic cell sorting from the same donor. 
mDC and fixed (a) or live (b) T cells were cultured alone, or together at a ratio of 3:1(T 
cells:mDC) in the presence or absence ofanti-TNF-a (100ng/ml), anti-IL-15 (lOOng/ml) or 
mouse (m) IgGJ (100nglml) negative control. In parallel assays, pDC and fixed (c) or live 
(d) T cells were cultured alone, or together at a ratio of 3: 1 (T cells:mDC) in the presence 
or absence of anti-TNF-a (lOOng/ml), anti-IL-15 (lOOnglml) or mouse (m) IgGJ 
(lOOng/ml) negative control. TNF-a levels in culture supematant were measured at 24 
hours by multiplex analysis at 24 hours. Values are the mean ± SEM of triplicate cultures. 
Similar data was obtained from 6 healthy donors. 
**p<O.OI, ***p<O.OOOI 
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Figure 5.15 CCL3 production in cultures of mDC and pDC with fixed or live CD3+ T 
cells. 
Prior to co-culture, CD3+ T cells from healthy donor peripheral blood (PB) were incubated 
in the presence of PHA (51lg/ml) for 48 hours. In half of experiments as denoted, T cells 
were then fixed in PBS/2%paraformaldehyde (Fixed) or left alone (Live), At 48 hours 
mDC and pDC were sequentially purified by magnetic cell sorting from the same donor. 
mDC and fixed (a) or live (b) T cells were cultured alone, or together at a ratio of 3:1(T 
cells:mDC) in the presence or absence of anti-TNF-a (lOOng/ml), anti-IL-15 (lOOng/ml) or 
mouse (m) IgG\ (lOOng/ml) negative control. In parallel assays, pDC and fixed (c) or live 
(d) T cells were cultured alone, or together at a ratio of 3:1(T cells:mDC) in the presence 
or absence of anti-TNF-a (lOOng/ml), anti-IL-15 (lOOng/ml) or mouse (m) IgG\ 
(lOOng/ml) negative control. CCL3 levels in culture supematant were measured at 24 
hours by multiplex analysis at 24 hours. Values are the mean ± SEM of triplicate cultures. 
Similar data was obtained from 6 healthy donors. 
*p<O.05 
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on DC subsets in synovium discussed earlier in this chapter, which suggested that TNF 
blockade may have differential effects on DC migration. 
5.3.3.3.3 CCL4 
CCL4, formerly designated MIP-l~, was measurable in supematants of fixed and live 
mDC/T cell cultures and fixed and live pDC/T cell cultures, but again pDC levels were 
lower than those measured from mDC. Similar to CCL3, anti-TNF-a and anti-IL-I5 did 
not significantly reduce CCL4 in fixed cell cultures (Fig. 5.16a and c). However, in live T 
cell co-culture with mDC both anti-TNF-a and anti-IL-I5 reduced CCL4 levels (significant 
for anti-TNF-a, p=O.045) (Fig. 5.l6b). As before, CCL4 was increased in two of three 
pDC co-cultures with live T cells in the presence of anti-TNF -a, but not anti-IL-I5 
(p=O.033) (Fig. 5.l6d). Mouse IgG\ isotype control did not alter CCL4 levels in fixed or 
live cultures. CCL4 was not measured in the supematant from the third donor. 
5.3.3.3.4 CXCL8 
CXCL8, formerly designated IL-8, was measurable in supernatants of fixed and live 
mDC/T cell cultures and fixed and live pDC/T cell cultures, but again pDC levels were 
much lower than those measured from mDC. In addition mDC alone were capable of high 
CXCL8 release, although this was enhanced by T cell contact. Anti-TNF-a and anti-IL-I5 
did not significantly reduce IL-8 in fixed cell cultures (Fig. 5.17a and c). However, in live 
T cell co-culture with mDC both anti-TNF-a and anti-IL-I5 reduced CXCL8 levels 
(significant for anti-IL-15, p=O.036) (Fig. S.l7b). As before CXCL8 was increased in pDC 
co-cultures with live T cells in the presence of anti-TNF-a, but not anti-IL-15, although 
this was not significant (Fig. 5.I7d). Mouse IgG\ isotype control did not alter CXCL8 
levels in fixed or live cultures. 
5.3.3.3.5IFN-a 
The increase in chemokine levels in pDC-T cell cultures induced by anti-TNF-a, but not 
anti-IL-15, was intriguing. Recent studies have demonstrated that IFN-a specifically 
triggers CCL2, CCL3 and CCL4 secretion by pDC, but not mDC (679). Furthermore, it 
has been hypothesised that TNF-a and IFN-a may counter-balance each other, with the 
fonner inhibiting secretion of the latter from pDC (591). Since pDC are the major type I 
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Figure 5.16 CCL4 production in cultures of mDC and pDC with fixed or live CD3+ T 
cells. 
Prior to co-culture, CD3+ T cells from healthy donor peripheral blood (PB) were incubated 
in the presence of PHA (5~g/ml) for 48 hours. In half of experiments as denoted, T cells 
were then fixed in PBS/2%paraformaldehyde (Fixed) or left alone (Live). At 48 hours 
mDC and pDC were sequentially purified by magnetic cell sorting from the same donor. 
mDC and fixed (a) or live (b) T cells were cultured alone, or together at a ratio of 3:1(T 
cells:mDC) in the presence or absence ofanti-TNF-a (lOOng/ml), anti-IL-15 (lOOng/ml) or 
mouse (m) IgG\ (lOOng/ml) negative control. In parallel assays, pDC and fixed (c) or live 
(d) T cells were cultured alone, or together at a ratio of 3:1(T cells:mDC) in the presence 
or absence of anti-TNF-a (lOOng/ml), anti-IL-15 (lOOng/ml) or mouse (m) IgG\ 
(100ng/ml) negative control. CCL4 levels in culture supematant were measured at 24 
hours by multiplex analysis at 24 hours. Values are the mean ± SEM of triplicate cultures. 
Similar data was obtained from 6 healthy donors. 
*p<O.05 
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Figure 5.17 CXCL8 production in cultures of mDC and pDC with fixed or live CD3+ 
T cells. 
Prior to co-culture, CD3+ T cells from healthy donor peripheral blood (PB) were incubated 
in the presence of PHA (5 flglml) for 48 hours. In half of experiments as denoted, T cells 
were then fixed in PBS/2%paraformaldehyde (Fixed) or left alone (Live). At 48 hours 
mDC and pDC were sequentially purified by magnetic cell sorting from the same donor. 
mDC and fixed (a) or live (b) T cells were cultured alone, or together at a ratio of 3:I(T 
cells:mDC) in the presence or absence of anti-TNF-a (100ng/ml), anti-IL-15 (IOOng/ml) or 
mouse (m) IgG\ (IOOnglml) negative control. In parallel assays, pDC and fixed (c) or live 
(d) T cells were cultured alone, or together at a ratio of 3: 1 (T cells:mDC) in the presence 
or absence of anti-TNF-a (IOOng/ml), anti-IL-15 (lOOnglml) or mouse (m) IgG\ 
(IOOng/ml) negative control. IL-8 levels in culture supernatant were measured at 24 hours 
by multiplex analysis at 24 hours. Values are the mean ± SEM of triplicate cultures. 
Similar data was obtained from 6 healthy donors. 
*p<O.05 
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IFN producing cell in the body, we sought to evaluate the possibility that TNF-a 
neutralisation enabled IFN-a driven secretion of CCL3, CCL4 and CXCL8 from pDC. 
Multiplex analysis indicated that IFN-a was absent from mDC cultures, but was present at 
low levels in pDC cultures and enhanced by T cell contact «1 OOpglml). In one of the two 
donors from whom pDC produced chemokines were measurable, anti-TNF-a but not anti-
IL-lS, increased IFN-a, although this was not significant (Fig. S.ISa). In the second donor 
anti-TNF-a and anti-IL-IS did not alter IFN-a levels (Fig. S.18b). Further analyses will be 
required in order to elucidate the role, if any, which TNF-a may have in the inhibition of 
IFN-a directed chemokine release from pDC. 
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Figure 5.18 IFN-a production in cultures ofpDC with live CD3+T cells. 
Prior to co-culture, CD3+T cells from healthy donor peripheral blood (PB) were incubated 
in the presence of PH A (5).tg/ml) for 48 hours. At 48 hours pDC were sequentially purified 
by magnetic cell sorting from the same donor. pDC and live T cells were cultured alone, 
or together at a ratio of 3:1(T cells:pDC) in the presence or absence of anti-TNF-a 
(100ng/ml), anti-IL-15 (lOOng/ml) or mouse (m) IgG\ (lOOng/ml) negative control. IFN-a 
levels in culture supematant were measured at 24 hours by mUltiplex analysis at 24 hours. 
Values are the mean ± SEM of triplicate cultures. The results from 2 healthy donors are 
shown (a) and (b). 
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5.4 Discussion 
This chapter has addressed three key areas concerning cytokine modification of DC 
function and broader area of synovial inflammation. Firstly, we have examined DC 
subsets in synovium after TNF-a. blockade. Second, we have examined the broader action 
of IL-15 on key DC derived cytokines within models of synovial inflammation. Third, and 
finally we have compared and contrasted the effects of both of these on DC subsets in 
vitro. 
The advent of cytokine-targeted therapies, in particular TNF-a blockade, has 
revolutionised the treatment of RA and, increasingly, PsA. However, TNF-a blockade 
fails to control disease in around 50% of patients, so there remains considerable unmet 
clinical need. A critical goal now is to identify the exact mechanisms by which cytokine 
blockade acts, such that current treatment strategies can be optimised and potential 
synergistic targets identified. Our investigations thus far have suggested an active role for 
DC subsets in the perpetuation of chronic inflammation within the synovial compartment. 
To date, only one other group has attempted to assess the direct effect of cytokine blockade 
on DC subsets in arthritis in a human setting (680). However, that study analysed only 
peripheral blood DC subsets and did not attempt to examine the inflamed synovial 
compartment. This study has sought therefore to examine the effect of TNF-a 
neutralisation, particularly on DC subsets in RA and PsA synovium, and IL-15 
neutralisation on DC subsets in order to address some of the outlying questions. Namely, 
what are the mechanisms of action of these therapies, and by elucidating these do we gain 
further insight into the contribution of DC to disease pathology? 
We observed decreased mDC infiltration, but not pDC infiltration, to the synovium of RA 
and PsA patients 48 hours after a single infusion of infliximab (3 mglkg). The decrease in 
mDC did not attain statistical significance, possibly attributable to their rarity in SM. 
However, our observation was consistent with previous analyses by the Division of 
Clinical Immunology and Rheumatology at the AMC, undertaken on the same tissue 
cohort, which demonstrated significant reduction in tissue infiltrating CD3+ T cells and 
CD6S+ macrophages after infliximab infusion (668, 669). These studies found that the 
reduction in synovial cellularity could not be explained by TNF-blockade induced 
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apoptosis at the site of inflammation, which has been reported to occur in Crohn's disease 
(681,682). 
It is important to note that these findings are in contrast to a recent report by Catrina et al. 
linking infliximab induced decrease of synovial tissue CD3+ T cells and CD68+ 
machrophages to apoptosis, in particular of macro phages (683). However, this discrepancy 
might be explained by a number of factors. First, in contrast to our assessment of the 
inflammatory infiltrate after 48 hours, the latter report analysed SM infiltrate 8 weeks after 
infliximab infusion. It is possible that the apoptotic events described by Catrina et al. 
occurred secondary to infliximab infusion, as a later event of inflammatory amelioration 
rather than an early mechanism of cellular reduction. Second, the specific link to 
macrophage apoptosis was identified by in vitro Annexin V analysis of synovial fluid (SF) 
derived macrophages. Annexin V binds phosphatidylserine (PS), externalised to the 
cellular surface early in apoptosis. However, PS externalisation is not exclusive to 
apoptosis, but can be triggered by intracellular calcium mobilisation and its expression on 
the surface of non-apoptotic primary macrophages is a requirement for the engulfment of 
apoptotic target cells (684, 685). As a result, Annexin V staining is not a good method by 
which to assess macrophage apoptosis. Furthermore, Catrina et al. did not find any 
evidence of infliximab induced SF CD3+ T cell apoptosis, and as such apoptosis fails to 
explain their rapid efflux from the synovium. 
We cannot exclude the possibility that infliximab induced apoptosis in DC subsets in 
compartments other than the SM, such as the PB, thereby affecting migration towards the 
synovial compartment. However, this possibility is unlikely. First, a study by Balanescu 
et al., examining DC subsets in RA PB pre- and post-infliximab infusion detected no 
significant decrease in CDllc+ mDC or CD123+ pDC, although surface CD83 was down-
regulated on both subsets (535). It is of course possible in that study that the detection of 
mDC and pDC using CDllc and CDl23 respectively, which are not specific to either 
subset (discussed in chapter 3), may have resulted in failure to detect comparatively small 
alterations in these rare cell types. Second, the aforementioned study by Catrina et al., 
detected no significant death in infliximab treated RA PBMC derived CD3+ T cells or 
CDI4+ monocytes (683). 
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Instead, we propose that infliximab infusion altered local SM adhesion molecule and 
chemokine expression, reducing leukocyte ingress to the SM, as has been demonstrated in 
other studies (662, 663). Our own observation that TNF-a neutralisation down-regulates T 
cell cognate induced mDC secretion of the inflammatory chemokines CCL3, CCL4 and 
CXCL8, is consistent with such a hypothesis. CCL3, CCL4 and CXCL8 are particularly 
chemotactic for monocytes, effector T cells and neutrophils and their release by immature 
DC upon TLR stimulation or CD40 ligation is considered a crucial first step in the 
initiation of an inflammatory response (686). However, DC release of these chemokines is 
rapidly downregulated as DC mature. As we have demonstrated (chapter 4), the arthritic 
SM contains large numbers of immature DC whose maturation may be inhibited by local 
TNF-a. In the absence of maturation it is possible that DC inflammatory chemokine 
release is not down-regulated, contributing to the continued recruitment of leukocytes to 
the SM. In addition to triggering mDC efflux from the SM, TNF-blockade could also 
enable DC maturation and down-regulation of CCL3, CCL4 and CXCL8, resulting in 
reduced immigration of leukocytes to the SM. 
In contrast to mDC, we made the intriguing observation that pOC in RA SM were, if 
anything increased 48 hours after infliximab infusion. In PsA however, pDC were slightly 
decreased in SM 48 hours after infliximab infusion. Given the Iow number of PsA patients 
examined in this study it is impossible to draw any conclusions about potential differences 
between diagnostic groups. Furthermore, neither of the observed alterations achieved 
statistical significance potentially due to cell rarity, Iow number of participant patients or 
the early time point examined. Nevertheless, the study may indicate trends suggesting the 
fascinating possibility that TNF-blockade affects DC subsets differentially. Such a 
supposition is consistent with our in vitro analyses that indicated TNF-a neutralisation 
induced an increase of the pro-inflammatory chemokines CCL3, CCL4 and CXCL8 from 
pDC co-culture with T cells. A number of groups have suggested that TNF-a inhibits the 
action and secretion of IFN-a (591) and IFN-a has been demonstrated to drive CCL2, 
CCL3 and CCL4 secretion from pDC, but not mDC (679). Conceivably, TNF-a 
neutralisation could enable the action of IFN-a. Consistent with this hypothesis, we 
detected Iow levels of IFN-a in pOC culture supematants, but not mDC culture 
supematants. Furthermore, IL-15 neutralisation did not increase pro-inflammatory 
chemokines in pOC culture - suggesting a TNF-a specific affect. Future analyses of the 
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interplay of IFN-a and TNF-a on pDC would be required in order to explore this 
hypothesis further. Elucidating such a mechanism may be of particular import given the 
high level of IFN-a expressing pDC in SM (chapter 4) and reports linking IFN-a infusion 
to arthritis induction (545, 619). Potentially, this could offer an explanation as to why 
some patients fail TNF-a therapy, while others do not. It would be of particular interest to 
examine IFN-a levels in SM pre- and post-TNF blockade, in order to evaluate any 
correlation to disease response. Since 90% of patients responded to infliximab therapy in 
this study, we were unable to ascertain any significant information on the potential 
correlation of DC subsets in SM to patient response. 
A further unexpected, but potentially informative observation from this study was the low 
overall pDC infiltration to the RA and PsA SM at baseline. This was in contrast to our 
earlier examinations identifying relatively large numbers of pDC, compared to mDC, in 
both RA and PsA SM (chapter 4). Importantly, all patients in the infliximab study were on 
a stable, high dose course of methotrexate (up to 25 mglkg). It is possible that the low 
pDC infiltrate was directly incurred by methotrexate treatment. Alternatively, it may 
reflect a lower DAS28 in this patient cohort than in those in the earlier studies. Of interest, 
mDC in SM at baseline did not appear altered as compared to our earlier studies, 
suggesting the intriguing possibility that methotrexate affects DC subsets differentially, but 
unlike TNF-a blockade, in a pDC specific manner. Of note, adenosine, a metabolic factor 
of methotrexate, has been demonstrated to be chemotactic for immature pDC, but inhibits 
CpG ODN stimulated cytokine release from pDC (687). This may also identify a 
mechanism by which methotrexate complements TNF-blockade in synergistic therapeutic 
treatment. The possibility that the reduced pDC count occurred due to the technical 
difficulties inherent in single session processing of such a large number of samples cannot 
be discounted. In either case, further ex vivo analysis is necessary and would be 
informative. 
An important observation of the current study was the different biological mechanisms of 
action ofIL-15 neutralisation in contrast to TNF-a neutralisation. We first demonstrated 
that IL-I5 neutralisation inhibited IFN-y release from SF mononuclear cells cultured in the 
presence of exogenous IL-I2 and IL-IS. We next found evidence that IL-IS neutralisation 
also reduced spontaneous TNF-Cl release from SF mononuclear cells, consistent with 
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neutralisation of endogenous IL-15. Together these data support an upstream role for anti-
IL-15 mediated inhibition of pro-inflammatory cytokines. 
Other factors are also likely to be significant biological targets of IL-15 neutralisation. 
This laboratory has previously described the anti-IL-15 mediated reduction of TNF-a 
release by macrophages induced by activated T cell contact (631). Here, for the first time, 
we show that anti-IL-15 also significantly reduces TNF-a released by mDC-T cell and 
pDC-T cell contact dependent cultures. Furthermore, CCL3 and CXCL8 were 
significantly reduced in mDC-T cell cultures, while the trend was towards a reduction in 
CCL3, CCL4 and CXCL8 in all mDC-T cell and pDC-T cell contact dependent cultures. 
The fact that TNF- a and the pro-inflammatory chemokines were only reduced in live, but 
not fixed, T cell cultures was particularly informative. Firstly, we have demonstrated that 
IL-15 antibody induces CD69 down-regulation of surface CD69. CD69 is both a marker 
of T cell activation and a molecule implicated in T cell-APC interactions at a functional 
level (631) thus its down-regulation is likely to hinder DC-T cell contact. However, this is 
an active process that cannot occur after T cell fixation thus CD69 down-regulation is 
implicated in the efficacy of anti-IL-15 in live T cell cultures. Secondly, as demonstrated 
here, IL-15 neutralising antibody can bind membrane bound IL-15. DC membrane bound 
IL-15 tightly co-regulates IL-2 production, a requirement of DC directed T cell activation, 
which in turn enhances release of pro-inflammatory cytokines from DC. Again, this 
mechanism is inhibited by T cell fixation. The direct neutralisation of IL-15 at this critical 
point in live cell contact therefore significantly impaired this process. Finally, and of 
particular note, 11-15 has recently been shown to have a critical role in the cross-regulation 
between DC subsets related to autocrine IL-15 enhanced CD40 expression (688). 
Therefore down-regulation of CD40 expression offers a third critical point at which 
cognate T cell-DC interactions can be blocked by IL-15 neutralisation. Moreover, it 
suggests a mechanism by which pDC-mDC contact could also be disrupted. Since the 
majority ofmDC and pDC in SM expressed IL-15 and both subsets were localised to T cell 
aggregates (chapter 4), this cognate interaction constitutes an important target of IL-15 
therapy by limiting DC driven T cell expansion and DC proinflammatory cytokine and 
chemokine release. 
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The search for new approaches through which disease amelioration can be achieved 
continues, and while promising candidates such as CTLA-4 Ig and CD20 have been 
developed, they have currently proved no more efficacious than cytokine blockade. The 
foregoing data indicates that TNF-a. and IL-I5 blockade may have biologically distinct, yet 
complementary mechanisms of action, in particular in regards their affects on DC subsets 
in T cell contact. As such, IL-lS targeting may, like methotrexate, be a potential candidate 
for synergistic therapeutic action alongside TNF -a. blockade. Furthermore, these studies 
have indicated that the contribution of mDC and pDC to disease pathology may be 
different, as exemplified by the differential affects of TNF-blockade and possibly, 
methotrexate treatment. This is consistent with our earlier observations that mDC and 
pDC in the inflamed SM express distinct cytokine profiles. However, it is difficult to 
unravel the relative contribution of mDC and pDC to disease initiation and perpetuation in 
the absence of experimental models, since one particular impediment to the functional 
analysis of immune cells within human disease is the lack of access to the joint proximal 
lymph node - a critical compartment particularly for the induction of autoimmune T cells. 
An important pre-requisite to the inference of particular immune pathways and cell types 
to disease pathology is therefore specific analysis within an in vivo disease setting. Thus in 
order to further elucidate the diverse functions of pDC and mDC in inflammatory arthritis 
it was necessary to investigate their action in a murine model of arthritis. The results of 
these analyses will be discussed in chapter six. 
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Chapter 6: Analysis of the functional role of pDC in a murine model of 
arthritis 
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6.1 Introduction 
The development of central tolerance in the thymus, whereby self-reactive T cells are 
eliminated through clonal deletion is an imperfect process, allowing some self-reactive 
lymphocytes to escape to the extra-thymic regions. Self-reactive lymphocytes are 
consequently present in the normal immune repertoire (500). The maintenance of 
peripheral tolerance by dendritic cells (DC), through cell-contact and cytokine mediated 
modulation of the immune response, is therefore critical in preventing pathological self-
reactivity. However, genetic and/or environmental factors can impair DC function and 
peripheral tolerance can fail, resulting in autoimmune diseases such as rheumatoid arthritis 
(RA) and psoriatic arthritis (PsA). While human studies, particularly those thus far 
described, have indicated a clear role for DC in the perpetuation of chronic inflammation, 
their role in disease initiation, in particular as it pertains to breach of tolerance has been 
impaired. 
Murine models have been fundamental in elucidating the specific mechanisms by which 
DC may, or may not, induct disease in vivo. In particular, numerous animal models of 
inflammatory arthritis have been instrumental in elucidating the aetiology and pathogenetic 
mechanisms of articular inflammation. In particular, the early infiltration of (m) DC to the 
target tissue of inflammation in collagen-induced arthritis (CIA), spontaneous arthritis in 
MRUlpr mice (550) and antigen-induced arthritis in rats (551, 552) has been 
demonstrated. Brewer and Leung demonstrated the capacity for DC to induce arthritis 
using ex vivo collagen type II-pulsed, bone-marrow differentiated mDC, to induce 
inflammation in joints adjacent to the site of injection (553). Furthermore, administration 
of TNF antagonists was sufficient to inhibit arthritic progression in this model. Similarly, 
adoptive transfer of T -box expressed in T cells (T -bet) expressing DC was sufficient to re-
constitute inflammation in RAG2-I-Tbef'- mice, otherwise resistant to collagen antibody-
induced arthritis (554). Of particular interest, transfer of DC, genetically modified to over-
express IL-4, to murine with established CIA reduced IFN-y production and collagen type 
11 reactivity thus reducing disease severity and demonstrating a potential for manipulation 
of DC as a therapeutic vector (555). To date, no comparative analysis of the functional 
contribution of distinct DC subsets, in particular pDC, to murine models of arthritis has 
been performed. 
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In the mouse, up to six DC subtypes have been identified and can be distinguished by CD4 
and CDS expression. Three distinct myeloid CDllchi DC subtypes have been delineated in 
spleen, CD4-/CDS+, CD4+CDS-, CD4-/CDS-. Lymph nodes contain two extra subtypes 
thought to have migrated from the tissue to the lymph nodes, CD4-/CDS-/CD20Slo/CDllb+ 
interstitial DC and CD4-/CDS10/CD20Shi/langerin+ langerhans cells (416-418). In recent 
years a CD4-1+/CD8-1+ plasmacytoid DC subset has been identified and can be distinguished 
from myeloid DC by CDllc10IMHC U1oIB220 hi 1l20G8+ /mPDCA-l+ expression (419-
422). Murine DC subsets are remarkably phenotypically similar to their human 
counterparts, with the exception of CD8 expression, although no evidence suggests this is 
functionally significant. In addition murine, but not human, pDC express CD 11 c, albeit at 
Iow levels. 
6.2 Aims and Objectives 
The studies examining mDC and pDC in RA and PsA thus far described, indicate a 
pathological role for both DC subsets, in particular as regards altered migration to the 
inflamed synovial compartment and lymphocyte aggregates therein, and expression of pro-
inflammatory cytokines that may expand Th 17 cells and perpetuate chronic inflammation. 
The aim of this chapter was to undertake an in vivo analysis of DC subsets within a murine 
model of arthritis in order to elucidate their comparative roles in disease induction. 
Specifically, I planned to address: 
• Whether mDC and pDC may (also) migrate towards to the lymph node, as well as the 
target inflamed synovial tissue, during a murine model of chronic arthritis. Specifically it 
was planned to examine draining lymph nodes from DBAlI undergoing collagen-induced 
arthritis. 
• To determine if a culture system could be developed by which relatively large numbers 
of murine bone marrow (BM) derived pDC could be differentiated and processed to high 
purity, for future in vitro functional analysis and potential adoptive transfer experiments. 
• To compare the ability of murine BM differentiated mDC and pDC to process and 
present antigen, by specific examination of their respective abilities to induce memory T 
cell proliferation to OVA and collagen type n. 
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• Finally, to deplete pDC using pDC specific depleting antibody 120G8 during the OVA 
TcR transgenic T cell adoptive transfer model of murine arthritis in order to gain insight 
into the functional role ofpDC and, by association, mDC to the pathogenesis of this model. 
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6.3 Results 
6.3.1 Animals 
6-8 week old female BALB/c mice were used for in vitro experiments and as Tg CD4+ 
1KJ1.26+ T cell transfer recipients in the OVA TcR transgenic model of arthritis. DO 11.1 0 
BALB/c TCR Tg mice containing CD4+T cells expressing a TCR that recognizes the 
chicken OVA peptide 323-339 complexed with the MHC class II molecule I-Ad (detected 
by the clonotypic mAb KJ1.26) (574), were used as Tg CD4 T cell donors (bred in-house, 
Central Research Facility, University of Glasgow, Glasgow, UK). 6-8 week old female 
DBAll mice were purchased from Harlan (Bicester, UK) and used for in vitro experiments 
and in the collagen-induced arthritis (CIA) model. 
6.3.2 pDC are expanded in the draining lymph nodes during collagen-induced 
arthritis. 
In RA and PsA, as we demonstrated in chapters 3 and 4, DC subsets are significantly 
reduced in the peripheral blood (PB) circulation; this may be explained by their 
preferential accumulation to the inflamed synovial compartment. Since reduced PB DC 
numbers could be correlated to active inflammation (as determined by CRP levels) and DC 
are known to migrate rapidly to the lymph nodes (LN) following inflammatory stimulation 
(689), it is likely that the reduction could reflect at least in part LN directed migration. 
However, due to ethical and technical restrictions we were unable to investigate if mDC 
and/or pDC also accumulated in the human LN. We therefore chose to investigate this 
possibility by analyzing DC subsets in the draining LN of DBAlt mice undergoing 
collagen-induced arthritis (CIA), an extensively characterized model of chronic arthritis. 
Draining popliteal and inguinal LN were harvested from DBAlt mice undergoing CIA (24-
25 days into model) and nai've DBAll mice. DC subsets were detected in single-cell 
suspensions by CDl1chigh (mDC) and mouse plasmacytoid dendritic cell antigen 
(mPDCA)-t + (pDC) expression, followed by fluorescent-activated cell sorting (FACS) 
analysis of viable cells. In nai've DBAll, pDC were the dominant DC population in the 
LN, comprising -0.36% of all LN cells compared to -0.29% for mDC (Fig. 6.1 a and c, 
respectively). In CIA DBAlt, pDC were expanded in the draining LN to -0.8% of all cells 
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(Fig. 6.1 b). In contrast, mDC comprised -0.6% of all cells however this did not represent 
subset expansion when compared to the matched isotype control (Fig. 6.1 d). The data 
indicate that pDC in the LN are expanded two-fold during chronic articular inflammation, 
commensurate with the LN as a target for pDC migration. 
6.3.3 Culture of pDC from murine bone marrow 
Previous studies from this laboratory have demonstrated that administration of collagen-
pulsed bone-marrow derived mDC to DBNl recipients is sufficient for the induction of 
arthritis (553). There have to date been no similar analyses of pDC in models of chronic 
arthritis, attributable to the technical challenges encountered when working with this rare 
cell population. It has been established that pDC do not phagocytose, process and load 
antigens onto MHC molecules as efficiently as mDC, although they can promote 
proliferation in antigen experienced T cells (453, 690). However, it is not clear whether 
pDC are able to directly prime naIve T cells. In addition, pDC surface MBC JI and co-
stimulatory molecule expression is lower than mDC (422). Thus the competence of pDC 
antigen-presentation is currently a controversial issue, and it has been hypothesized that 
they act complementary to mDC, inducing the differentiation of unpolarized T cells 
previously expanded by mDC (453, 690). We therefore considered it necessary to 
investigate the ability of pDC to process and present antigen by a panel of ill vitro assays, 
prior to any potential analysis of their in vivo influence on arthritis. To do this it was first 
necessary to develop a method by which pDC could be differentiated from murine bone 
marrow. 
The differentiation ofmDC from murine bone marrow by supplementation using GM-CSF 
is well-established in the literature. The differentiation ofpDC from murine bone marrow, 
however, is not well characterized - at best 70%pDC in culture can be achieved (691, 692). 
Culture of murine bone marrow in RPMI 1640 complete mediumJlO%FCS supplemented 
with human Flt-3L (100ng/ml) gave a peak pDC population of routinely -60% purity by 
day 7 of culture, as determined by mPDCA-l + expression (Fig. 6.2a). Around 80% of cells 
were CDllc+ (Fig. 6.2b) but isolated murine pDC are CDllc10 and those generated from 
bone marrow have been demonstrated to stain high for CDllc (691) thus only 25% of 
these were likely to be APC other than pDC. Cultures were then purified further by 
mPDCA-I positive magnetic cell sorting and application to two magnetic columns. While 
this method yielded a relatively pure popUlation, routinely >95%, as assessed by 
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Figure 6.1 pDC, but not mDe are expanded in the draining lymph nodes in collagen-
induced arthritis. 
The number ofmDC and pDC in lymph nodes taken from normal DBA-I mice or DBA-I 
mice undergoing collagen induced arthritis was assessed by staining with PDCA-I (pDC) 
in comparison to the isotype control (a and b) or CDllc (mDChigh/pDClo) in comparison to 
the isotype control (c and d) and analysed by FACS. 
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Figure 6.2 Phenotype of rhFIt-3L cultured murine bone marrow cells. 
The percentage ofpDC in murine bone marrow cells cultured with lOOnglml rhFlt-3L was 
determined on day 7 of culture by staining with mPDCA-l (pDC) compared to isotype 
control Rat IgGza (a) or CDllc (mDChigh/pDCIO) compared to isotype control Hamster 
IgGn. (b) and analysing by FACS. The purity of pDC after positive selection using 
mPDCA-l microbeads was determined by double staining with B220/CD11c as compared 
to the isotype control (c) and confirmed usingPDCA-1 (d). 
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CDllc+1B220+ staining (Fig. 6.2c) and confinned by mPDCA-l+ staining (Fig. 6.2d), the 
actual cell yield was very low. 
6.3.4 mDC and pDC present OVA peptide to DOll.IO GFP transgenic T cells. 
We first examined the antigen-presentation potential of BALB/c bone marrow 
differentiated mDC and pDC by presentation of the chicken OVA peptide 323-339 
(DV A323-339) to DO 1l.1O GFP transgenic (Tg) T cells. The DO 11.10 GFP T cell 
hybridoma is a cell line that responds to presentation of OV A323-339 on the MHC Class 11 
molecule (I-Ad). When the T cell hybridoma receives appropriate stimulation, it induces 
transcription of Nuclear Factor of activation of T cells (NF AT). Modification of the 
hybridoma by the addition of a NF AT reporter construct means that when NF A T is 
produced, it binds to a NFAT specific binding site, which regulates a green fluorescent 
protein (GFP) inducing promoter (575). In essence, when the T cell hybridoma sees 
MHC/peptide complex, it fluoresces. 
Culture of DOll.1 0 Tg T cells for 24 hours, with or without OVA, did not induce GFP 
production in the absence of APC (Fig. 6.3a and b). Similarly, culture of DOl 1.10 Tg T 
cells for 24 hours with bone marrow derived mDC, but no OVA, did not induce T cell 
fluorescence (Fig. 6.3c). However, co-culture of DO 11.10 Tg T cells with bone marrow 
derived mDC pre-pulsed with OVA for 6 hours, induced GFP production (Fig. 6.3d) 
illustrating the necessity for both MHC and peptide to induce transcription of NFAT. In 
parallel assays, DOl 1.10 Tg T cells were co-cultured with bone marrow derived pDC 
alone (Fig. 6.3e), or pDC that had been pre-pulsed with OVA (Fig. 6.31). As with mDC, 
pDC pre-pulsed in OVA induced fluorescence in the DOII.IO Tg T cells. The data 
indicate therefore, that pDC are competent at antigen uptake, processing and presentation 
by MHC/peptide complex. In order to enhance the surface expression of MHC II and co-
stimulatory receptors, pDC were stimulated with the TLR9 specific CpG ODN 1826 2 
hours prior to co-culture with the Tg T cells, but after OVA pulsing. However, this did not 
appear to further enhance their antigen-presentation potential (Fig. 6.3g). 
6.3.5 mDC and pDC induce collagen type 11 specific T cell expansion. 
While the above described model demonstrated the ability of both mDC and pDC to take 
up, process and present antigen, it did not evaluate their ability to induce proliferation of 
the target cell. In addition, we were specifically interested in the mDC and pDC uptake of 
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Figure 6.3 mDe and pDC present OVA peptide to DOl1.10 GFP transgenic T cells. 
FACS analysis ofCD4 expression (PE, FL2 channel) and GFP fluorescence (FL1 channel) 
on OVA transgenic DOIl.I0 GFP T cells incubated for 24 hours alone (a), with 5mglml 
OVA (b), with mDC (c), mDC pre-pulsed for 6 hours with 5mglml OVA (d), pDC (e), 
pDC pre-pulsed for 6h with 5mglml OVA (1) or pDC pre-pulsed for 6h with 5mglml OVA 
followed by 2h with 3.2J.lglml CpG ODN 1826 (g). OVA transgenic DOll.I0 cells are 
identified as CD4+ and when engaging av A peptide on MHC II molecules fluoresce green 
thus becoming double positive CD4+/GFP+. 
One example of three replicable experiments is shown. 
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Type 11 collagen (Cll). Cll is the most abundant fibrillar protein of articular cartilage and 
an important autoantigen in the pathogenesis of CIA in mice and RA in humans (296, 693). 
It has previously been demonstrated that mDC predominantly take CIl up by 
macropinocytosis (694) a function at which pDC are generally considered poor (449). We 
therefore chose to examine the ability of bone marrow derived pDC and mDC to present 
collagen to CD4+ T cells, purified by positive magnetic cell sorting from the draining 
lymph nodes of CIA DBA-l mice, in comparison to nai've animals. Since Cll alone has 
been shown to deliver a maturation stimulus to DC, possibly via TLR4, additional 
inflammatory stimuli such as LPS were not considered necessary to enable DC induced T 
cell proliferation (694, 695). To ensure purification of sufficient numbers of CD4+ T cells 
from nai've mice, both lymph nodes and spleen were harvested. Although APC in the 
spleen also express CD4, the contamination of these after purification was <3% as assessed 
by CD 11 c + staining (Fig. 6.4a). 
Cll (50Ilglml) pulsed mDC induced a low level of proliferation in CD4+ T cells from naiVe 
DBAll mice as measured by thymidine incorporation after 72 hours co-culture (Index of 
Stimulation, 1.73, p=O.049) (Fig. 6.4b). In contrast, CII (50Ilglml) pulsed pDC did not 
induce any significant proliferation in CD4+ T cells (Index of Stimulation, 1.15) (Fig. 
6.4c). Arguably, an index of stimulation less than 2 may not indicate 'real' proliferation 
but reflect culture artefact. Alternatively, the low level proliferation induced in mDC/T 
cell cultures may be indicative of a small number of self-reactive T cells in culture and lor 
suboptimal timepoint of evaluation. I-A q haplotype possessing DBAlI mice are highly 
susceptible to CIA and it has been shown that expansion of antigen-specific CD4+ T cells 
after intradennal injection of cn emulsified in complete Freund's adjuvant (CFA) occurs 
early in vivo, before the onset of arthritis (696). We have also observed that during CIA, 
some animals develop arthritis (as assessed by paw swelling) prior to day 21 CIl challenge 
(unpublished observations). Potentially these data may suggest a role for mDC, but not 
pDC in the initial CD4+T cell expansion phase of CIA. 
Purity of CD4+ T cells isolated from the draining popliteal LN from DBNl mice 
undergoing CIA was routinely >96% (Fig. 6.5a). cn (50Ilglml) pulsed mDC induced a 
significant high level of proliferation in CD4+ T cells from CIA DBA-1 mice as measured 
by thymidine incorporation after 72 hour co-culture (Index of Stimulation, 3.524, p=O.OO I) 
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Figure 6.4 Collagen pulsed mDC, but not pDC, induce proliferation in naive CD4+ T 
cells. 
The phenotype of CD4+ T cells purified from spleen and lymph nodes taken from naive 
DBA-l mice was confirmed by FACS (a, b and c) and revealed less than 3.5% 
contamination with CDllc+ cells. The proliferation of the CD4+ T cells following 72h 
incubation with either bone marrow derived mDC in media alone or containing 50~g/ml 
collagen Cd) or bone marrow derived pDC in media alone or containing 50Ilg/ml collagen 
( e) was assessed by thymidine incorporation. Results are expressed as the stimulation 
index of an experiment carried out in triplicate. Results are representative of three 
replicable experiments. 
*<0.05 
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Figure 6.5 mDe and pDC induce proliferation in collagen specific CD4+ T cells. 
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undergoing collagen induced arthritis was confirmed by F ACS (a, band c) and revealed 
less than 2% contamination with CDllc+ cells. The proliferation of the CD4+ T cells 
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containing 50llglml collagen or pDC matured with 3.21lglml CpG ODN 1826 for 2h 
following incubation with collagen (e), was assessed by thymidine incorporation. Results 
are expressed as the stimulation index of an experiment carried out in triplicate. Results 
are representative of three replicable experiments. 
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(Fig. 6.5b). cn (50Ilglml) pulsed pDC also induced significant proliferation in C04+ T 
cells (Index of Stimulation, 12.96, p=O.OOI) (Fig. 6.5c). Of interest, CpG ODN 1826 
(3.2Jlg/ml) maturation ofpDC prior to CD4+ T cell co-culture, but after 6 hour pulse in cn 
(501lg/ml) did not further enhance CD4+ T cell proliferation, but appeared instead to inhibit 
proliferation as compared to pDC that had not been matured. However, CD4+ T cell 
proliferation was still significantly enhanced in these cultures compared to base-line (Index 
of Stimulation, 5.57, p=O.049). This result was consistent with our foregoing data that 
indicated CpG ODN 1826 induced pDC maturation did not further enhance MHC/OV A-
peptide induced fluorescence of hybridoma T cells (section 6.2.4). Since pDC 
macropinocytosis is poor, it is likely that additional maturation stimuli down-regulated 
pDC cn uptake as cells matured, thus actual antigen uptake may have been sub-optimal 
for subsequent immunogenic CD4+ T cell expansion. The time of onset of CIA differs 
between individual DBNI, therefore draining LN were harvested on different days placing 
restrictions on cell numbers. As a consequence of this technical restriction pDC and mDC 
were not assayed in parallel and therefore no direct comparison can be made between these 
two groups. 
CIA in DBAlI mice has been used extensively to investigate the relative contribution of 
different immune cell subsets to disease pathology and to evaluate the efficacy of different 
therapeutics therein. However, the contribution of the individual agents eliciting CIA (e.g. 
adjuvant components) are ill-defined, thus interpreting the mechanisms contributing 
directly to articular inflammation is difficult. To resolve this issue, this laboratory has 
developed new models of arthritis whereby the mechanisms inciting disease are more 
clearly defined, thus facilitating investigation of the immune cells contributing directly to 
pathology (697). One of these models established that activated mDC presenting cn 
peptide can induce arthritis upon transfer to naive recipients (553), demonstrating their 
capacity to break self-tolerance. However, the ability of pOC to break self-tolerance, or 
not, was not addressed previously. The foregoing data indicated that both mDC and pDC 
could take-up, process and present cn. However, it also suggested the possibility that 
pDC would not be able to induce naive CII specific C04+ T cell expansion alone. In 
addition, culture of bone marrow derived pDC proved difficult, with only relatively small 
numbers obtainable after microbead purification. We therefore decided that unlike mDC, 
bone marrow derived pDC pulsed ex vivo with CII and transferred to naive OBAll mice 
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would be unlikely to induce arthritis. Furthermore, the technical difficulties associated 
with pDC culture precluded such an experiment since the number of mice and reagents 
required was prohibitive. pDC were, however, clearly efficient at expanding antigen 
experienced CD4+ T cells, commensurate with an active role during the antigen-specific 
adaptive stage of arthritis. We therefore decided to analyse pDC contribution to a second 
murine model of arthritis developed by this laboratory using the pDC specific depleting 
antibody, 120G8. 
6.3.6 T cell transfer model of arthritis 
6.3.6.1 Model 
This laboratory has demonstrated that transfer ofThl, but not Th2 polarised, OVA-specific 
TcR Tg T cells to BALB/c recipient mice produces arthritis in joints proximal to the site of 
OVA inoculation (697). The model is outlined in figure 6.6. Briefly, at 11 days prior to 
challenge, 2xl06 OVA TcR transgenic Thl cells were transferred by Lv injection to all 
recipient female 6-8 week old BALB/c mice. One day following adoptive transfer, 
recipients received s.c injection of 1 OOllg OVA in CF A. At day 0 all animals were injected 
peri-articular to the left ankle joint with 100Jlg of heat-aggregated OVA (HAO) in 50 III of 
saline. The development of arthritis was monitored from day 0 to day 7 by measuring paw 
thickness with a dial caliper. At day 7 the in vivo experiment was concluded, mice 
sacrificed and hind limbs removed and fixed in 10% neutral-buffered formalin. Blood was 
collected for the analysis of serum antibody. The draining popliteal and inguinal lymph 
nodes were harvested for proliferation, cytokine and T ell analysis. 
We decided to deplete pDC at either the priming stage or challenge stage of disease in 
order to estimate the kinetics of their relative contribution, if any, to pathology (Fig. 6.6). 
pDC were depleted by s.c. injection of 120G8 rat IgGIK pDC depleting antibody and 
disease progression measured in comparison to animals given the irrelevant isotype control 
antibody YCATE.55.9.1 (Rat anti-Dog CD8 IgG 1K) or PBS. Using paw swelling as the 
primary outcome measure, we estimated that group sizes of 10 were required to have a 
90% power of demonstrating significant increases at the 1 % level in two sided Student's t 
test (mean paw diameter increases from 2.1 to 2.3 mm, with standard deviation of 0.11 
mm). However, limits in the amount of 120G8 depleting antibody and isotype control 
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Figure 6.6 Protocol for the depletion of pDC in the OVA TcR transgenic T cell 
transfer model of experimental arthritis. 
At 11 days (d-11) prior to challenge (dO) 2xl06 OVA TcR transgenic Thl cells were 
transferred by i.v injection to all recipient female 6-8 week old BALB/c mice (n=42). One 
day following adoptive transfer (d-10) recipients received S.c injection of 100llg OVA in 
CF A. At 11 (d-l1), 10 (d-1 0), 9 (d-9) and 8 (d-8) days prior to challenge some animals 
received 200llg of 120G8 rat JgGh: pDC depleting antibody (n=6) or 200llg of 
YCATE.SS.9.1 rat anti-dog CD8 JgG1K irrelevant isotype control (n=6) i.p and are thus 
designated as the Early test groups. At day 0 all animals were injected s.c close to the left 
ankle joint with IOOllg of heat-aggregated OVA (HAD) in SOIlI of saline. At 1 day (d-l) 
prior to challenge, on the day of challenge (dO) and 1 (d!) and 2 (d2) days post-challenge 
animals that had not yet received pDC depleting antibody or isotype control were given 
200llg of 12008 rat JgGIK pDC depleting antibody (n=lO) or 200llg of YCATE.SS.9.1 rat 
anti-dog CD8 Jg01 K irrelevant isotype control (n=10) Lp and are thus designated as the 
Late test groups. The remaining mice were given 200111 PBS i.p on d-l, dO, dl and d2 
(n=10) and are the control group. The development of arthritis was monitored from dO to 
d7 by measuring paw thickness with a dial caliper. At d7 the in vivo experiment was 
concluded, mice sacrificed and hind limbs removed and fixed in 10% neutral-buffered 
formalin. Blood was collected for the analysis of serum antibody. The draining popliteal 
and inguinal lymph nodes were harvested for restimulation assays and T cell analysis. 
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available placed restrictions on the number of animals we could examine. Since we were 
particularly interested in the disease outcome following pDC depletion at the challenge 
stage and we therefore decided to examine 10 mice per group at this stage, with smaller 
numbers examined at early depletion time points. A preliminary study of this model 
suggested that pDC were more likely to participate in disease pathology at the challenge 
stage. Furthermore, the challenge stage was considered more relevant to human disease 
since patients presenting in the clinic already have established arthritis. 
There were therefore 5 groups of animals: PBS injection (n=IO) (I, positive control); 
120G8 pDC depletion at the time of OVA Tg T cell transfer (n=6) (2, early pDC 
depletion); YCATE.55.9.1 isotype control at the time of OVA Tg T cell transfer (n=6) (3, 
early isotype control); 120G8 pDC depletion at the time of OVA challenge (n= 10) (4, late 
pDC depletion); and YCATE.55.9.1 isotype control at the time of OVA challenge (n=IO) 
(5, late isotype control). 
6.3.6.2 120GS depletion of pDC 
To confirm pDC depletion after 4 s.c injections of 120G8 (200jlg) 1 animal from each 
group (120G8, YCATE.55.1 irrelevant isotype control antibody or PBS) was sacrificed and 
LN and spleen harvested. pDC in single cell suspensions were detected by CD11c101B220+ 
and mPDCA-l+ staining as analyzed by FACS. pDC were depleted from BALB/c by 
120G8 (Fig. 6.7b and e), but not from PBS (Fig. 6.7a and d) or isotype control group (Fig. 
6.7c and f). CD11c101B220+ pDC were not depleted in the PBS group (0.8% of cells, Fig. 
6.7a) or isotype control group (0.65% of cells, Fig. 6.7c), but were depleted by -70% in the 
120G8 group (0.36% of cells, Fig. 6.7b). Of interest, pDC as analyzed by mPDCA-l+ 
staining were, again, not depleted in PBS (0.46% of cells, Fig. 6.7d) or isotype control 
groups (0.4%, Fig. 6.7t), but were almost completely depIcted from the 120G8 group 
(0.06%, Fig. 6.7e). The latter is a more specific measurement ofpDC, since mPDCA-l is 
expressed by pDC only, but B cells are B220+/CD11c-- and mDC are B220-/CDIlc+. 
6.3.6.3 Phenotype of OVA TCR Tg T cells 
We purified naIve CD4+ T cells from pooled LN cells harvested from DOIl.I0 mice by 
negative selection. T cell differentiation was induced by co-culture with mitomycin C 
treated APC and O.3J.lM OVA323-339. Thl phenotype was induced by supplementing 
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Figure 6.7120G8 depletion ofpDC. 
The pDC and mDC in spleen and lymph nodes harvested on day 5 from Balb-c mice given 
200111 PBS (a and d), 200llg 120G8 pDC depleting antibody (b and e) or 200llg Rat anti-
Dog CD8 JgG2a irrelevant isotype control (c and 1) i.p per day for 4 days, was determined 
by double staining with B220 and CDl1c or the relevant isotype controls and confirmed 
with the pDC specific PDCA-1 or relevant isotype controls. pDC are 
B220+/CD 11 c1oIPDCA-1+, mDC are B220-/CDllchighIPDCA-1- and B cells are 
B220+/CD 11 c-IPDCA-1-. FACS analysis of spleen samples is shown. 
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cultures with IL-12 (Snglml) and anti-IL-4 mAb (lOJlglml). After 3 days of culture, cells 
were harvested for transfer to recipient BALB/c. To ensure transfer of 2x I 06 DV A TcR 
transgenic cells to recipients, their percentage in culture was detected by CD4+ IKJ1.26+ 
staining and FACS analysis and was routinely >53% (Fig. 6.8a). Intracellular staining and 
FACS analysis demonstrated that >66% ofTg T cells expressed IFN-y, confirming the Thl 
phenotype (Fig. 6.8b). 
6.3.6.4 Clinical effects of cellular depletion 
The swelling of the left hind paw (site of HAD injection) was measured using dial calipers. 
Transfer of Th 1 cells into recipient mice induced swelling in all groups, first evident at day 
1, and peaking at day 2, after challenge with HAD. The early pOC depletion group 
displayed more swelling that was slower to resolve, than did the PBS or parallel isotype 
control groups, significant at day 1 (PBS vs Early pOC depletion, p = 0.008) (Fig. 6.9a). 
The late pOC depletion group developed lower levels of inflammation that were quicker to 
resolve, than did the PBS control or parallel isotype control, significant at day 2 (PBS vs 
Late pOC depletion, p = 0.042) (Fig. 6.9b). There was no appreciable swelling in the right 
hind paws in any of the groups (Fig. 6.IOa and b) indicating no contra-lateral disease 
transfer. 
6.3.6.5 Histological analysis 
We performed sequential histological analyses on left hind paws removed at sacrifice and 
fixed in 10% neutral-buffered formalin. The PBS control group exhibited a modest 
infiltration of inflammatory cells to the involved joint and a partial to moderate level of 
cartilage erosion as assessed by loss of toluidine blue staining (Fig. 6.11 a and b). The 
early and late isotype controls displayed similar inflammatory cell infiltration and loss of 
cartilage integrity, comparable to the PBS group (6.11e-f and i-j respectively). 
Unexpectedly, the early pOC depletion group, although displaying the most swelling, as 
determined using dial calipers, exhibited a lower inflammatory cell infiltrate than did the 
parallel isotype control or PBS control groups, and there was only minimal evidence of 
cartilage erosion in this group (Fig. 6.11c-d). In contrast, the late pOC group, although 
displaying the least joint swelling, displayed the most extensive synovial hyperplasia and 
inflammatory cell infiltration to the involved joint (Fig. 6.11 g) as compared to the parallel 
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Figure 6.8 Thl phenotype of KJ1.26+/CD4+ OVA specific transgenic T cells. 
CD4+ T cells from pooled LN cells DOl 1.10 mice were purified by negative selection and 
cultured with mitomycin-C treated APC in the presence of 0.3 Jlm OVA + 5nglml IL-12 + 
10Jlglml anti-IL-4 mAb for 3 days in order to drive a Th1 skewed expansion ofTcR OVA 
specific transgenic T cells. Prior to transfer to recipient mice, the percentage of TcR OVA 
specific transgenic T cells in culture was determined by double staining with KJ1.26 and 
CD4 and analysing by FACS (a) and their Th1 phenotype confirmed by intracellular IFN-y 
staining ofKJ1.26+/CD4+ cells (b). A total of2xl06 TcR OVA specific transgenic T cells 
were injected i.v into BALB/c recipients. 
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Figure 6.9 Left hind paw swelling. 
The left hind paw thickness in mm of animals was measured using dial calipers just before 
challenge with HAG and every day thereafter for 7 days (dO-d7). Graphs show the 
swelling in animals given early injections of 120G8 pDC depleting antibody or isotype 
control as compared to control mice (a) and the swelling in animals given late injections of 
120G8 pDC depleting antibody or isotype control as compared to control mice (b). 
(a) day 1, ** PBS vs pDC deplete = 0.008, 0 PBS vs isotype control = 0.011 
(b) day 2, * PBS vs pDC deplete = 0.042 
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6.10 Right hind paw swelling. 
The thickness of the right hind paw in mm of animals was measured using dial calipersjust 
before challenge with HAO and every day thereafter for 7 days (dO-d7). Graphs show the 
swelling in animals given early injections of 120G8 pDC depleting antibody or isotype 
control as compared to control mice (a) and the swelling in animals given late injections of 
120G8 pDC depleting antibody or isotype control as compared to control mice (b). 
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Figure 6.11 Histological analysis of arthritis in recipient mice. 
Sections of the left hind limbs were taken and stained with toluidine blue (a, c, e, g, i) or 
haematoxylin and eosin (b, d, f, h, j). The ankle joints of PBS recipient mice 
demonstrated a lightened toluidine blue staining (a) indicative of cartilage erosion (t) and 
some synovial hyperplasia and inflammatory cell infiltration (*) (b). Recipients of early 
pDC depleting antibody demonstrated strong toluidine staining (c) indicative of a normal 
cartilage integrity and little inflammatory cell infiltration (d) while the early isotype 
control resembled the PBS recipient group (e and f). The ankle joints of late pDC 
depleting antibody recipient mice demonstrated reduced toluidine blue staining indicative 
of extensive cartilage and bone erosion (g), increased synovial hyperplasia and 
inflammatory cell infiltration (h), while the late isotype control group demonstrated 
comparatively less severe inflammation, resembling the PBS recipient group (i and j). 
One typical example from each group is shown. 
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isotype control and PBS group. In addition, there were moderate levels of cartilage erosion 
in this group (Fig. 6.11 h). This was intriguing for a number of reasons. Firstly, it 
suggested that paw swelling used by many as an indicator of disease, is not necessarily 
appropriate in all murine models. Secondly, the data indicated that depletion of pDC at the 
challenge stage of disease increased disease severity. Thirdly however because histology 
was being assessed early in the model (previously assessed at 14 days) it is possible that 
the differences noted were not of real significance (noting that hind limb swelling had 
settled largely by this time point). Further studies are required to characterize the effects on 
the kinetics of histologic changes observed. 
6.3.6.6 Anti-OVA, anti-collagen and anti-IgGza antibody production ill vivo 
At day 7, serum was obtained from all animals and serum levels of anti-OVA, anti-
collagen and anti-IgG2a measured by ELISA. As expected, all animals were able to 
produce high levels of anti-DV A Abs (Fig. 6.12a and b). Anti-collagen Ab in the early 
pDC depletion group (Fig. 6.12c) was lower, although not significantly, than the PBS 
control and parallel isotype control group. In contrast, anti-collagen Ab was significantly 
higher in the late pDC depletion group (Fig. 6.12d) as compared to PBS and parallel 
isotype control group (p<O.Ol). Similarly, anti-IgG2a Ab (a measure of rheumatoid factor) 
were significantly lower in the early pDC depletion group (p<0.05) but significantly higher 
in the late pDC depletion group (p<0.05) as compared to the PBS and parallel isotype 
controls (Fig. 6.12 e and f respectively). Antibody production from the isotype control 
groups did not differ significantly from the PBS control. Together these data are 
consistent with the histological data indicating more severe pathology in the late pDC 
depletion group than the early pDC depletion group. 
6.3.6.7 Cytokine profile and cellular proliferation of OVA-specific cells ex vivo 
Draining popliteal LN were removed from all mice at 7 day post challenge with HAO and 
single-cell suspensions cultured in vitro with or without 1 mg/ml OVA or with 50 jlg/ml 
CII. Supematants were harvested at 72 hours and cytokine profile measured by multiplex 
analysis. Proliferation was measured by tritiated thymidine incorporation at 96 hours of 
culture (Fig. 6.13a and b). Little proliferation was apparent in the absence of stimulation in 
all groups. In vitro culture in the presence of OVA induced proliferation to similar levels 
in all groups. Of interest, collagen also induced proliferation in all groups, however this 
was significantly higher in the late pDC depletion group as compared to the PBS control 
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Figure 6.12 Serum anti-QV A Ab, anti-collagen Ab and anti-IgGza Ab titration. 
Serum anti-OVA IgG2a (a and b), anti-collagen IgG2a (c and d) and anti-IgG2a (e and t) Ab 
levels were measured on day 7 by ELISA by doubling serum titration. Serum levels were 
measured for each individual animal per group (PBS control n=10, early pDC depletion 
n=6, early isotype control n=6, late pDC depleting antibody n=10 and late isotype control 
n=10) with results presented as mean +/- SEM. The serum antibody titres of isotype 
controls did not differ significantly from controls and are not shown. 
(d) 1:50, ** PBS vs pDC deplete = 0.003, 1:100, ** PBS vs pDC deplete = 0.003, 1:200, 
** PBS vs pDC deplete = 0.002, 1 :400, ** PBS vs pDC deplete = 0.005. 
(e) 1:50, * PBS vs pDC deplete = 0.043,1:100, * PBS vs pDC deplete = 0.044. 
(t) 1:50, ** PBS vs pDC deplete = 0.001,1:100, ** PBS vs pDC deplete = 0.002, 1:200, ** 
PBS vs pDC deplete = 0.004, 1:400, * PBS vs pDC deplete = 0.011, 1:800, * PBS vs pDC 
deplete = 0.045. 
206 
(a) 
2.5 
.0 
« 
« 
> O ~ 1.5 
. 0 
. _ Ul 
- " 
.:i8 1 
05 
(c) 
1.2 
~ 
c: 8, 0.8 
~ ~ 
'0 g 0.6 
u 3 
• 0 
°E 0.4 
« 
0.2 
(e) 
1.4 
1.2 
.. 
d" ~ 0.8 
J2l ~ 
. " 
._- 0 06 
c: 0 . 
« 0.4 
0.2 
Early 
• 
oL-----------------------------
(b) 
25 
E 1.5 
c 
o 
Ul 
" o o 1 
0.5 
(d) 
2.5 
~ 1.5 
g 
g 1 
0.5 
(1) 
25 
E 1 5 
c 
o 
'" 
" g 1 
0.5 
Late 
.«:;'0 • -$>'0 ~ . ~~ 
s;) ~'0 __ ------------------~. ~ ~ . .~ 
• PBS 
• 120GB antibody EARLY 
• 120GB antibody LATE 
X Normal BALB/c serum 
~ . 
Figure 6.13 Ex vivo cellular proliferation. 
Draining lymph nodes were collected at day7 and cultured separately for each individual 
animal with medium alone, Img/ml OVA or 50Ilg/ml collagen H. eH) Thymidine 
incorporation was measured at 96h. Results are presented as the mean stimulation index 
+/- SEM for each group (PBS control n=10, early pDC depletion n=6, early isotype control 
n=6, late pDC depleting antibody n=10 and late isotype control n=10). 
* control vs late pDC depleting antibody = 0.02831 
o late pDC depleting antibody vs late isotype control = 0.01185 
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and parallel isotype control (PBS vs Late pDC depletion, p = 0.02831, Isotype control vs 
Late pDC depletion, p = 0.01185) (Fig.6.l3b). Draining LN cultures taken from all groups 
continued to produce IFN-y after stimulation with OVA (Fig. 6.14a and b ). OVA 
stimulation also induced moderate levels of IL-5 in all cultures (Fig. 14c and d), but 
relatively low levels of IL-4, IL-lO and GM-CSF (Fig. 14e-j). Cytokine secretion from 
cells taken from the late pDC depletion group tended to be greater than PBS control or 
parallel isotype control, but this was significant for IL-5 only (p = 0.049). 
6.3.6.8 Profile of CD4+ Teells in draining LN 
In order to determine if any of the differences we observed thus far could be attributed to 
differences in the numbers of CD4+ T cells expanded in each group, or the phenotype 
thereof, we analysed single-cell suspensions from draining LNs taken at day 7 for CD4+ 
and KJ.l+ expression (Fig. 6.l5a and b) and we determined the number of Tregulatory 
(Treg) cells therein by co-staining ofCD4 with intracellular Forkhead-box (Fox) p3, a Treg 
specific marker. 
By day 7, there were minimal KJI.26+ OVA323-339 peptide-specific TCR Tg T cells as 
assessed by CD4+ 1KJ1.26+ staining and FACS analysis (Fig. 6.15a). The overall 
expansion of CD4+ cells was comparable in all groups at -50% of all cells in the draining 
LNs. Similarly, Tregs comprised 7.4-8.4% of all CD4+ cells and there were no differences 
between groups (Fig. 6.16). Together these results indicate that the differences in disease 
severity observed in the early and late pDC depletion groups could not be explained by 
differing levels of CD4+ T cells, or Treg cells. 
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Figure 6.14 Ex vivo cytokine profile of lymph nodes. 
Draining lymph nodes were collected at day7 and cultured separately for each individual 
animal (PBS control n=10, early pDC depletion n=6, early isotype control n=6, late pDC 
depleting antibody n=10 and late isotype control n=lO) in triplicate.with medium alone, 
1 mg/ml av A or 50~g/ml collagen 11. The levels of the cytokines IFN-y (a and b), IL-5 (c 
and d), IL-4 (e and f), IL-IO (g and h) and GM-CSF (i and j) in the culture supematant at 
72h were measured by Luminex analysis. The results represent the mean +/- SEM. 
(b) * control vs late pDC depleting antibody = 0.049 
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Figure 6.15 Percentage of CD4+ cells in draining lymph nodes. 
The percentage of CD4+/KJ1.26+ (TcR OVA specific transgenic T cells) in the draining lymph 
nodes of mice receiving PES, early pDC depleting antibody, early isotype control, late pDC 
depleting antibody and late isotype control was measured at day 7 by F ACS analysis. The 
percentage of CD4+/KJ1.26+ in all groups was minimal «0.2%) (a). One respresentative 
FACS plot is shown. CD4+/KJ1.26" cells were expanded in the draining lymph nodes from all 
groups (b). Results represent the mean +/- SEM for three animals per group. 
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Figure 6.16 Foxp3+ Treg analysis of draining lymph nodes. 
The percentage of CD4+/Foxp3+ (Tregs) in the draining lymph nodes of mice receiving 
PBS (a), early pDC depleting antibody (b), early isotype control (c), late pDC depleting 
antibody (d) and late isotype control (e) was measured at day 7 by FACS analysis. The 
percentage ofCD4+/Foxp3+ cells in all groups was comparable. One respresentative FACS 
plot from each group is shown. 
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6.4 Discussion 
Dendritic cells (DC) are critical to the generation and maintenance of central and 
peripheral tolerance, as well as the priming of innate and adaptive immunity. As such, DC 
play an essential role in the initiation and perpetuation of inflammatory arthritis as loss of 
self-tolerance is a critical component of autoimmune disease. Maffia et al. recently 
reported that adoptive transfer of Th 1 differentiated OVA TCR Tg T cells induced arthritis 
in recipient mice following OVA immunization (697). It was subsequently postulated that 
local regulatory mechanisms that maintain self-tolerance, particularly those sustained by 
DC, could be overwhelmed by a strong Th 1 response to irrelevant antigen, enabling the 
production of autoreactive T cells. Similar murine models have been described that have 
demonstrated that respiratory viruses can break inhalation tolerance to harmless antigens 
(698, 699). Moreover, numerous infectious agents including bacteria, mycobacteria, 
viruses and parasites have been implicated in triggering and exacerbating RA and PsA 
(211-214, 221). We have now analyzed the contribution of pDC to the aetiology of this 
model and provide evidence indicating that pDC may be important in supporting the 
suppression of autoimmune inflammatory arthritis. 
We first established that both pDC and mDC are expanded in the draining lymph node of 
mice undergoing collagen-induced arthritis (CIA). That pDC exceeded mDC was expected 
as pDC comprise the most abundant DC population in the lymph node owing to their high 
level expression of lymph node homing chemokine receptors including CD62L, CXCR3 
and CCR 7 (442). This was commensurate with our previous hypothesis that reduced pDC 
and mDC numbers in the peripheral circulation of RA and PsA patients could, at least in 
part, be explained by lymph node directed migration, in addition to the observed 
infiltration to the target inflamed synovial tissue and psoriatic skin lesions (Chapter 3 and 
4), particularly since reduced PB DC subsets could be correlated with active inflammation. 
However, this did not provide information regarding the immunogcnic potential of the 
migrating DC subsets. 
The competence of pDC to take up whole antigens, other than viruses, and elicit antigcn-
specific responses is controversial as they do not phagocytose, process or load antigens to 
MHC molecules as efficiently as do their myeloid counterparts. We have demonstrated 
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here that pDC are capable of processing and presenting OVA peptide to OVA TCR Tg T 
cells. Similar observations have been made by de Heer et aI, who found however that 
unlike mDC, OVA-loaded pDC could not induce proliferation of nai've TCR-transgenic 
OVA specific T cells ex vivo (700). While it is generally accepted that pDC can expand 
antigen-experienced T cells (453, 690), their ability to expand nai've T cells is a more 
contentious issue, particularly as pDC have only low MHC 11 and co-stimulatory receptor 
expression compared to mDC, even when terminally matured. We observed that although 
bone marrow derived mDC and pDC could both elicit collagen-specific expansion of CD4+ 
T cells isolated from the draining lymph nodes of DB NI mice undergoing CIA, only mDe 
elicited low level proliferation to collagen in lymph node derived CD4+ T cells isolated 
from naIve DBNl mice. It is possible that the proliferation induced in mDC/T cell 
cultures was indicative of a small number of self-reactive T cells in culture. I-A q haplotype 
DBNI mice are highly susceptible to CIA and it has been shown that expansion of 
antigen-specific CD4+ T cells after intradermal injection of CII emulsified in complete 
Freund's adjuvant (CFA) occurs early in vivo, before the onset of arthritis (696). We have 
also observed that during CIA, up to 10% of animals develop arthritis (as assessed by paw 
swelling) prior to intraperitoneal CIl challenge (unpublished communication from Dr J.A. 
Gracie). In addition to this, it has been suggested that collagen may deliver a direct 
maturation stimulus to mDC possibly through TLR4 signaling (694, 695), thus enhancing 
their immunogenic potential. While murine mDC mature rapidly to TLR4 stimulation, 
murine pDC are only weakly responsive (701) and their human pDC counterparts do not 
respond to TLR4 agonists at all (490, 499). It is therefore unlikely that collagen-loaded 
pDC would be immunogenic in the absence of external inflammatory stimuli. However, 
we observed that TLR 9 stimulation with CpG OON did not enhance pDC antigen-specific 
stimulation of T cells. Together the data supports a central role for mDC, but not 
necessarily pDC, in the initial naIve CD4+ T cell expansion phase of CIA. It has been 
postulated that pDC act complementary to mDC, directing the differentiation of 
unpolarized T cells previously expanded by mDC (453) - this possibility requires further 
investigation. Of particular interest, it has been indicated in several murine models that 
pDC are important to the maintenance of tolerance (700, 702). 
The direct contribution of mDC to the pathogenesis of various murine models of arthritis 
has been reported earlier by us (553) and others (550,551), however there has as yet been 
no attempt to analyze the relative contribution of pDC to arthritic pathology in a murine 
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model. We next performed experiments aimed at elucidating the potential pathogenic role 
of pDC in a murine model of arthritis. Technical restrictions precluded the expansion of 
sufficient numbers of bone marrow derived pDC to enable in vivo transfer experiments. 
We also chose not to utilize the collagen-induced arthritis in DBNl model as, although it 
was informative in our in vitro analyses, significant problems exist in interpreting in vivo 
disease mechanisms attributable to the multifactorial contribution of eliciting agents. In 
addition, we were specifically interested in analyzing DC subsets, and thus concluded that 
this would be better achieved using the Th 1 av A TcR Tg adoptive transfer model of 
arthritis, particularly as autoimmunity is postulated to arise from a DC specific breach of 
self-tolerance (697). We therefore chose to use the pDC specific antibody 120G8 to 
deplete pDC at the time of adoptive T cell transfer in comparison to pDC depletion at the 
time of av A challenge in the OVA TCR Tg adoptive transfer model of arthritis. 
We first observed that all animals, whether depleted of pDC or not, developed transient 
inflammation at the site of av A immunization. However, the magnitude of this 
inflammation and the kinetics of its resolution were significantly altered betwecn groups. 
Mice from which pDC had been depleted at the time of adoptive T cell transfer had 
significantly more footpad swelling that was slower to resolve than did control animals or 
mice from which pDC had been depleted at the later time of av A challenge. Indeed, the 
later pDC depleted group had significantly less footpad swelling at early time points than 
did control animals. However, footpad swelling was not indicative of dcstructive joint 
pathology. Histological examination revealed that late pDC depleted animals exhibited 
more extensive synovial hyperplasia, inflammatory cell infiltration and cartilage erosion in 
the involved joint than did mice from the early pDC depletion or parallel control groups. 
Commensurate with this, animals within the later pDC depleted group had significantly 
higher levels of serum av A, collagen and host IgG2a specific antibodies than did PBS and 
isotype control groups, and their draining lymph node cells displayed significantly 
increased collagen-specific proliferation. Thus an intriguing observation in this model was 
that depletion of pDC at the later challenge stage of disease appeared to hasten the onset of 
the antigen-specific adaptive (auto) immune response, while early pDC depletion appeared 
to slow the onset of adaptive immunity. The specific mechanisms by which these 
contrasting events appeared to alter the kinetics of disease requires further investigation, 
but two-photon imaging of the actual cellular interactions occurring in vivo, particularly 
with regard to cognate DCfT cell contact may prove informative. 
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These experiments proved particularly infonnative. First, and of clear relevance to all 
murine models of arthritis, foot pad swelling may not be suitable to use as a sole outcome 
measurement of pathology, but should be accompanied by histological examination -
perhaps the kinetics of swelling and correlation with immune response parameters also 
requires careful attention. It is also possible that given the onset of swelling on day two 
and its relatively rapid resolution, the swelling in this instance may have resulted from 
delayed-type hypersensitivity to the footpad injection. Second, it appears that consistent 
with other models of arthritis, mDC are capable of eliciting autoimmune disease in the 
absence ofpDC, suggesting that they may constitute the primary DC subset involved in the 
induction of autoimmunity. Since no specific murine mDC marker has, as yet, been 
defined, it would be extremely difficult to examine murine pDC elicited autoimmunity in 
the absence of mDe by a similar method, although our in vitro data suggests this unlikely. 
Third, this model demonstrates that pDC may have a central role in regulating mDC driven 
autoreactive T cell expansion and autoantibody production. This last observation is 
consistent with a number of groups reporting that pDC are essential to supporting effective 
suppression of autoimmunity (700, 703). 
The regulation of self-reactive effector responses by specialized populations of regulatory 
T cells (Tregs) is considered a major mechanism by which tolerance is maintained and 
autoimmune disease avoided. A number of groups have reported that tolerising pDC in the 
lymph node are essential for the induction of CD4+CD2S+Foxp3+ Tregs, particularly in 
relation to the prolongation of graft survival in transplant immunology (704, 705). We 
therefore examined the number ofCD4+Foxp3+ Tregs in the draining lymph nodes from all 
groups. However, FACS analysis did not identify any significant alterations in the number 
of Foxp3 expressing T cells between groups. Moreover, we identified comparable CD4+ 
expansion in the draining lymph nodes of all groups. Because we were restricted in our 
examination of Tregs to one time point, the possibility that we missed any differences in 
this relatively small group cannot be discounted. However, the excessive loss of self-
tolerance in the pDC depleted group could potentially be explained by other factors. 
Murine pDC have been credited with an ability to express indoleamine 2,3-dioxygenase 
(IDO) function (706). IDO is an enzyme that mediates the immunosuppressive pathway of 
tryptophan catabolism, required during the maintenance of T cell homeostasis and the 
induction of antigen-specific tolerance (514). Indeed, IDO expressing pDC have been 
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demonstrated to potently suppress T cell responses to antigens presented by pDC 
themselves and importantly, in a dominant fashion, antigens presented by immunogenic 
mDC (707). Furthennore, CTLA-4 Ig engagement ofB7 conditions DC to produce IFN-y 
which promotes IDO induction, thereby initiating degradation of tryptophan to 
kyrenurenines in the local tissue micro environment and concomitant Th 1 apoptosis (515). 
This may explain some of the therapeutic efficacy of CTLA-4 Ig in arthritis beyond the 
inhibition of APC/T cell contact. Of interest, it has also been shown that engagement of 
CD200R on pDC, upregulated upon maturation. by soluble CD200-Ig fusion protein elicits 
IDO enzyme expression and these cells become capable of suppressing Ag-specific 
responses in vivo (708). It is possible in our model that the loss of pDC produced 100 has 
led to the exacerbation of pathology, but this requires further examination by analysis of 
serum kynurenine levels, the product of tryptophan catabolism, in depleted and non-
depleted animals. 
Based upon our investigations thus far, we propose a model whereby tolerogenic mDC 
patrolling the joint are induced to mature by T cells of irrelevant specificity (in our model 
av A TCR Tg T cells) (Fig. 6.17). It is possible that DC maturation and concomitant 
acquisition of immunogenicity is triggered by av A-specific cognate interactions with the 
Th 1 polarised OVA TcR Tg T cells. Alternatively, non-specific soluble factors released in 
the joint in response to intra-articular OVA injection and T cell accumulation may promote 
DC maturation. Further analysis by two-photon imaging of the joint would resolve this 
issue. Migration of the immunogenic mDC carrying peptides derived from self (joint)-
antigens to the draining lymph nodes could thereafter drive (auto) antigen-specific T cell 
responses followed by autoantibody production. Since pDC circulate throughout the 
peripheral blood, migrating directly to the lymph nodes via the high endothelial venulcs, 
we propose that at this initial phase of inflammation they retain a predominantly 
tolerogenic phenotype, allowing them to suppress (although not completely), mDC driven 
autoreactive T cell expansion. Whether pDC need to present antigen to suppress 
autoimmunity in an antigen-specific direction in this model is not clear, but again could be 
resolved by tracking ill vivo. In addition, the specific mechanisms for disease suppression 
have not yet been defined and may variously include the expansion of antigen-specific 
Tregs, the production of IDO, or negative T cell signaling through programmed death 
receptor ligand-l (PDCD-l). It is probable that pDC migration to the joint occurs 
secondary to the initial inflammatory insult in response to up-regulation of 
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Figure 6.17 Proposed role of DC subsets in the induction of immunogenicity vs 
tolerogenicity in the OVA TcR Tg adoptive transfer model of arthritis. 
Following intra-articular OVA challenge, Thl polarised av A TcR Tg T cells activate 
maturation and acquisition of immunogenicity in tissue-sentinel mDC, by the release of 
soluble factors such as TNF-a and/or cognate interactions (CD40ICD40L). The self-
peptide bearing immunogenic mDC migrate to the regional (popliteal) draining lymph 
node where they induce (auto) antigen-specific expansion of T cells. pDC migrating 
directly to the lymph node from the peripheral blood may suppress, although not 
completely, this autoimmune response directly through IDO induced tryptophan 
catabolism, negative signaling through PDCD-l or by expansion of antigen-specific Treg . 
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pro-inflammatory chemokines and synovial angiogenesis. While mDC may be directly 
pathogenic in triggering inflammatory arthritis, as has been indicated in several murine 
models, pDC may at this initial phase have more of a tolerogenic role vital to the 
suppression of autoimmunity. Clearly in this model, the transfer of Th 1 cells constituted a 
significantly severe insult that overwhelmed pDC tolerogenic mechanisms. However, 
Maffia et al also described a low to moderate transient arthritis induced by adoptive 
transfer of Th2 differentiated OVA TCR Tg T cells(697}. It would therefore be 
informative to this hypothesis to repeat this model by transfer of Th2 cells into pDC 
depleted animals. 
The observation in this study that depletion of pDC at the time of adoptive T cell transfer 
reduced disease pathology, whereas depletion at OVA challenge increased disease severity, 
was intriguing. Although sub-optimal numbers of mice for statistical analysis were used in 
the early depletion model due to technical restrictions, the observations made may suggest 
that pDC are necessary at this early stage to enable or enhance disease mani festation in this 
model. Since pDC are thought to have a life span in murine systems of approximately two 
weeks (399), it is probable that they were still reduced at the challenge stage, thus the 
decrease in disease severity could not be accounted for by re-constituted pDC autoimmune 
suppression. It is more likely that pDC have different functional roles depending upon 
physiological setting, as presumed by their established plasticity (402). Further analyses of 
this particular component of the model, in groups of a larger, statistically significant size, 
will be required in order to confirm the result. As such, elucidating the mechanisms by 
which pDC depletion induces disease suppression compared to enhancement thereof, 
particularly in relation to kinetics, may prove particularly informative. 
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Chapter 7: General Discussion 
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Dendritic cells (DC) are a highly motile heterogeneous network of professional antigen-
presenting cell (APC) critical to the initiation and regulation of adaptive immunity, as well 
as the maintenance of both central and peripheral tolerance. As such, DC biology 
embodies an important line of investigation in the pursuit of the underlying mechanisms 
culpable for breach of self-tolerance and generation of chronic autoimmune inflammatory 
arthritis. However, to date there have been relatively few studies examining the phenotype 
and function of DC in disease aetiology, particularly with reference to the DC subsets, 
plasmacytoid (p) DC and myeloid (m) DC. This may be attributed to the complexity 
inherent in studying a low frequency population of cells, their geographical location in 
tissues that are not easily accessed and the paucity of specific DC markers available. 
Accordingly, this thesis utilized novel DC markers in a combination of in vitro and in vivo 
analyses in order to elucidate the contribution of different DC subsets to the initiation, 
modulation and perpetuation of the inflammatory arthritides, rheumatoid arthritis (RA) and 
psoriatic arthritis (PsA). 
The first major component of this thesis sought to examine the profile of human DC 
subsets in RA and PsA, particularly with regard to phenotype, tissue localization and 
function in order to gain further insight into the contribution of DC to disease pathology. 
A number of important observations have subsequently emerged: 
• First, we have demonstrated that circulating pDC and mDC are reduced in the 
peripheral blood (PB) of RA and PsA patients, but are accumulated to the 
inflammatory synovial fluid (SF) and synovial membrane (SM), commensurate 
with altered migration. 
• Second, we have established that, although mature cells are present, the majority of 
pDC and mDC within the synovial compartment displayed a predominantly 
immature phenotype as identified by the low to absent expression of specific co-
stimulation and maturation markers including CD80, CD83, CD86 and DC-LAMP. 
• Third, we demonstrated that the lack of DC maturation, particularly surprising 
given the local abundance of TLR stimulating factors such as heat shock proteins 
and necrotic cellular debris (266), was not a result of an intrinsic functional defect, 
since SF purified mDC and pDC could mature and release cytokines comparable to 
their normal PB purified counterparts. 
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• Fourth, we demonstrated that synovlUm localized DC also retain functional 
capacity, expressing the pro-inflammatory cytokines IL-12p70, IL-23p 19, IL-IS, 
IL-18 and IFN-alp commensurate with arthritogenicity. Furthermore, mDC and 
pDC displayed differential cytokine expression. mDC were the predominant IL-
12p70 and IL-23p19 expressing cells, commensurate with a central role in the 
regulation and expansion of T cells, in particular Th17 (625). In contrast, pDC 
expressed predominantly IL-15 and IL-18, cytokines that can enhance IL-12 
induced IFN-y release and inhibit T cell apoptosis (628, 629), thus amplifying and 
prolonging inflammation. Furthermore, pDC also expressed IFN-alp in abundance. 
Numerous cases of arthritis triggered by IFN-a therapy of previously non-arthritic 
patients, which resolved following cessation of treatment, have been reported (543-
549), implicating this type I interferon in disease pathology and, by association, the 
cells which produce it. Indeed, Nestle et al. have recently demonstrated a critical 
role for pDC derived IFN-a in the early pathogenesis of psoriasis, a defining extra-
articular feature of PsA (437). Since pDC exceeded mDe in both RA and PsA 
synovium, this may have pathological implications commensurate with disease 
severity and may indicate divergent contributions to disease pathology and, by 
association, resolution. 
In light of the observations gathered thus far, the second component of this thesis sought to 
examine the effect of cytokine modification of DC function and broader area of synovial 
inflammation. Specifically, we have examined DC subsets in synovium after TNF-a 
blockade (infliximab) and thereafter compared and contrasted the effects of both TNF-a 
and IL-15 on DC subsets in in vitro assays. In so doing we sought to elucidate further the 
contribution of DC to disease pathology and, more specifically, resolution. While this 
component of the study was hampered by cell rarity, low number of participant patients 
and the early time point examined after infliximab infusion, it indicated a number of 
potentially informative trends. 
• First, in in vivo clinical studies using synovial biopsies obtained before and 48 
hours after infliximab infusion, we observed a trend towards decreased mDC, but 
not pDC, in RA and PsA synovial membrane. 
• Second, we established a co-culture system in which cross regulation between T 
cells and Des could be examined ill vitro. These studies demonstrated that TNF 
221 
neutralization down-regulated mDC release of the pro-inflammatory chemokines 
CCL2, CCL4 and CXCL8 following mDC/T cell contact, but not pDC/T cell 
contact. Indeed, TNF neutralization appeared to increase the release of pro-
inflammatory chemokines from pDC/T cell contact. A number of groups have 
suggested that TNF-a may hinder the action and secretion oflFN-a (591) and IFN-
a has been demonstrated to drive CCL2, CCL3 and CCL4 secretion from pDC, but 
not mDC (679). Thus TNF blockade may enable IFN-a activity, and as such 
enhance pDC arthritogenicity in the longer term. 
• Third, using the same in vitro system we compared and contrasted these effects of 
TNF with those oflL-15, an important innate response cytokine heavily implicated 
in DC effector biology. IL-15 blockade in vitro did not increase pro-inflammatory 
chemokine release from mDC/T cell or pDC/T cell co-cultures, but did decrease 
TNF-a release in both. The study may therefore suggest the fascinating possibility 
that TNF-blockade affects distinct DC subsets differentially, which may have 
therapeutic consequences for patients with a pDC dominant synovial DC infiltrate. 
As the number of pDC in the inflamed synovium from our patient cohorts 
undertaking infliximab infusion was low compared to mDe and the majority of 
patients responded to therapy, we were unable to investigate this hypothesis further. 
However, it may indicate a point at which IL-15 blockade may complement TNF-a 
blockade, given the ability of the former to directly inhibit DC/r cell cognate 
interactions at a point upstream in the inflammatory cascade from TNF-a. 
In addition to enhancing pro-inflammatory chemokine release, TNF-a has been 
demonstrated to limit the maturation, but prolong the life of CD34+ progenitor cultured DC 
(655, 656). Thus the local abundance of TNF-a in the inflamed synovium may be 
considered a candidate extrinsic factor facilitating the accumulation of immature DC to the 
inflamed synovial compartment. As such, immature DC in the synovium could be 
'frustrated' by their inability to mature. However, the identification of a small population 
of CD83+ and DC-LAMP+ mDC and pDC may indicate that some DC can escape this 
mechanism. Indeed, the pattern of immature to mature pDC and mDC infiltration to the 
SM may be indicative of a local maturation gradient, commensurate with DC migration to, 
and maturation within, the synovium. Given the abundance of self (auto) antigen in the 
SF, if mature SM localised DC originate from the pool of immature SF DC, there is 
222 
potential for in situ presentation of arthritogenic peptide to autoreactive T cells. Indeed, 
both pDC and mDC within the SM could be co-localised to CD4+ and CDS+ T cell 
aggregates commensurate with cell contact. However, while a number of studies have 
identified oligoclonal CD4+ and CD8+ T cells in RA and PsA SM, it is unclear whether 
clonal expansion occurs in situ or in the regional lymph node with attendant remigration to 
the tissue thereafter. Studies ongoing in our laboratories are directly addressing this 
question using two-photon microscopy to track antigen activated T cells in vivo. 
One problem with such studies had been until now the lack of good arthritis model systems 
in which to address such issues. However, we were able to take advantage of a recently 
developed antigen driven arthritis model generated in our laboratory to evaluate the role of 
DC subsets in evolving articular inflammation. Comparative analysis of the function of DC 
subsets in the OVA TCR murine model of arthritis demonstrated that pDC in particular, 
may be vital to the suppression of autoimmunity by the maintenance of peripheral 
tolerance. Adoptive transfer of Th! polarized OVA-specific TcR Tg T cells to BALB/c 
recipients produces arthritis in joints proximal to the site of OVA inoculation, 
(presumably) by triggering immunogenic maturation of tissue circulating, self-peptide 
bearing DC and consequently auto-reactive T cell expansion (697). We demonstrated that 
depletion of pDC in this model significantly increased disease severity, as ascertained by 
histology, serum auto-antibodies and (self) antigen-specific CD4+ memory T cell 
proliferation, thus suggesting a regulatory role for pDC in auto immune suppression. 
Moreover, this model demonstrated that mDC can instigate autoimmunity in the absence of 
pDC. Indeed, in vitro examination of the collagen type 11 processing and presentation 
capacity of murine bone marrow differentiated mDC and pDC established that while both 
subsets could induce antigen-specific memory CD4+ expansion, only mDC elicited 
expansion of (presumably) naive autoreactive T cells. Together these data imply that mDC 
may constitute the dominant DC subset culpable for eliciting arthritogcnic autoimmunity, 
whereas pDC may be vital to its suppression, at least during the expansion or initiation 
phase of the disease process. However, the circumstantial human studies contained in this 
thesis clearly indicate that both mDC and pDC exhibit the potential to be pathologic within 
the synovial compartment during the chronic phase of arthritic inflammation, not least via 
cytokine release. 
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The presence, or absence, of tolerogenic DC in the inflamed synovial compartment in 
human disease has not yet been established. Of interest, TNF-a has been shown to induce 
tolerogenic DC, as defined by a semi-mature phenotype, capable of inducing antigen-
specific protection from auto immunity in a number of murine models (709, 710). 
Commensurate with this, we observed that mDC and pDC within both RA and PsA SF 
displayed partial upregulation of maturation receptors, potentially indicative of a semi-
mature/tolerogenic phenotype. Furthermore SF, but not healthy donor PB, purified mDC 
and pDC released IL-lO, a major defining functional feature of tolerogenicity. In the 
steady-state, DC maintenance of peripheral tolerance by induction of antigen-specific 
regulatory T cells (Treg) is perceived to occur in the regional lymph node. While 
CD4+CD2S+Foxp3+ Treg have been identified in RA SF and synovium (711, 712), it has 
not yet been established if Treg migrate to, or di fferentiate within, the synovial 
compartment. In any event IL-15, which is dispersed throughout the synovial 
compartment and expressed by both pDC and mDC, has been shown to abrogate the 
suppressive activity of Treg (713). As such, IL-IS blockade in disease may release Treg 
modulation of aberrant immunity. It is clear however, that in the context of chronic 
autoimmunity, self-tolerance is broken and the mechanisms that would normally re-
establish it overwhelmed. 
IL-IS blockade currently constitutes a promising biological therapy in inflammatory 
arthritis (341). We therefore sought to elucidate the broader biological mechanisms by 
which IL-15 neutralisation could operate, particularly as it was expressed by both pDC and 
mDC within the inflamed synovium. Specifically, we sought to characterize points by 
which IL-IS neutralisation may hinder T cell cognate interactions with DC. 
• First, we demonstrated that neutralization of exogenous IL-IS suppressed 
proliferation and induced apoptosis of an IL-15 sensitive cell-line. 
• Second, we established that IL-IS blockade neutralised exogenous IL-I2/IL-IS 
induced IFN-y release from SF derived mononuclear cells (SFMC), thus 
confirming it's bioactivity. Moreover, we demonstrated that IL-15 blockade 
neutralised not only induced, but also spontaneous TNF-a release from SFMC, thus 
confirming its role upstream from TNF-a in the inflammatory cytokine cascade. 
• Third, we confirmed effective neutralization of endogenous IL-I 5 from SF purified 
leukocytes by demonstrating IL-15 blockade induced down-regulation of CD69 on 
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SF derived T cells. Since CD69 is implicated in cognate interactions with APC 
(630), this may therefore indicate a mechanism by which IL-lS neutralization could 
inhibit cognate DCfT cell contact. In addition, we demonstrated that IL-1S 
neutralising antibody could bind IL-15 at the cell surface thus inhibiting juxtacrine 
IL-15 interactions. 
The critical challenge in therapeutics now is to re-establish tolerance, such that therapeutic 
remission can be maintained. It has now been demonstrated by a number of studies that 
combination therapy using methotrexate and TNF-blockade, early in disease during a so-
called "window of opportunity", induces significant, sustained remission in RA patients 
even after withdrawal ofTNF-blockade (714, 715). It is likely that the relative success of 
early intervention is possible by halting disease progression prior to establishment of the 
amplifying feedback loop between (adaptive) autoimmune cartilage f bone destruction and 
(innate) TLR stimulation. But what of tolerance induction in patients suffering long-term 
destructive disease? Promisingly, rituximab (anti-CD20) depletion ofB cells from patients 
with active RA has been shown capable of inducing extended periods of disease remission 
in about 50% of patients, sustained for up to one year after rituximab infusion (290). 
However, as with TNF-blockade, B cell depletion is effective in only a proportion of 
patients. A possible explanation may be that these therapies target specific arms of the 
immune system, which may prove successful in (for example) genetically susceptible 
patients, but fails patients in whom both innate and adaptive immunity play a collaborative, 
destructive role. Moreover, these patients may not be 'immunologically tolerant', but the 
force of such studies is the indication that long term manipulation of inflammatory 
responses is feasible and that given the appropriate reagents and clinical intervention 
strategy, it may be possible to truly modify disease. 
Optimal adaptive immunity requires induction by innate immune effector and regulatory 
pathways in the initiation and effector phase of arthritis. This is demonstrated in the 
KlBxN murine model of arthritis, whereby pathological activation of macrophages, 
neutrophils and mast cells is triggered by immune complexes formed by autoantibody 
against the ubiquitously expressed protein glucose-6-phosphate isomerase (GP!) (322-
325). However, the production of anti-GPI antibodies requires complement CS, as Cs-
deficient mice do not develop disease. In humans, only a very low association has been 
made between arthritis and the presence of auto-antibodies to GPI (308, 315). Conversely, 
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numerous studies have identified the presence of anti-CCP antibodies, identifiable in 
circulation as early as 10 years before the onset of clinical disease, as a major risk factor in 
the development of RA and severe PsA, Moreover, an interrelated association has been 
described between anti-CCP antibodies, cigarette smoking and HLA-DR shared epitope 
expression, inferring involvement of both innate and adaptive immunity to the underlying 
disease pathology. As DC are the immune cells inducting innate immunity and conducting 
adaptive immunity and, as has been demonstrated in this study, may be important not only 
to the initiation and prolongation of chronic arthritis but also the suppression thereof, DC 
may constitute promising therapeutic targets in the 'pre-c1inical disease' phase of 
rheumatologic autoimmunity. Of note, while inhibition of DC pro-inflammatory functions 
may have immediate benefit, the next challenge may be to uncover mechanisms by which 
DC tolerogenicity can be "released" and immune tolerance "re-set". Of note, CTLA-4Ig 
infusion, which has demonstrated moderate therapeutic success supposedly by inhibition of 
APC/T cell contact, also induces pDC to release IDO, thus enhancing tryptophan 
catabolism and T cell apoptosis (515). Thus re-establishing mechanisms of immune 
suppression may be possible. Furthennore, adoptive transfer of tolerogenic DC has been 
shown to induce disease amelioration in murine models of arthritis (716). 
The current study addressing as it does a rare cell population functioning in difficult tissue 
locations, has by necessity a number of weaknesses. In particular, it was difficult to 
establish whether pDC and mDC from the synovial compartment were hyper-responsive to 
TLR stimulation, which has been implied by other studies analyzing monocyte-derived DC 
(614), or indeed if they were hypo-responsive, which may be further indication of a 
tolerogenic phenotype. The difficulty was largely attributable to low useable sample 
numbers and the technical difficulties inherent in purifying any cell, let alone rare ones, 
from SF. Furthennore, due to the decreased PB mDC and pDC in RA and PsA, the 
function of these could not be investigated at all due to ethical restrictions. In future, novel 
analyses by which the function of very rare PB DC can be investigated will be required. 
Investigation of the IL-to expression, or lack thereof, by mDC and pDC within synovium 
will be required to determine whether membrane DC represent a heterogeneous population 
of arthritogenic and tolerogenic DC. A further weakness of the study was that the effect of 
TNF-blockade on PB circulating mDC and pDC was not undertaken due to clinical trial 
prohibition. While this has been attempted by one other group (680), they did not use 
specific DC markers, thus the results are difficult to interpret. In light of our observation 
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that TNF-a affects DC subsets differentially, such an analysis in future, particularly using 
the sensitive assay system described in chapter 3, may be informative. Finally, although 
this study has attempted to examine the cognate interactions between mDC, pDC and T 
cells, it has not addressed DC interactions with B cells. Since recent studies have indicated 
that DC, in particular pDC, may interact with B cells directly, inducing isotype class 
switching (399, 717, 718), such investigations will be required to elucidate the potential 
direct contribution of DC to autoantibody production. 
In summary, the present thesis represents a parallel design clinical, in vitro and ex vivo 
analysis of the role played by DC subsets in inflammatory arthritis. It has defined for the 
first time the definitive phenotype of a variety of DC subsets in RA and PsA. Inevitably it 
has raised a new set of questions and has only partially answered those questions present at 
outset. A number of studies are now urgently required. 
• First, ex vivo analysis of circulating pDC and mDC subsets pre- and post-TNF 
blockade should be performed. By undertaking these experiments it is hoped to 
elucidate further the differential effects ofTNF-a on the DC subsets. 
• Second, commensurate with the above, analysis of type I IFN expression in SM 
taken before and after TNF blockade, particularly as related to clinical response 
measures, could potentially give further insight into why certain patients fail TNF-(l 
blockade. 
• Third, while we co-localised mDC and pDC to T cell aggregates in the inflamed 
synovium, we did not analyse their distribution in relation to germinal centres. 
Considering that pDC in particular have been demonstrated to interact directly with 
B cells, inducing IgG class switching (717, 718), this could prove informative. 
• Fourth, given the predominant immature phenotype of SF residing mDC and pDC, 
and their concomitant potential for self (auto) antigen presentation, analysis of 
mDC and pDC infiltration to the local cartilage would be enlightening. 
• Fifth, in order to expand our understanding of the role of pDC in the murine model 
of arthritis presented here, depletion of pDC in an adoptive transfer model using 
Th2, as opposed to Th 1, polarized CV A specific T cells is required. Maffia et al 
have previously reported that transfer of Th2 polarised av A specific Tg T cells 
induces only a very mild transient arthritis in recipient BALB/c (697). If pDC 
suppress autoimmunity in a 'blanket' manner, it would be expected that their 
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depletion in Th2 transfer would instigate more severe pathology. Alternatively, if 
Th2 transfer drives pDC function towards a more arthritogenic as opposed to 
tolerogenic functional phenotype, particularly given that pDC were originally 
defined as 'DC2' - Th2 polarising DC, the reverse would be expected. 
• Finally two photon imaging of the joint during this arthritis model would allow us 
to determine whether av A TcR Tg T cell cognate interactions induce 
immunogenicity in the tissue sentinel DC, or whether this pivotal point in the 
breach of self-tolerance is driven by non-specific soluble factors released during 
inflammation. 
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